
<html lang="en"     class="pb-page"  data-request-id="8b5011d9-70ce-45ae-9843-626d581c46cb"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c00082;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-10"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor" /></meta><meta name="dc.Creator" content="Baomin  Liu" /></meta><meta name="dc.Creator" content="Kuo  Gai" /></meta><meta name="dc.Creator" content="Hui  Qin" /></meta><meta name="dc.Creator" content="Jie  Wang" /></meta><meta name="dc.Creator" content="Xushi  Liu" /></meta><meta name="dc.Creator" content="Yuan  Cao" /></meta><meta name="dc.Creator" content="Qin  Lu" /></meta><meta name="dc.Creator" content="Dandan  Lu" /></meta><meta name="dc.Creator" content="Deyang  Chen" /></meta><meta name="dc.Creator" content="Hengqiao  Shen" /></meta><meta name="dc.Creator" content="Wei  Song" /></meta><meta name="dc.Creator" content="Jia  Mei" /></meta><meta name="dc.Creator" content="Xiaojin  Wang" /></meta><meta name="dc.Creator" content="Hongjiang  Xu" /></meta><meta name="dc.Creator" content="Yinsheng  Zhang" /></meta><meta name="dc.Description" content="We describe a study leading to the discovery of compound 11, a pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with excellent potency, metabolic stability, and pharm..." /></meta><meta name="Description" content="We describe a study leading to the discovery of compound 11, a pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with excellent potency, metabolic stability, and pharm..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 15, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00082" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00082" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00082" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00082" /></link>
        
    
    

<title>Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00082" /></meta><meta property="og:title" content="Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0011.jpeg" /></meta><meta property="og:description" content="We describe a study leading to the discovery of compound 11, a pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with excellent potency, metabolic stability, and pharmacokinetics (PK). Compound 11 incorporating a 4-silapiperidine group was discovered by further optimizing our previous lead with a triethylsilyl moiety. It displayed great potency against genotype 1 subtype a (GT1a), -1b, -2a, -3a, -4a, -5a, and -6a with an EC50 range of 0.33–17 pM and improved potency against the resistance-associated variant GT1a_M28T. Pharmacokinetics (PK) study indicated that compound 11 has reasonable PK exposures with a high liver distribution in preclinical animal species (mouse, rat, and dog). The results of a 14 day repeat-dose toxicity study identified the safety of compound 11." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00082"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00082">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00082&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00082&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00082&amp;href=/doi/10.1021/acs.jmedchem.0c00082" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 5312-5323</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00160" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00192" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Baomin Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Baomin Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Innovative Drug Discovery, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Baomin++Liu">Baomin Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kuo Gai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kuo Gai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Innovative Drug Discovery, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kuo++Gai">Kuo Gai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hui Qin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hui Qin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Innovative Drug Discovery, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hui++Qin">Hui Qin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jie Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jie Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Innovative Drug Discovery, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jie++Wang">Jie Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xushi Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xushi Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Innovative Drug Discovery, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xushi++Liu">Xushi Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuan Cao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuan Cao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuan++Cao">Yuan Cao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qin Lu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qin Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qin++Lu">Qin Lu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dandan Lu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dandan Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dandan++Lu">Dandan Lu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Deyang Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Deyang Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Deyang++Chen">Deyang Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hengqiao Shen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hengqiao Shen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hengqiao++Shen">Hengqiao Shen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Song</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Song</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Song">Wei Song</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jia Mei</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jia Mei</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jia++Mei">Jia Mei</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaojin Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaojin Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaojin++Wang">Xiaojin Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hongjiang Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hongjiang Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hongjiang++Xu">Hongjiang Xu</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Yinsheng Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yinsheng Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#c4bebdb784a7b0b0b5eaa7aba9"><span class="__cf_email__" data-cfemail="5b2122281b382f2f2a75383436">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yinsheng++Zhang">Yinsheng Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5390-671X" title="Orcid link">http://orcid.org/0000-0001-5390-671X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00082&amp;href=/doi/10.1021%2Facs.jmedchem.0c00082" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 5312–5323</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 15, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>2 February 2020</li><li><span class="item_label"><b>Published</b> online</span>15 April 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 May 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00082" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00082</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5312%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBaomin%2BLiu%252C%2BKuo%2BGai%252C%2BHui%2BQin%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D10%26contentID%3Dacs.jmedchem.0c00082%26title%3DDiscovery%2Bof%2Ba%2BSilicon-Containing%2BPan-Genotype%2BHepatitis%2BC%2BVirus%2BNS5A%2BInhibitor%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5323%26publicationDate%3DMay%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00082"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">846</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00082" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Baomin&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Kuo&quot;,&quot;last_name&quot;:&quot;Gai&quot;},{&quot;first_name&quot;:&quot;Hui&quot;,&quot;last_name&quot;:&quot;Qin&quot;},{&quot;first_name&quot;:&quot;Jie&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Xushi&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Yuan&quot;,&quot;last_name&quot;:&quot;Cao&quot;},{&quot;first_name&quot;:&quot;Qin&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Dandan&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Deyang&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Hengqiao&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Jia&quot;,&quot;last_name&quot;:&quot;Mei&quot;},{&quot;first_name&quot;:&quot;Xiaojin&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Hongjiang&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Yinsheng&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;5312-5323&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00082&quot;},&quot;abstract&quot;:&quot;We describe a study leading to the discovery of compound 11, a pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with excellent potency, metabolic stability, and pharmacokinetics (PK). Compound 11 incorporating a 4-silapiperidine group was discovered by further optimizing our previous lead with a triethylsilyl moiety. It displayed great potency against genotype 1 subtype a (GT1a), -1b, -2a, -3a, -4a, -5a, and -6a with an EC50 range of 0.33–17 pM and improved potency against the resistance-associated variant GT1a_M28T. Pharmacokinetics (PK) study indicated that compound 11 has reasonable PK exposures with a high liver distribution in preclinical animal species (mouse, rat, and dog). The results of a 14 day repeat-dose toxicity study identified the safety of compound 11.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00082&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00082" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00082&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00082" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00082&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00082" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00082&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00082&amp;href=/doi/10.1021/acs.jmedchem.0c00082" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00082" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00082" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00082%26sid%3Dliteratum%253Aachs%26pmid%3D32293179%26genre%3Darticle%26aulast%3DLiu%26date%3D2020%26atitle%3DDiscovery%2Bof%2Ba%2BSilicon-Containing%2BPan-Genotype%2BHepatitis%2BC%2BVirus%2BNS5A%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D10%26spage%3D5312%26epage%3D5323%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292444" title="Molecular structure">Molecular structure</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/jmcmar.2020.63.issue-10/20200528/jmcmar.2020.63.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00082&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We describe a study leading to the discovery of compound <b>11</b>, a pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with excellent potency, metabolic stability, and pharmacokinetics (PK). Compound <b>11</b> incorporating a 4-silapiperidine group was discovered by further optimizing our previous lead with a triethylsilyl moiety. It displayed great potency against genotype 1 subtype a (GT1a), -1b, -2a, -3a, -4a, -5a, and -6a with an EC<sub>50</sub> range of 0.33–17 pM and improved potency against the resistance-associated variant GT1a_M28T. Pharmacokinetics (PK) study indicated that compound <b>11</b> has reasonable PK exposures with a high liver distribution in preclinical animal species (mouse, rat, and dog). The results of a 14 day repeat-dose toxicity study identified the safety of compound <b>11</b>.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44301" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44301" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The World Health Organization (WHO) estimates that about 71 million people worldwide are infected with hepatitis C virus (HCV).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> HCV infection often leads to severe liver diseases including cirrhosis, hepatocellular carcinoma, and other complications.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Traditional therapy for HCV infection relies upon a combination of pegylated interferon-α and ribavirin, a poorly tolerated regimen with relatively low sustained virologic response (SVR) rates (40–65%).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In recent years, a significant improvement in treating HCV has been made due to the development of direct-acting antiviral agents (DAAs) with higher rates of SVR and less side effects, such as the NS3/4A protease inhibitors simeprevir,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> paritaprevir,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> grazoprevir,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and glecaprevir;<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> the NS5B polymerase inhibitors sofosbuvir<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and dasabuvir;<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and the nonstructural protein 5A (NS5A) inhibitors daclatasvir,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> ombitasvir,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> ledipasvir,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> elbasvir,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> velpatasvir,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and pibrentasvir<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Administration of a combination of all oral DAAs has become the current treatment paradigm for HCV with improved efficacy, shorter treatment duration, and less adverse effects. Several DAA-based regimens have been approved for the treatment of pan-genotypic HCV infection with SVR rates over 95% only requiring 12 or 8 weeks of therapy, such as sofosbuvir/velpatasvir,<a onclick="showRef(event, 'ref8 ref15'); return false;" href="javascript:void(0);" class="ref ref8 ref15">(8,15)</a> grazoprevir/elbasvir,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and glecaprevir/pibrentasvir.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structure of HCV NS5A inhibitors approved by FDA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00082&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Hepatitis C virus nonstructural protein 5A (NS5A) has been considered as an attractive viral target for HCV therapy. NS5A has no known enzymatic activity but plays an essential role in HCV RNA replication and virus assembly.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The mechanism of HCV NS5A inhibitors remains unclear. In the absence of enzymatic activity for NS5A, the identification of inhibitors has been driven by cell-based replicon activities. The NS5A inhibitors have become the most commonly used DAAs combined with an NS5B polymerase inhibitor and/or an NS3/4A protease inhibitor for treating patients who have HCV. First-generation NS5A inhibitors demonstrated high SVR rates in patients with HCV genotype 1 subtype a (GT1a) and exhibited weak activity against several other genotypes. In addition, most NS5A inhibitors approved for the market showed a low resistance barrier to GT1a.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Therefore, many research groups have been working toward the discovery of more potent HCV NS5A inhibitors against a wider variety of genotypes as well as NS5A resistance mutations particularly in the prevalent GT1a.</div><div class="NLM_p">Incorporation of a silicon atom into drug molecules provides an innovative avenue and a source of chemical diversity in drug discovery.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Silicon has a larger covalent radius than carbon and also a larger carbon–silicon bond length compared to the corresponding carbon–carbon bond. Silicon-containing analogs are more lipophilic than their carbon counterparts. These unique physicochemical properties of silicon render it ideal for medicinal applications that no other element can effectively achieve.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Our previous research efforts have identified a pan-genotype HCV NS5A inhibitor <b>1</b> through a “silicon–carbon switch” strategy<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Despite its potency against HCV genotypes 1a, 1b, 2a, 3a, 4a, and 5a in the single picomolar range, <b>1</b> showed relatively low activity against 6a with sub-nM activity. In a continued effort to develop pan-genotype HCV NS5A inhibitors, we explored the impact of structural modifications to <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), with the goal of improving potency against GT6a and maintaining good potency against the other genotypes. Herein, we disclose a novel series of silicon-containing NS5A inhibitors and identification of compound <b>11</b> with pan-genotypic potency and ideal pharmacokinetics (PK) profiles.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structure of compound <b>1</b> and structural modification strategy for a novel NS5A inhibitor design.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00082&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70460" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70460" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In our previous work, compound <b>1</b> was discovered as a silicon-containing pan-genotype HCV NS5A inhibitor with considerably less potency against GT6a than GT1 ∼ 5.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> We sought to explore the impact of silicon-containing groups as “X groups”, and the “cap” groups as “Y groups”, with the goal of improving the potency against GT6a (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Replacing the Moc-Val-“end-capping” group of compound <b>1</b> with the Moc-Thr(OMe)-capping group led to compound <b>3</b> and modifying the 4-position of the central <i>N</i>-phenyl ring with silyl groups yielded compounds <b>2</b> and <b>4</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). These compounds were tested in GT1a, GT1b, GT3a, and GT6a subgenomic replicon assays. <i>In vitro</i> biological data for those compounds are demonstrated in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. As indicated in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, all of the compounds provided picomolar activity against the genotypes GT1a, -1b, and -3a, and the new compounds <b>2</b>, <b>3</b>, and <b>4</b> delivered an obvious improvement in performance against GT6a (80–274 <i>vs</i> 817 pM). However, those compounds still exhibited relatively weaker potencies against GT6a than other genotypes. Compared with compound <b>1</b>, Moc-Thr(OMe)-cap analogue <b>3</b> showed potency improvement across the genotypes tabulated. Particularly, compound <b>3</b> was approximately 7-fold more potent than compound <b>1</b> against GT6a, suggesting that the incorporation of O-methylthreonine might be beneficial for GT6a inhibition. Of the three new compounds, compound <b>4</b>, which has a SiMe<sub>2</sub>t-Bu group at the 4-position of the central <i>N</i>-phenyl ring, showed the best activity against GT6a. It was approximately 10-fold more potent than compound <b>1</b> against GT6a. However, the SiMe<sub>3</sub>-substituted analogue <b>2</b> showed the least potency improvement in GT6a compared with <b>3</b> and <b>4</b>. There appears to be a general trend that bulky substituents at the 4-position of the central <i>N</i>-phenyl ring correlate with an improved ability to suppress GT6a.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. <i>In Vitro</i> Activity of Compounds <b>1</b>–<b>6</b> against HCV GT1a, GT1b, GT3a, and GT6a in the Replicon Assay</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0007.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0008.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Mean of triplicate well values. EC<sub>50</sub> stands for 50% effective concentration.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last"><i>In vitro</i> biological data for compound <b>1</b> are slightly different from the previous report, and the differences might result from experimental error.</p></div></div><div></div></div><div class="NLM_p">Improvement in potencies against GT6a was attainable by modifying the X group and Y group while retaining potent activities against GT1a, GT1b, and GT3a. Our primary results gave us confidence that greater potencies with comparable activities across the various HCV genotypes could be achieved by exploring modifications of the X group and/or the Y group. We next followed the trend mentioned above to introduce more bulky sila-groups to the 4-position of the central <i>N</i>-phenyl ring with the aim to obtain potent pan-genotype inhibitors. Analogues with a 4-silapiperidine group at the 4-position of the central <i>N</i>-phenyl ring were synthesized and evaluated in our research. To avoid the possible undesired PK properties, a fluorine atom was introduced to the 3-position of the central <i>N</i>-phenyl ring. As demonstrated in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, the compounds were tested as either the pure 2<i>S</i>, 5<i>S</i> or 2<i>R</i>, 5<i>R</i> diastereomers. The valine capped compounds <b>5</b>–<b>8</b> showed high potent activities against GT1a and GT1b, with replicon potencies in the 0.4–0.9 pM range of EC<sub>50</sub>. A comparison of the 2<i>S</i>, 5<i>S trans</i>-pyrrolidine compound <b>5</b> with the 2<i>R</i>, 5<i>R</i> isomer <b>6</b> revealed that the stereochemistry at carbons 2 and 5 was unrelated with their potencies against GT1a and GT1b. Difference was also not observed between the 2<i>S</i>, 5<i>S trans</i>-pyrrolidine compound <b>7</b> and its 2<i>R</i>, 5<i>R</i> counterpart <b>8</b> in GT1a and GT1b inhibition. The trend was not in line with what we and others reported of a stereochemical dependence for potencies of compounds against GT1a.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> However, the antiviral activities of the valine capped compounds <b>5</b>–<b>8</b> against GT3a and GT6a revealed a stereochemical dependence. The 2<i>S</i>, 5<i>S</i> isomer <b>5</b> was approximately 5.8- and 4.6-fold more potent than the 2<i>R</i>, 5<i>R</i> isomer <b>6</b> against GT3a and GT6a, respectively. Likewise, the 2<i>S</i>, 5<i>S</i> isomer <b>7</b> was more active against GT3a (3.4-fold) and GT6a (5.3-fold) than the 2<i>R</i>, 5<i>R</i> isomer <b>8</b>. Comparison of compounds <b>5</b> and <b>7</b> revealed that introduction of an additional fluorine atom to the 5-position of the central <i>N</i>-phenyl ring of the valine capped compounds barely affected the potencies against GT1a, GT1b, and GT3a but led to 2-fold improved potency against GT6a.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. <i>In Vitro</i> Activity of Compounds <b>5</b>–<b>12</b> against HCV GT1a, GT1b, GT3a, and GT6a in the Replicon Assay</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0009.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0010.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Mean of triplicate well values. All experiments were performed at least twice. EC<sub>50</sub> stands for 50% effective concentration.</p></div></div><div></div></div><div class="NLM_p">Testing the O-methylthreonine capped compounds also demonstrated a stereochemical dependence for their replicon potencies. The 2<i>S</i>, 5<i>S</i> isomer <b>9</b> was 1.9- to 5.5-fold more potent against the genotypes tested than the corresponding 2<i>R</i>, 5<i>R</i> isomer <b>10</b>. Activity comparison of compounds <b>11</b> with <b>12</b> revealed a similar trend of increased potency for the 2<i>S</i>, 5<i>S</i> isomer against genotypes tested <i>vs</i> the corresponding 2<i>R</i>, 5<i>R</i> isomer, with the exception that the potencies of the two isomers against GT1b remained unchanged. Compound <b>12</b> (2<i>R</i>, 5<i>R</i> isomer) was significantly less active against GT1a (10-fold) and GT6a (6.7-fold) than compound <b>11</b> (2<i>S</i>, 5<i>S</i> isomer), with similar activity against GT3a. Compound <b>11</b> exhibited significantly improved activity against GT6a (14.2-fold) <i>vs</i> compound <b>9</b>, indicating that introduction of an additional fluorine atom to the 5-position of the central <i>N</i>-phenyl ring contributed to the improvement of potency against GT6a.</div><div class="NLM_p">As a result of its desirable potency shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, compound <b>11</b> was selected for further <i>in vitro</i> virologic evaluation. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, <b>11</b> demonstrated picomolar potency across GT1–GT6, with replicon potencies in the 0.33–3.0 pM range for GT1-GT5 and 17 pM for GT6a. To determine the <i>in vitro</i> resistance profile of compound <b>11</b>, replicon resistance selection was conducted with <b>11</b> in HCV replicons containing NS5A from GT1a or GT1b. As indicated in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, the greatest resistance emerged with the Q30E, Y93H, Y93C, and Y93N variants in genotype 1a. GT1a_Q30E, GT1a_Y93H, GT1a_Y93C, and GT1a_Y93N conferred 175.3- to >833-fold resistance to <b>11</b>. Examination of the data reveals that <b>11</b> demonstrated a similar potency against resistant variants in GT1a when compared to the known NS5A inhibitor ombitasvir although there are some differences in fold resistance and variants selected. One particular exception is found for GT1a_M28T, which was susceptible to <b>11</b> (1.9-fold) but showed high fold resistance for Ombitasvir.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Variants of genotype 1b, where tested, showed lower fold resistance to <b>11</b> when compared to variants of genotype 1a, especially for Y93H (>833 <i>vs</i> 12.2) and L31V (>23 <i>vs</i> 2.3). GT1b_L31W and GT1b_L31V conferred 11.4- and 2.3-fold resistance, respectively. GT1b_P32L remained fully susceptible to inhibition by <b>11</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Antiviral Activity of 11 in HCV Replicon Cell Lines Containing NS5A from GT1–6</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="7" align="center">replicon EC<sub>50</sub> (pM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left">GT1a</th><th class="colsep0 rowsep0" align="left">GT1b</th><th class="colsep0 rowsep0" align="left">GT2a</th><th class="colsep0 rowsep0" align="left">GT3a</th><th class="colsep0 rowsep0" align="left">GT4a</th><th class="colsep0 rowsep0" align="left">GT5a</th><th class="colsep0 rowsep0" align="left">GT6a</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">0.38</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">0.33</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">17</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Mean of triplicate well values. All experiments were performed at least twice. EC<sub>50</sub> stands for 50% effective concentration.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Activity of 11 against HCV Genotypes 1a and 1b NS5A Resistance-Associated Variants <i>In Vitro</i></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">HCV genotype</th><th class="colsep0 rowsep0" align="center">variant</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (pM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">fold resistance<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1a</td><td class="colsep0 rowsep0" align="left">M28T</td><td class="colsep0 rowsep0" align="left">2.37</td><td class="colsep0 rowsep0" align="left">1.90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">L31M</td><td class="colsep0 rowsep0" align="left">12.2</td><td class="colsep0 rowsep0" align="left">9.90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">L31V</td><td class="colsep0 rowsep0" align="left">27.0</td><td class="colsep0 rowsep0" align="left">23.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Q30K</td><td class="colsep0 rowsep0" align="left">37.5</td><td class="colsep0 rowsep0" align="left">30.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Q30E</td><td class="colsep0 rowsep0" align="left">216</td><td class="colsep0 rowsep0" align="left">175</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Y93H</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>833</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Y93C</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">>203</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Y93N</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">>203</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1b</td><td class="colsep0 rowsep0" align="left">Y93H</td><td class="colsep0 rowsep0" align="left">20.4</td><td class="colsep0 rowsep0" align="left">12.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">L31W</td><td class="colsep0 rowsep0" align="left">19.1</td><td class="colsep0 rowsep0" align="left">11.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">L31V</td><td class="colsep0 rowsep0" align="left">3.81</td><td class="colsep0 rowsep0" align="left">2.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">P32L</td><td class="colsep0 rowsep0" align="left">1.64</td><td class="colsep0 rowsep0" align="left">1.00</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">As determined in transient-transfection assays.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Fold resistance is relative to the value of the respective wild-type replicon.</p></div></div></div><div class="NLM_p">Given its <i>in vitro</i> pan-genotypic potency, we turned our attention to pharmacokinetic (PK) profiles of compound <b>11</b>. <i>In vitro</i> metabolic stabilities in mouse, rat, and human microsomes (MLM, RLM, and HLM, respectively) for compound <b>11</b> and ombitasvir are shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. The rat and human microsomal stabilities of compound <b>11</b> were similar to that of ombitasvir.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. <i>In Vitro</i> Metabolic Stability Data</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">MLM (% remaining<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a>)</th><th class="colsep0 rowsep0" align="center" char=".">RLM (% remaining<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a>)</th><th class="colsep0 rowsep0" align="center" char=".">HLM (% remaining<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">60.4</td><td class="colsep0 rowsep0" align="char" char=".">76.3</td><td class="colsep0 rowsep0" align="char" char=".">80.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ombitasvir</td><td class="colsep0 rowsep0" align="char" char=".">63.5</td><td class="colsep0 rowsep0" align="char" char=".">73.5</td><td class="colsep0 rowsep0" align="char" char=".">82.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Percentage of parent compound remaining after 60 min of incubation.</p></div></div></div><div class="NLM_p">Pharmacokinetic characterization of compound <b>11</b> in mouse is summarized in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. Its <i>T</i><sub>1/2</sub> (half-life) and area under curve (AUC) were similar to those of ombitasvir. A low oral bioavailability (7.2%) of compound <b>11</b> was observed, with similarity to the reported oral bioavailability of pibrentasvir (7.9%),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> an approved pan-genotype HCV NS5A inhibitor. The dog PK profile of compound <b>11</b> was also investigated. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, compound <b>11</b> demonstrated a longer <i>T</i><sub>1/2</sub> in dog than in mouse (21.2 <i>vs</i> 12.2). The AUC was also acceptable considering its picomolar-level potency against GT1 ∼ 6 and the similar AUCs with ombitasvir.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. PK study of compound <b>11</b> in dog (PO 5 mpk).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00082&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetics of Compound 11 in Mouse<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="6" align="center">iv</th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">po</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>c</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>last</sub> (ng/(h mL))</th><th class="colsep0 rowsep0" align="center" char=".">CLp (L/(h kg))</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>last</sub> (ng/(h mL))</th><th class="colsep0 rowsep0" align="center">F (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">12.2</td><td class="colsep0 rowsep0" align="char" char=".">1.56</td><td class="colsep0 rowsep0" align="char" char=".">17 863</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">8.0</td><td class="colsep0 rowsep0" align="char" char=".">7.3</td><td class="colsep0 rowsep0" align="char" char=".">454</td><td class="colsep0 rowsep0" align="char" char=".">6446</td><td class="colsep0 rowsep0" align="left">7.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ombitasvir<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">7.7</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">583</td><td class="colsep0 rowsep0" align="char" char=".">6480</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Formulation: po 2:2:96 (v/v) alcohol:Tween 80:glucose injection, iv: diluted po formulation for 2.5 times with 10% glucose injection.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Not tested.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">The data was disclosed in our previous report.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></p></div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Dog PK Profile of Compound 11 after Oral Administration<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mpk)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–48h</sub> (ng/(h mL))</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–∞</sub> (ng/(h mL))</th><th class="colsep0 rowsep0" align="center">MRT (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">21.2</td><td class="colsep0 rowsep0" align="left">5.3</td><td class="colsep0 rowsep0" align="left">395</td><td class="colsep0 rowsep0" align="left">8020</td><td class="colsep0 rowsep0" align="left">10 104</td><td class="colsep0 rowsep0" align="left">17.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Formulation: Phosal 53 MCT/PEG-400/Poloxamer 124/Cremophor RH40 (40/20/20/20, by weight).</p></div></div></div><div class="NLM_p">To learn more metabolic properties, the liver distribution of both <b>11</b> and pibrentasvir was evaluated in mouse and rats. The concentrations of <b>11</b> and pibrentasvir in plasma and liver after oral administration are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>. At each time point, the concentration of <b>11</b> in mouse and rat plasma was lower than that of pibrentasvir, but the situation in the liver was just the opposite. The maximum concentration of <b>11</b> and pibrentasvir occurred at 3 h in the plasma and liver. The liver concentration of <b>11</b> was much higher than its plasma concentration at the same time point, suggesting that <b>11</b> was an NS5A inhibitor with high liver distribution. The mean plasma concentration ratios (LPRs) of <b>11</b> at 3 h in mouse and rat were 24.6 and 5.2, respectively, suggesting that <b>11</b> can distribute into the liver easily. In contrast, LPRs of pibrentasvir were much lower in mouse and rat, with LPRs of 0.39 and 1.1 at 3 h in mouse and rat, respectively, indicating that pibrentasvir did not possess a liver-targeting effect.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Liver Distribution of <b>11</b> and Pibrentasvir in Mouse and Rat (mean ± standard deviation (SD), <i>n</i> = 3)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="4" align="center"><b>11</b></th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">pibrentasvir</th><th class="colsep0 rowsep0" align="left" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">time (h)</th><th class="colsep0 rowsep0" align="center" char="±">plasma (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±">liver (ng/g)</th><th class="colsep0 rowsep0" align="center" char=".">LPR<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">plasma (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±">liver (ng/g)</th><th class="colsep0 rowsep0" align="center" char=".">LPR<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char="±">160 ± 57.5</td><td class="colsep0 rowsep0" align="char" char="±">436 ± 126</td><td class="colsep0 rowsep0" align="char" char=".">8.8</td><td class="colsep0 rowsep0" align="char" char="±">414 ± 97.9</td><td class="colsep0 rowsep0" align="char" char="±">94 ± 42</td><td class="colsep0 rowsep0" align="char" char=".">0.43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char="±">308 ± 57.6</td><td class="colsep0 rowsep0" align="char" char="±">1585 ± 131</td><td class="colsep0 rowsep0" align="char" char=".">24.6</td><td class="colsep0 rowsep0" align="char" char="±">1541 ± 171</td><td class="colsep0 rowsep0" align="char" char="±">193 ± 67</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char="±">58.6 ± 6.8</td><td class="colsep0 rowsep0" align="char" char="±">625 ± 147</td><td class="colsep0 rowsep0" align="char" char=".">17.9</td><td class="colsep0 rowsep0" align="char" char="±">718 ± 114</td><td class="colsep0 rowsep0" align="char" char="±">69.6 ± 13</td><td class="colsep0 rowsep0" align="char" char=".">0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char="±">40.9 ± 16.2</td><td class="colsep0 rowsep0" align="char" char="±">359 ± 107</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char="±">103 ± 17.0</td><td class="colsep0 rowsep0" align="char" char="±">155 ± 23.2</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char="±">45.2 ± 7.2</td><td class="colsep0 rowsep0" align="char" char="±">1111 ± 202</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char="±">96.4 ± 40.2</td><td class="colsep0 rowsep0" align="char" char="±">102 ± 50.6</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char="±">16.4 ± 6.4</td><td class="colsep0 rowsep0" align="char" char="±">293 ± 39.1</td><td class="colsep0 rowsep0" align="char" char=".">10.7</td><td class="colsep0 rowsep0" align="char" char="±">30.1 ± 5.85</td><td class="colsep0 rowsep0" align="char" char="±">18.9 ± 4.71</td><td class="colsep0 rowsep0" align="char" char=".">0.63</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Dosing at 10 mg/kg.</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">Mean liver concentration/mean plasma concentration ratio (LPR).</p></div></div></div><div class="NLM_p">The <i>in vitro</i> cell toxicity of compound <b>11</b> was assessed using Huh7 cells. The CC<sub>50</sub> value of compound <b>11</b> was determined to be >50 μM, indicating that no cell toxicity was observed in the assay.</div><div class="NLM_p last">To evaluate the safety of compound <b>11</b>, a 14 day repeated oral dose toxicity study was conducted, and the results are available in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00082/suppl_file/jm0c00082_si_001.zip" class="ext-link">Supporting Information</a>. Mice were administered <b>11</b> once daily by gavage at a high dose of 300 mg/kg. All animals were observed daily and clinical signs were detailed until they were killed after the 14th administration. As demonstrated in Table 9, there was no statistically significant difference in body weight between the control and <b>11</b>. In addition, no abnormality was observed on the organs. Also, hematology data showed no statistically significant difference between the control and <b>11</b> (Table 10). Blood chemistry data indicated a statistically significant increase of cholesterol in <b>11</b> (<i>P</i> < 0.01) (Table 11), with no abnormality in other liver-related indicators. In summary, animal studies identified no toxicity with <b>11</b>.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14212" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14212" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, compounds <b>2</b>–<b>4</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) were synthesized starting from silicon-containing dianiline compounds <b>13a</b>, <b>13b</b>, and <b>13c</b>, which were prepared according to previous methods and purified as single 2<i>S</i>, 5<i>S</i> isomers.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The amide side chains were attached to the central pyrrodine core by peptide-coupling compounds <b>13a</b>, <b>13b</b>, and <b>13c</b> with <i>N</i>-(methoxycarbonyl)-O-methyl-<span class="smallcaps smallerCapital">l</span>-threonyl-<span class="smallcaps smallerCapital">l</span>-proline <b>14</b>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0004.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Compounds <b>2–4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00082&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI), 1-hydroxybenzotriazole (HOBt), <i>N</i>-methylmorpholine (NMM), dimethylformamide (DMF), 60 °C, 2 h, 29–47% yield.</p></p></figure><div class="NLM_p">Compounds <b>5</b>–<b>8</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) were obtained using the preparation illustrated in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. 4,4-Dimethyl-1,4-azasilinane hydrochloride <b>15</b>, 3,4-difluoronitrobenzene <b>16a</b>, and 3,4,5-trifluoronitrobenzene <b>16b</b> were purchased, while (1<i>R</i>,4<i>R</i>)-1,4-bis(4-nitrophenyl)butane-1,4-diyl dimethanesulfonate and (1<i>S</i>,4<i>S</i>)-1,4-bis(4-nitrophenyl)butane-1,4-diyl dimethanesulfonate were prepared based on known procedures.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a><b>16a</b> and <b>16b</b> were treated with <b>15</b> under an alkaline condition to give nitro compounds <b>17a</b> and <b>17b</b>, respectively, which were in turn reduced by hydrogen under Pd/C to the corresponding aniline compounds <b>18a</b> and <b>18b</b>. The aniline compounds were reacted with <i>S</i>,<i>S</i>-dimesylate or <i>R</i>,<i>R</i>-dimesylate to give <i>R</i>,<i>R</i>-pyrrolidine derivatives (<b>19b</b>, <b>19d</b>) or <i>S</i>,<i>S</i>-pyrrolidine derivatives (<b>19a</b>, <b>19c</b>), respectively. Reduction of the nitro groups by catalytic hydrogenation gave dianiline compounds (<b>20a</b>, <b>20b</b>, <b>20c</b>, and <b>20d</b>). Hydrogenation with platinum (IV) oxide was the best condition to minimize stereochemical isomerization. A (methoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-valyl-<span class="smallcaps smallerCapital">l</span>-proline moiety was finally introduced to give <b>5</b>–<b>8</b>. As demonstrated in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, compounds <b>9–12</b> were also synthesized in a similar method by switching the valine and O-methylthreonine caps in the preparation.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0005.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Compounds <b>5–8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00082&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) triethylamine, DMF, r.t., 12 h; (ii) H<sub>2</sub>, 10% Pd/C, tetrahydrofuran (THF), r.t., 12 h; (iii) (1<i>R</i>,4<i>R</i>)-1,4-bis(4-nitrophenyl)butane-1,4-diyl dimethanesulfonate (<b>19r</b>) or (1<i>S</i>,4<i>S</i>)-1,4-bis(4-nitrophenyl)butane-1,4-diyl dimethanesulfonate (<b>19s</b>), DMF, 60 °C, 24 h; (iv) H<sub>2</sub>, platinum dioxide, THF, r.t, 3 h; and (v) EDCI, HOBt, <i>N</i>-methylmorpholine, DMF, 55 °C, 2 h.</p></p></figure><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Compounds <b>9–12</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00082&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: EDCI, HOBt, <i>N</i>-methylmorpholine, DMF, 60 °C, 2 h.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86104" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86104" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have disclosed several novel silicon-containing <i>N</i>-phenylpyrrolidines as HCV NS5A inhibitors. By incorporating a 4-silapiperidine group with an O-methylthreonine cap, we identified compound <b>11</b> as an HCV NS5A inhibitor with significantly improved potency against the GT6a (EC<sub>50</sub> = 17 pM). This lead also showed an excellent <i>in vitro</i> profile in many other genotypes with an EC<sub>50</sub> range of 0.33–3.0 pM against GT1a, 1b, 2a, 3a, 4a, and 5a. An improved potency against variant GT1a_M28T was also observed for compound <b>11</b> when compared to ombitasvir. Compound <b>11</b> showed a good stability profile in mouse, rat, and human microsomes, and further <i>in vivo</i> studies revealed that <b>11</b> also demonstrated an acceptable rat and dog PK profile in combination with high liver distribution in both mouse and rat. Results of the cytotoxicity test and the 14 day repeat-dose toxicity study identified the good safety profile of compound <b>11</b>. All of the encouraging results suggested that compound <b>11</b> is a promising silicon-containing pan-genotype HCV NS5A inhibitor.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71426" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71426" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Replicon Assays</h3><div class="NLM_p last">Detailed replicon biological assays were conducted according to our previous report.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The methods to measure the effects of individual amino acid variants on the activity of an inhibitor in HCV replicon cell culture assays have been described previously. Briefly, the resistance-associated variants in NS5A were each introduced into GT1a-H77, GT1b-Con1, or chimeric replicons. In transient assays, the replicon containing the variant was transfected via electroporation into a Huh-7-derived cell line. The inhibitory effect of compounds on HCV replication was determined by measuring the decrease in the luciferase signal. The percent inhibition of HCV replicon replication was calculated for each compound concentration, and the EC<sub>50</sub> value was calculated using nonlinear regression curve fitting to the 4-parameter logistic equation in GraphPad Prism software.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Pharmacokinetic Profiles</h3><div class="NLM_p"><i>In vitro</i> PK assessment was performed using pooled mouse, rat, and human liver microsomes obtained from BD Gentest. A typical standard reaction mixture of 300 mL consisted of the pooled liver microsomes 0.5 mg/mL, 1 mM NADPH, 5 mM MgCl<sub>2</sub>, 100 mM potassium phosphate buffer (pH 7.4), and 1 μM test compounds. After a 5 min preincubation at 37 °C, the reactions were initiated by addition of NADPH and incubation proceeded for 60 min at 37 °C in a shaking metal bath. The reaction was stopped by transferring 60 mL of aliquots to the tubes on ice and adding 120 mL of ice-cold acetonitrile containing internal standards. Concentration of the test compounds was measured by ultraperformance liquid chromatography-mass spectrometry analysis (UPLC-MS/MS).</div><div class="NLM_p last"><i>In vivo</i> PK assessment: Compound <b>11</b> was dosed in overnight fasted mice, rats, or dogs via intravenous (iv) and per os (po) administration. Unless otherwise noted, compound <b>11</b> was formulated in 2:2:96 (v/v) alcohol:Tween 80:glucose injection for single 10 mg/kg po dosing in mouse. In addition, po formulation was diluted by glucose injection for 2.5 times as iv formulation for single 2 mg/kg iv dosing in mouse. Compound <b>11</b> was formulated in Phosal 53 MCT/PEG-400/Poloxamer 124/Cremophor RH40 (40/20/20/20, by weight) for single 5 mg/kg po dosing in dog. The concentration of compounds in the plasma and liver was measured by the ultraperformance liquid chromatography-mass spectrometry analysis (UPLC-MS/MS).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Toxicity Study</h3><div class="NLM_p last">Cytotoxicity test was performed as in a previous method.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Repeated-dose toxicity study was carried out for 14 days. After acclimation, animals were randomly allocated to two groups, each containing five males and five females, and orally administered compound <b>11</b> at the dose of 300 mg/kg or the vehicle alone once daily by gavage. Mice were killed after the 14th administration. Animals in all groups were observed daily, and detailed clinical signs evident. Their body weights and food intake were monitored on day 1 of administration and thereafter twice per week. Body weights were used for calculation of the volume of the test chemical to be administered. Hematology, blood biochemistry, and serum hormone measurements and histopathology were performed according to previous methods.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Chemistry</h3><div class="NLM_p">Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. <sup>1</sup> H NMR spectra (500 MHz) were collected on a Bruker-500 FT NMR spectrometer with tetramethylsilane (TMS) as the internal standard. Mass spectra (MS) were recorded on an AB SCIEX 3200 Q TRAP mass spectrometer. High-resolution mass spectra (HRMS) were recorded on an AB SCIEX Triplet TOF 4600 mass spectrometer. All final compounds were purified to >96% purity as determined by HPLC analysis. Reverse-phase HPLC purity determinations were performed on an Agilent 1260 HPLC system. Compounds <b>14</b>, <b>15</b>, <b>16a</b>, <b>16b</b>, and <b>21</b> were purchased from commercial resources. Compounds <b>13a</b>, <b>13b</b>, and <b>13c</b>, (1<i>S</i>,4<i>S</i>)-1,4-bis(4-nitrophenyl)butane-1,4-diyl dimethanesulfonate, (1<i>R</i>,4<i>R</i>)-1,4-bis(4-nitrophenyl)butane-1,4-diyl dimethanesulfonate, and compound <b>1</b> were prepared according to the reported methods.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Ombitasvir and pibrentasvir were synthesized according to the reported methods with 99% purity.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a></div><div id="sec5_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Dimethyl ((2<i>S</i>,2′<i>S</i>,3<i>R</i>,3′<i>R</i>)-((2<i>S</i>,2<i>′S</i>)-(((((2<i>S</i>,5<i>S</i>)-1-(4-(Trimethylsilyl)phenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl))bis(carbonyl))bis(pyrrolidine-2,1-diyl))bis(3-methoxy-1-oxobutane-1,2-diyl))dicarbamate (<b>2</b>)</h4><div class="NLM_p last">A mixture of <b>13a</b> (0.54 g, 1.35 mmol), <i>N</i>-(methoxycarbonyl)-O-methyl-<span class="smallcaps smallerCapital">l</span>-threonyl-<span class="smallcaps smallerCapital">l</span>-proline (1.16 g, 4.04 mmol), EDCI (0.77 g, 4.0 mmol), HOBt (0.55 g, 4.04 mmol), and <i>N</i>-methylmorpholine (0.41 g, 4.04 mmol) in DMF (10 mL) was stirred at 60 °C for 2 h. The mixture was diluted with ethyl acetate (50 mL), washed with water and brine, and dried over sodium sulfate. The drying agent was filtered off, and the solvent was concentrated in vacuo. The residue was purified by column chromatography on silica gel using ethyl acetate to give compound 2 (0.36 g, 47%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.87 (s, 2H), 7.44–7.42 (m, 4H), 7.13–7.11 (m, 4H), 6.99–6.96 (m, 2H), 6.33–6.31 (m, 2H), 5.73–5.71 (m, 2H), 5.14–5.13 (m, 2H), 4.83–4.81 (m, 2H), 4.69–4.67 (m, 2H), 3.79–3.77 (m, 2H), 3.75–3.72 (m, 4H), 3.75–3.72 (s, 6H), 3.34 (s, 6H), 2.50–2.45 (m, 4H), 2.06–2.01 (m, 8H), 1.20 (d, <i>J</i> = 6 Hz, 6H), 0.16 (s, 6H), 0.08 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 170.2, 169.0, 156.8, 144.7, 139.5, 136.6, 128.6, 126.6, 120.0, 114.0, 62.7, 60.8, 60.4, 57.4, 55.5, 52.4, 48.0, 32.3, 27.6, 24.9, 14.7, 1.92, 1.32; MS (ESI) <i>m</i>/<i>z</i> 964.5 (M + Na)<sup>+</sup>; HPLC: 98.2% purity; HRMS (ESI) <i>m</i>/<i>z</i> calcd for [M + H]<sup>+</sup> C<sub>49</sub>H<sub>67</sub>N<sub>7</sub>O<sub>10</sub>Si: 942.4797, found 942.4854.</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Dimethyl ((2<i>S</i>,2′<i>S</i>,3<i>R</i>,3′<i>R</i>)-((2<i>S</i>,2′<i>S</i>)-(((((2<i>S</i>,5<i>S</i>)-1-(4-(Triethylsilyl)phenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl))bis(carbonyl))bis(pyrrolidine-2,1-diyl))bis(3-methoxy-1-oxobutane-1,2-diyl))dicarbamate (<b>3</b>)</h4><div class="NLM_p last">A mixture of <b>13b</b> (0.60 g, 1.35 mmol), <i>N</i>-(methoxycarbonyl)-O-methyl-<span class="smallcaps smallerCapital">l</span>-threonyl-<span class="smallcaps smallerCapital">l</span>-proline (1.23 g, 4.05 mmol), EDCI (0.63 g, 4.05 mmol), HOBt (0.54 g, 4.05 mmol), and <i>N</i>-methylmorpholine (0.68 g, 6.75 mmol) in DMF (10 mL) was stirred at 60 °C for 4 h. The mixture was poured into water (50 mL) and extracted with dichloromethane (50 mL × 3), and the combined organic layers were dried with Mg<sub>2</sub>SO<sub>4</sub>. The drying agent was filtered off, and the solvent was concentrated in vacuo. The residue was purified on a C18 column (DAC 100 × 250 mm<sup>2</sup>, YMC Triart Prep C18-S), eluting with a mixture of 82% acetonitril and 18% water to give compound <b>3</b> (0.43 g, 32.4%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 500 MHz) δ 9.93 (s, 2H), 7.51 (d, <i>J</i> = 8.5 Hz, 4H), 7.29 (d, <i>J</i> = 8.0 Hz, 2H), 7.15 (d, <i>J</i> = 8.5 Hz, 4H), 7.03 (d, <i>J</i> = 8.5 Hz, 2H), 6.28 (d, <i>J</i> = 8.5 Hz, 2H), 5.19 (d, <i>J</i> = 6.5 Hz, 2H), 4.43 (dd, <i>J</i> = 5.0 Hz, 8.0 Hz, 2H), 4.27 (d, <i>J</i> = 7.5 Hz, 2H), 3.68 (m, 2H), 3.54 (m, 2H), 3.49 (s, 6H), 3.47 (m, 2H), 3.26 (s, 6H), 2.46 (m, 2H), 2.07 (m, 2H), 1.99 (d, <i>J</i> = 6.5 Hz, 2H),1.90 (m, 2H), 1.88 (t, <i>J</i> = 5.0 Hz, 2H), 1.63 (d, <i>J</i> = 5.5 Hz, 2H), 1.15 (d, <i>J</i> = 6.0 Hz, 6H), 0.83 (t, <i>J</i> = 8.0 Hz, 9H), 0.60 (q, <i>J</i> = 8.0 Hz, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.6, 157.1, 145.7, 138.1, 134.8, 126.7, 119.6, 113.8, 76.8, 62.3, 60.6, 57.4, 56.6, 51.9, 47.8, 32.4, 29.9, 25.1, 15.9, 7.9, 3.5, 1.6; MS (ESI) <i>m</i>/<i>z</i>: 1006.5 [M + Na]<sup>+</sup>; HPLC: 99.9% purity; HRMS (ESI) <i>m</i>/<i>z</i> calcd for [M + H]<sup>+</sup> C<sub>52</sub>H<sub>73</sub>N<sub>7</sub>O<sub>10</sub>Si: 984.5266, found 984.5347.</div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Dimethyl ((2<i>S</i>,2′<i>S</i>,3<i>R</i>,3′<i>R</i>)-((2<i>S</i>,2′<i>S</i>)-(((((2<i>S</i>,5<i>S</i>)-1-(4-(<i>tert-</i>Butyldimethylsilyl)phenyl) Pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl))bis(carbonyl))bis(pyrrolidine-2,1-diyl))bis(3-methoxy-1-oxobutane-1,2-diyl))dicarbamate (<b>4</b>)</h4><div class="NLM_p last">A mixture of <b>13c</b> (0.50 g, 1.1 mmol), <i>N</i>-(methoxycarbonyl)-O-methyl-<span class="smallcaps smallerCapital">l</span>-threonyl-<span class="smallcaps smallerCapital">l</span>-proline (0.98 g, 3.3 mmol), EDCI (0.65 g, 3.3 mmol), HOBt (0.46 g, 3.3 mmol), and <i>N</i>-methylmorpholine (0.34 g, 3.3 mmol) in DMF (10 mL) was stirred at 60 °C for 2 h. The mixture was diluted with ethyl acetate (50 mL), washed with water and brine, and dried over sodium sulfate. The drying agent was filtered off, and the solvent was concentrated in vacuo. The residue was purified by column chromatography on silica gel using ethyl acetate and a C18 column (DAC 100 × 250 mm<sup>2</sup>, YMC Triart Prep C18-S), eluting with a mixture of 82% acetonitril and 18% water to give compound <b>4</b> (0.32 g, 29%) as a white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.90 (s, 2H), 7.43 (d, <i>J</i> = 8.0 Hz, 4H), 7.12–7.09 (m, 6H), 6.29 (d, <i>J</i> = 8.0 Hz, 2H), 5.72 (d, <i>J</i> = 7.5 Hz, 2H), 5.12 (d, <i>J</i> = 5.0 Hz, 2H), 4.81 (s, 2H), 4.67 (s, 2H), 3.78–3.68 (m, 10H), 3.40–3.33 (m, 6H), 2.49–2.44 (m, 4H), 2.09–2.03 (m, 8H), 1.74 (d, <i>J</i> = 4.5 Hz, 2H), 1.20 (d, <i>J</i> = 4.0 Hz, 6H), 0.78 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 170.3, 169.0, 156.8, 145.2, 139.7, 136.6, 135.0, 126.5, 121.9, 120.0, 113.3, 62.6, 60.8, 57.4, 55.5, 52.4, 48.0, 32.2, 27.5, 26.6, 24.9, 17.1, 14.7, 14.2, −6.1; MS (ESI) <i>m</i>/<i>z</i> 1006.5 (M + Na)<sup>+</sup>; HPLC: 98.4% purity; HRMS (ESI) <i>m</i>/<i>z</i> calcd for [M + H]<sup>+</sup> C<sub>52</sub>H<sub>73</sub>N<sub>7</sub>O<sub>10</sub>Si: 984.5266, found 984.5347.</div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 1-(2-Fluoro-4-nitrophenyl)-4,4-dimethyl-1,4-azasilinane (<b>17a</b>)</h4><div class="NLM_p last">To a suspension of 4,4-dimethyl-1,4-azasilinane hydrochloride (<b>15</b>, 19.3 g, 105.8 mmol) in DMF (200 mL) was added triethylamine (48.2 g, 349.1 mmol) dropwise at room temperature and stirred for 10 min. Then, 3,4-difluoronitrobenzene (16.8 g, 105.8 mmol) was added dropwise at 0 °C, and the mixture was stirred at room temperature overnight. The reaction solution was poured into water (1 L) and stirred for 10 min. The solid was collected by filtration and washed with water to give compound <b>17a</b> as a yellow solid (28.1 g, 99.0%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.91–7.95 (m, 2H), 7.10 (d, <i>J</i> = 9.5 Hz, 1H), 3.71 (t, <i>J</i> = 6.3 Hz, 4H), 0.86 (t, <i>J</i> = 6.3 Hz, 4H), 0.10 (s, 6H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 151.5, 144.3, 137.2, 122.1, 117.0, 113.3, 49.1, 13.7, −2.4; MS (ESI) <i>m</i>/<i>z</i> 269.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-(4,4-Dimethyl-1,4-azasilinan-1-yl)-3-fluoroaniline (<b>18a</b>)</h4><div class="NLM_p last">To a solution of 1-(2-fluoro-4-nitrophenyl)-4,4-dimethyl-1,4-azasilinane (<b>17a</b>, 28.0 g, 104.3 mmol) in THF (200 mL) was added 10% palladium on carbon (5.0 g). The reaction container was flushed with N<sub>2</sub>, and the mixture was stirred under 1 atm H<sub>2</sub> overnight. The mixture was filtered through Celite, and the filtrate was concentrated under vacuum to give a crude product that was purified by stirring in petroleum ether. The title compound was obtained as a white solid (22.1 g, 88.9%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.75–6.79 (m, 1H), 6.25–6.31 (m, 2H), 4.90 (s, 2H), 3.04–3.06 (m, 4H), 0.79–0.81 (m, 4H), 0.08 (s, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 155.8, 145.5, 131.8, 122.5, 109.9, 102.3, 52.2, 15.1, −2.4; MS (ESI) <i>m</i>/<i>z</i> 239.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 1-(4-((2S,5S)-2,5-Bis(4-nitrophenyl)pyrrolidin-1-yl)-2-fluorophenyl)-4,4-dimethyl-1,4-azasilinane (<b>19a</b>)</h4><div class="NLM_p last">The mixture of (1<i>R</i>,4<i>R</i>)-1,4-bis(4-nitrophenyl)butane-1,4-diyl dimethanesulfonate (1.5 g, 3.1 mmol) and 4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluoroaniline (<b>18a</b>, 7.32 g, 31 mmol) in DMF (15 mL) was stirred at 60 °C for 24 h. The reaction solution was poured into 2 N aq HCl (100 mL) and stirred for 10 min. The solid was collected by filtration and dissolved in dichloromethane (50 mL). The mixture was washed with water and dried over sodium sulfate, filtered, and concentrated under vacuum to give a crude product that was purified by column chromatography on silica gel using a solvent gradient of 10% ethyl acetate in petrol to give <b>19a</b> as a yellow solid (1.2 g, 75%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.24 (s, 4H), 7.36 (d, <i>J</i> = 8.0 Hz, 4H), 6.71 (s, 1H), 6.00 (m, 2H), 5.29 (s, 2H), 3.11 (s, 2H), 2.63 (s, 2H), 1.96 (s, 2H), 1.58 (m, 2H), 0.85 (m, 4H), 0.07 (s, 6H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 144.7, 126.8, 124.4, 63.4, 32.1, 27.1, 11.1, −3.0; MS (ESI) <i>m</i>/<i>z</i>: 535.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 4,4′-((2<i>S</i>,5<i>S</i>)-1-(4-(4,4-Dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)pyrrolidine-2,5-diyl)dianiline (<b>20a</b>)</h4><div class="NLM_p last">To a solution of <b>19a</b> (1.67 g, 3.13 mmol) in THF (20 mL) was added platinum dioxide (0.7 g, 3.13 mmol). The reaction container was flushed with N<sub>2</sub>, and the mixture was stirred under 1 atm H<sub>2</sub> for 3 h. The mixture was filtered through Celite, and the filtrate was concentrated under vacuum to give a crude product that was purified by column chromatography on silica gel using a solvent gradient of 0–20% ethyl acetate in petrol to give <b>20a</b> as a white solid (1.2 g, 81%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 6.95 (d, <i>J</i> = 8.0 Hz, 4H), 6.64 (d, <i>J</i> = 8.5 Hz, 4H), 6.06 (m, 3H), 4.98 (d, <i>J</i> = 7.0 Hz, 2H), 3.12 (s, 2H), 2.50 (s, 2H), 1.75 (d, <i>J</i> = 5.0 Hz, 2H), 1.26 (m, 2H), 0.88 (m, 4H), 0.12 (s, 6H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 159.7, 147.6, 137.3, 131.4, 126.9, 120.7, 115.5, 114.4, 108.1, 107.9, 62.6, 52.1, 50.9, 32.9, 15.1, 14.5, −2.4, −2.5; MS (ESI) <i>m</i>/<i>z</i> 475.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Dimethyl ((2<i>S</i>,2′<i>S</i>,3<i>R</i>,3′<i>R</i>)-((2<i>S</i>,2′<i>S</i>)-(((((2<i>S</i>,5<i>S</i>)-1-(4-(4,4-Dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl))bis(carbonyl)) bis(pyrrolidine-2,1-diyl))bis(3-methoxy-1-oxobutane-1,2-diyl))dicarbamate (<b>9</b>)</h4><div class="NLM_p last">The mixture of <b>20a</b> (0.53 g, 1.12 mmol), <i>N</i>-(methoxycarbonyl)-O-methyl-<span class="smallcaps smallerCapital">l</span>-threonyl-<span class="smallcaps smallerCapital">l</span>-proline (0.97 g, 3.35 mmol), EDCI (0.64 g, 3.35 mmol), HOBt (0.45 g, 3.35 mmol), and <i>N</i>-methylmorpholine (0.68 g, 6.75 mmol) in DMF (10 mL) was stirred at 55 °C for 12 h. The mixture was poured into water (50 mL). The solid was collected by filtration and dissolved in dichloromethane (50 mL). The mixture was washed with brine, dried over sodium sulfate, filtered, and concentrated under vacuum to give a crude product that was purified by column chromatography on silica gel using a solvent gradient of 0–66% ethyl acetate in petrol to give <b>9</b> as a white solid (0.5 g, 44%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 9.93 (s, 2H), 7.50 (d, <i>J</i> = 8.5 Hz, 4H), 7.29 (d, <i>J</i> = 8.0 Hz, 2H), 7.13 (d, <i>J</i> = 8.5 Hz, 4H), 6.71 (m, 1H), 5.96 (m, 2H), 5.13 (d, <i>J</i> = 6.0 Hz, 4H), 4.44 (m, 2H), 4.28 (m, 2H), 3.82 (m, 2H), 3.65 (m, 2H), 3.54 (s, 6H), 3.48 (m, 2H), 3.26 (s, 6H), 2.98 (m, 4H), 2.45 (m, 2H), 2.16 (m, 2H), 2.09 (m, 2H), 1.89 (m, 4H), 1.62 (d, <i>J</i> = 5.5 Hz, 2H), 1.14 (d, <i>J</i> = 6.0 Hz, 6H), 0.73 (t, <i>J</i> = 5.5 Hz, 2H), 0.04 (s, 6H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 170.6, 169.2, 157.1, 139.1, 138.1, 126.7, 119.7, 76.8, 62.6, 60.7, 57.4, 56.6, 52.0, 47.8, 32.6, 29.2, 25.1, 22.6, 16.0, 15.0, 14.4, −2.5; MS (ESI) <i>m</i>/<i>z</i> 1015.7 [M + H]<sup>+</sup>; HPLC: 96.0% purity; HRMS (ESI) <i>m</i>/<i>z</i> calcd for [M + H]<sup>+</sup> C<sub>52</sub>H<sub>71</sub>FN<sub>8</sub>O<sub>10</sub>Si: 1015.5124, found 1015.5170.</div></div><div id="sec5_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 1-(2,6-Difluoro-4-nitrophenyl)-4,4-dimethyl-1,4-azasilinane (<b>17b</b>)</h4><div class="NLM_p last">To a suspension of 4,4-dimethyl-1,4-azasilinane hydrochloride (20.6 g, 124.4 mmol) in DMF (200 mL) was added triethylamine (51.6 g, 3373.0 mmol) dropwise at room temperature and stirred for 10 min. Then, 3,4,5-trifluoronitrobenzene (20.0 g, 113.0 mmol) was added dropwise at 0 °C, and the mixture was stirred at room temperature overnight. The reaction solution was poured into water (1 L) and stirred for 10 min. The solid was collected by filtration and washed with water to give compound <b>17b</b> as a yellow solid (31.2 g, 96.4%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.93 (dd, <i>J</i> = 10.0 Hz, 1.0 Hz, 2H), 3.49–3.51 (m, 4H), 0.85–0.88 (m, 4H), 0.12 (s, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 155.8, 153.9, 136.6, 109.4, 50.8, 15.1, −2.6; MS (ESI) <i>m</i>/<i>z</i> 287.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 4-(4,4-Dimethyl-1,4-azasilinan-1-yl)-3,5-difluoroaniline (<b>18b</b>)</h4><div class="NLM_p last">To a solution of 1-(2,6-difluoro-4-nitrophenyl)-4,4-dimethyl-1,4-azasilinane (31.0 g, 108.3 mmol) in THF (200 mL) was added 10% palladium on carbon (5.0 g). The reaction container was flushed with N<sub>2</sub>, and the mixture was stirred under 1 atm H<sub>2</sub> overnight. The mixture was filtered through Celite, and the filtrate was concentrated under vacuum to give a crude product that was purified by stirring in petroleum ether. The title compound was obtained as a white solid (23.4 g, 84.3%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 6.10–6.12 (m, 2H), 5.34 (s, 2H), 3.10–3.13 (m, 4H), 0.77–0.79 (m, 4H), 0.08 (s, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i>) δ 161.2, 159.3, 118.9, 97.3, 52.4, 15.7, −2.4; MS (ESI) <i>m</i>/<i>z</i> 257.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 1-(4-((2<i>R</i>,5<i>R</i>)-2,5-Bis(4-nitrophenyl)pyrrolidin-1-yl)-2-fluorophenyl)-4,4-dimethyl-1,4-azasilinane (<b>19b</b>)</h4><div class="NLM_p last">The mixture of (1<i>S</i>,4<i>S</i>)-1,4-bis(4-nitrophenyl)butane-1,4-diyl dimethanesulfonate (2.5 g, 5.1 mmol) and 4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluoroaniline (9.8 g, 40.9 mmol) in DMF (20 mL) was stirred at 60 °C for 24 h. The reaction solution was poured into 2 N aq HCl (100 mL) and stirred for 10 min. The solid was collected by filtration and dissolved in dichloromethane (50 mL). The mixture was washed with water, dried over sodium sulfate, filtered, and concentrated under vacuum to give a crude product that was purified by column chromatography on silica gel using a solvent gradient of 10% ethyl acetate in petrol to give <b>19b</b> as a brown solid (1.5 g, 53.6%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.21 (d, <i>J</i> = 5.5 Hz, 4H), 7.37 (d, <i>J</i> = 6.5 Hz, 4H), 6.74 (s, 1H), 5.99 (m, 2H), 5.28 (s, 2H), 3.11 (s, 2H), 2.59 (s, 2H), 1.89 (s, 2H), 1.58 (s, 2H), 0.85 (s, 4H), 0.07 (s, 6H); <sup>13</sup> C NMR (125 MHz, CDCl<sub>3</sub>) δ 147.4, 127.0, 124.1, 121.8, 109.1, 62.9, 51.9, 32.2, 14.8, −3.1; MS (ESI) <i>m</i>/<i>z</i>: 535.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 4,4′-((2<i>R</i>,5<i>R</i>)-1-(4-(4,4-Dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)pyrrolidine-2,5-diyl)dianiline (<b>20b</b>)</h4><div class="NLM_p last">To a solution of <b>19b</b> (1.5 g, 2.72 mmol) in THF (20 mL) was added platinum dioxide (0.3 g, 1.36 mmol). The reaction container was flushed with N<sub>2</sub>, and the mixture was stirred under 1 atm H<sub>2</sub> for 3 h. The mixture was filtered through Celite, and the filtrate was concentrated under vacuum to give a crude product that was purified by column chromatography on silica gel using a solvent gradient of 0–20% ethyl acetate in petrol to give <b>20b</b> as a white solid (0.6 g, 46.5%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 6.95 (d, <i>J</i> = 8.0 Hz, 4H), 6.64 (d, <i>J</i> = 8.0 Hz, 4H), 6.05 (m, 3H), 4.98 (s, 2H), 3.11 (s, 4H), 2.49 (s, 2H), 1.74 (s, 2H), 0.85 (m, 4H), 0.09 (s, 6H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 144.9, 127.0, 115.3, 102.2, 62.9, 32.6, 29.7, −3.0; MS (ESI) <i>m</i>/<i>z</i>: 475.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Dimethyl ((2S,2′S,3R,3′R)-((2S,2′S)-(((((2R,5R)-1-(4-(4,4-Dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene)) bis(azanediyl))bis(carbonyl))bis (pyrrolidine-2,1-diyl))bis(3-methoxy-1-oxobutane-1,2-diyl))dicarbamate (<b>10</b>)</h4><div class="NLM_p last">The mixture of <b>20b</b> (0.55 g, 1.2 mmol), <i>N</i>-(methoxycarbonyl)-O-methyl-<span class="smallcaps smallerCapital">l</span>-threonyl-<span class="smallcaps smallerCapital">l</span>-proline (1.0 g, 3.5 mmol), EDCI (0.67 g, 3.5 mmol), HOBt (0.5 g, 3.5 mmol), and <i>N</i>-methylmorpholine (0.71 g, 7 mmol) in DMF (10 mL) was stirred at 55 °C for 12 h. The mixture was poured into water (50 mL). The solid was collected by filtration and dissolved in dichloromethane (50 mL). The mixture was washed with brine, dried over sodium sulfate, filtered, and concentrated under vacuum to give a crude product that was purified by column chromatography on silica gel using a solvent gradient of 0–66% ethyl acetate in petrol to give <b>10</b> as a white solid (0.55 g, 46.6%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.94 (s, 2H), 7.51 (d, <i>J</i> = 8.5 Hz, 4H), 7.29 (d, <i>J</i> = 7.5 Hz, 2H), 7.13 (d, <i>J</i> = 8.5 Hz, 4H), 6.70 (m, 1H), 5.96 (m, 2H), 5.13 (d, <i>J</i> = 6.0 Hz, 2H), 4.44 (dd, <i>J</i> = 5.0 Hz, 8.0 Hz, 2H), 4.28 (t, <i>J</i> = 7.5 Hz, 2H), 3.69 (m, 2H), 3.54 (m, 2H), 3.49 (s, 6H), 3.47 (d, <i>J</i> = 6.5 Hz, 2H), 3.25 (s, 6H), 2.98 (m, 4H), 2.44 (m, 2H), 2.15 (m, 2H), 2.00 (d, <i>J</i> = 6.0 Hz, 2H), 1.89 (m, 4H), 1.62 (d, <i>J</i> = 5.5 Hz, 2H), 1.13 (d, <i>J</i> = 6.5 Hz, 6H), 0.74 (t, <i>J</i> = 6.0 Hz, 4H), 0.04 (s, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.6, 169.2, 157.2, 155.3, 141.7, 139.1, 138.1, 131.1, 126.7, 122.1, 119.6, 109.5, 101.9, 76.8, 62.5, 60.7, 57.5, 56.6, 52.0, 47.8, 32.6, 29.9, 25.1, 16.0, 15.0, 1.6, −2.5; MS (ESI) <i>m</i>/<i>z</i>: 1037.50 [M + Na]<sup>+</sup>; HPLC: 97.9% purity; HRMS (ESI)<i>m</i>/<i>z</i> calcd for [M + H]<sup>+</sup> C<sub>52</sub>H<sub>71</sub>FN<sub>8</sub>O<sub>10</sub>Si: 1015.5124, found 1015.5170.</div></div><div id="sec5_4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 1-(4-((2<i>S</i>,5<i>S</i>)-2,5-Bis(4-nitrophenyl)pyrrolidin-1-yl)-2,6-difluorophenyl)-4,4-dimethyl-1,4-azasilinane (<b>19c</b>)</h4><div class="NLM_p last">The mixture of (1<i>R</i>,4<i>R</i>)-1,4-bis(4-nitrophenyl)butane-1,4-diyl dimethanesulfonate (1.5 g, 3.0 mmol) and 4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3,5-difluoroaniline (7.88 g, 30.71 mmol) in DMF (10 mL) was stirred at 60 °C for 24 h. The reaction solution was poured into 2 N aq HCl (200 mL) and stirred for 10 min. The solid was collected by filtration and dissolved in dichloromethane (50 mL). The mixture was washed with water, dried over sodium sulfate, filtered, and concentrated under vacuum to give a crude product that was purified by column chromatography on silica gel using a solvent gradient of 10% ethyl acetate in petrol to give <b>19c</b> as a yellow solid (1.2 g, 70.6%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.24 (d, <i>J</i> = 8.5 Hz, 4H), 7.37 (d, <i>J</i> = 8.5 Hz, 4H), 5.78 (d, <i>J</i> = 11.5 Hz, 2H), 5.25 (d, <i>J</i> = 6.5 Hz, 2H), 3.29 (s, 4H), 2.60 (s, 2H), 2.06 (s, 2H), 0.97 (s, 4H), 0.10 (s, 6H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 149.7, 147.4, 126.8, 124.3, 97.9, 97.7, 63.0, 53.1, 32.1, 14.6, −3.2; MS (ESI) <i>m</i>/<i>z</i>: 553.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 4,4′-((2<i>S</i>,5<i>S</i>)-1-(4-(4,4-Dimethyl-1,4-azasilinan-1-yl)-3,5-difluorophenyl)pyrrolidine-2,5-diyl)dianiline (<b>20c</b>)</h4><div class="NLM_p last">To a solution of <b>19c</b> (2.1 g, 3.8 mmol) in THF (20 mL) was added platinum dioxide (0.43 g, 1.9 mmol). The reaction container was flushed with N<sub>2</sub>, and the mixture was stirred under 1 atm H<sub>2</sub> for 3 h. The mixture was filtered through Celite, and the filtrate was concentrated under vacuum to give a crude product that was purified by column chromatography on silica gel using a solvent gradient of 0–20% ethyl acetate in petrol to give <b>20c</b> as a white solid (0.72 g, 40%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 6.94 (d, <i>J</i> = 8.0 Hz, 4H), 6.65 (d, <i>J</i> = 8.5 Hz, 4H), 5.82 (d, <i>J</i> = 12.0 Hz, 2H), 4.95 (d, <i>J</i> = 5.5 Hz, 2H), 3.17 (s, 4H), 2.49 (s, 2H), 1.73 (d, <i>J</i> = 5.5 Hz, 2H), 0.82 (s, 4H), 0.07 (s, 6H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 160.8, 158.9, 145.0, 142.6, 133.2, 126.9, 115.4, 97.3, 63.0, 52.3, 32.6, 15.5, 14.1, −3.0; MS (ESI) <i>m</i>/<i>z</i>: 493.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Dimethyl ((2<i>S</i>,2′<i>S</i>,3<i>R</i>,3′<i>R</i>)-((2<i>S</i>,2′<i>S</i>)-(((((2<i>S</i>,5<i>S</i>)-1-(4-(4,4-Dimethyl-1,4-azasilinan-1-yl)-3,5-difluorophenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl))bis(carbonyl))bis(pyrrolidine-2,1-diyl))bis(3-methoxy-1-oxobutane-1,2-diyl))dicarbamate (<b>11</b>)</h4><div class="NLM_p last">The mixture of <b>20c</b> (0.50 g, 1.02 mmol), <i>N</i>-(methoxycarbonyl)-O-methyl-<span class="smallcaps smallerCapital">l</span>-threonyl-<span class="smallcaps smallerCapital">l</span>-proline (0.9 g, 3.05 mmol), EDCI (0.58 g, 3.05 mmol), HOBt (0.42 g, 3.05 mmol), and <i>N</i>-methylmorpholine (0.62 g, 6.1 mmol) in DMF (10 mL) was stirred at 55 °C for 12 h. The mixture was poured into water (50 mL). The solid was collected by filtration and dissolved in dichloromethane (50 mL). The mixture was washed with brine, dried over sodium sulfate, filtered, and concentrated under vacuum to give a crude product that was purified by column chromatography on silica gel using a solvent gradient of 0–66% ethyl acetate in petrol to give <b>11</b> as a white solid (0.6 g, 57.1%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.95 (s, 2H), 7.52 (d, <i>J</i> = 8.5 Hz, 4H), 7.29 (d, <i>J</i> = 8.0 Hz, 2H), 7.14 (d, <i>J</i> = 8.5 Hz, 4H), 5.81 (d, <i>J</i> = 12.5 Hz, 2H), 5.15 (d, <i>J</i> = 6.0 Hz, 2H), 4.44 (dd, <i>J</i> = 4.5 Hz, 8.0 Hz, 2H), 4.28 (d, <i>J</i> = 8.0 Hz, 2H), 3.83 (m, 2H), 3.68 (d, <i>J</i> = 7.0 Hz, 2H), 3.54 (s, 6H), 3.49 (t, <i>J</i> = 6.5 Hz, 2H), 3.23 (s, 6H), 3.04 (t, <i>J</i> = 5.5 Hz, 4H), 2.45 (m, 2H), 2.16 (m, 2H), 2.00 (d, <i>J</i> = 6.0 Hz, 2H), 1.90 (m, 4H), 1.62 (d, <i>J</i> = 5.5 Hz, 2H), 1.15 (d, <i>J</i> = 6.0 Hz, 6H), 0.71 (t, <i>J</i> = 6.0 Hz, 4H), 0.04 (s, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.6, 169.2, 160.7, 158.8, 157.1, 142.8, 138.5, 126.7, 119.7, 118.7, 97.7, 76.8, 62.6, 60.7, 57.4, 56.6, 52.3, 47.8, 32.5, 29.9, 25.1, 16.0; MS (ESI) <i>m</i>/<i>z</i>: 1055.3 [M + Na]<sup>+</sup>; HPLC: 98.2% purity; HRMS (ESI) <i>m</i>/<i>z</i> calcd for [M + H]<sup>+</sup> C<sub>52</sub>H<sub>70</sub>F<sub>2</sub>N<sub>8</sub>O<sub>10</sub>Si: 1033.5030, found 1033.5068.</div></div><div id="sec5_4_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 1-(4-((2<i>R</i>,5<i>R</i>)-2,5-Bis(4-nitrophenyl)pyrrolidin-1-yl)-2,6-difluorophenyl)-4,4-dimethyl-1,4-azasilinane (<b>19d</b>)</h4><div class="NLM_p last">The mixture of (1<i>S</i>,4<i>S</i>)-1,4-bis(4-nitrophenyl)butane-1,4-diyl dimethanesulfonate (2.0 g, 4.09 mmol) and 4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3,5-difluoroaniline (8.4 g, 32.75 mmol) in DMF (20 mL) was stirred at 60 °C for 24 h. The reaction solution was poured into 2 N aq HCl (50 mL) and stirred for 10 min. The mixture was partitioned between water and ethyl acetate (20 mL × 2). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under vacuum. The crude product was purified by column chromatography on silica gel using a solvent gradient of 10% ethyl acetate in petrol to give <b>19d</b> as a yellow solid (2.0 g, 88%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.31–8.24 (m, 4H), 7.60–7.58 (m, 2H), 7.38–7.36 (m, 4H), 5.76 (d, <i>J</i> = 11 Hz, 2H), 3.30–3.20 (m, 4H), 2.70–2.60 (m, 3H), 2.03–2.02 (m, 1H), 0.92–0.90 (m, 4H), 0.09 (s, 6H); MS (ESI) <i>m</i>/<i>z</i> 553.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_4_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4,4′-((2<i>R</i>,5<i>R</i>)-1-(4-(4,4-Dimethyl-1,4-azasilinan-1-yl)-3,5-difluorophenyl)pyrrolidine-2,5-diyl)dianiline (<b>20d</b>)</h4><div class="NLM_p last">To a solution of <b>19d</b> (2.0 g, 3.62 mmol) in THF (20 mL) was added platinum dioxide (0.82 g, 3.62 mmol). The reaction container was flushed with N<sub>2</sub>, and the mixture was stirred under 1 atm H<sub>2</sub> for 3 h. The mixture was filtered through Celite, and the filtrate was concentrated under vacuum to give a crude product that was purified by column chromatography on silica gel using a solvent gradient of 0–20% ethyl acetate in petrol to give <b>20c</b> as a white solid (0.95 g, 53%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 6.95 (d, <i>J</i> = 8 Hz, 4H), 6.66 (d, <i>J</i> = 8 Hz, 4H), 5.82 (d, <i>J</i> = 11.5 Hz, 2H), 4.95 (d, <i>J</i> = 6 Hz, 2H), 3.17–3.15 (m, 4H), 2.51–2.47 (m, 2H), 1.74–1.72 (m, 2H), 0.83–0.81 (m, 4H), 0.08 (s, 6H); MS(ESI) <i>m</i>/<i>z</i> 493.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_4_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Dimethyl ((2<i>S</i>,2′<i>S</i>,3<i>R</i>,3<i><i>′</i>R</i>)-((2<i>S</i>,2′<i>S</i>)-(((((2<i>R</i>,5<i>R</i>)-1-(4-(4,4-Dimethyl-1,4-azasilinan-1-yl)-3,5-difluorophenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl))bis(carbonyl)) bis(pyrrolidine-2,1-diyl))bis(3-methoxy-1-oxobutane-1,2-diyl))dicarbamate (<b>12</b>)</h4><div class="NLM_p last">The mixture of <b>20d</b> (0.40 g, 0.81 mmol), <i>N</i>-(methoxycarbonyl)-O-methyl-<span class="smallcaps smallerCapital">l</span>-threonyl-<span class="smallcaps smallerCapital">l</span>-proline (0.70 g, 2.44 mmol), EDCI (0.47 g, 2.44 mmol), HOBt (0.33 g, 3.44 mmol), and <i>N</i>-methylmorpholine (0.41 g, 4.05 mmol) in DMF (10 mL) was stirred at 60 °C for 1 h. The mixture was poured into water (30 mL). The mixture was partitioned between water and ethyl acetate (20 mL × 2). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under vacuum. The crude product was purified by column chromatography on silica gel using a solvent gradient of 66% ethyl acetate in petrol to give <b>12</b> as a white solid (0.32 g, 38%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.94 (s, 2H), 7.51 (d, <i>J</i> = 8.5 Hz, 4H), 7.29 (d, <i>J</i> = 7.5 Hz, 2H), 7.13 (d, <i>J</i> = 8.5 Hz, 4H), 6.70 (m, 1H), 5.96 (m, 2H), 5.13 (d, <i>J</i> = 6.0 Hz, 2H), 4.44 (dd, <i>J</i> = 5.0 Hz, 8.0 Hz, 2H), 4.28 (t, <i>J</i> = 7.5 Hz, 2H), 3.69 (m, 2H), 3.54 (m, 2H), 3.49 (s, 6H), 3.47 (d, <i>J</i> = 6.5 Hz, 2H), 3.25 (s, 6H), 2.98 (m, 4H), 2.44 (m, 2H), 2.15 (m, 2H), 2.00 (d, <i>J</i> = 6.0 Hz, 2H), 1.89 (m, 4H), 1.62 (d, <i>J</i> = 5.5 Hz, 2H), 1.13 (d, <i>J</i> = 6.5 Hz, 6H), 0.73 (t, <i>J</i> = 6.0 Hz, 4H), 0.04 (s, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.6, 169.2, 157.2, 155.3, 141.7, 139.1, 138.1, 131.1, 126.7, 122.1, 119.6, 109.5, 101.9, 76.8, 62.5, 60.6, 57.5, 56.6, 52.0, 47.8, 32.6, 29.9, 25.1, 16.0, 15.0, 1.6, −2.5; MS (ESI) <i>m</i>/<i>z</i>: 1055.50 [M + Na]<sup>+</sup>; HPLC: 96.73% purity; HRMS (ESI) <i>m</i>/<i>z</i> calcd for [M + H]<sup>+</sup> C<sub>52</sub>H<sub>70</sub>F<sub>2</sub>N<sub>8</sub>O<sub>10</sub>Si: 1033.5030, found 1033.5134.</div></div><div id="sec5_4_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Dimethyl ((2<i>S</i>,2′<i>S</i>)-((2<i>S</i>,2′<i>S</i>)-(((((2<i>S</i>,5<i>S</i>)-1-(4-(4,4-Dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl))bis(carbonyl))bis (pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-1,2-diyl))dicarbamate (<b>5</b>)</h4><div class="NLM_p last">It was prepared from <b>20a</b> and (methoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-valyl-<span class="smallcaps smallerCapital">l</span>-proline (<b>21</b>) in the same method as <b>9</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.97 (s, 2H), 7.50 (d, <i>J</i> = 8.5 Hz, 4H), 7.28 (d, <i>J</i> = 8.5 Hz, 2H), 7.13 (d, <i>J</i> = 8.5 Hz, 4H), 6.71–6.72 (m, 1H), 5.95–6.05 (m, 2H), 5.12 (d, <i>J</i> = 6.5 Hz, 2H), 4.44–4.43 (m, 2H), 4.04–4.10 (m, 2H), 3.82–3.75 (m, 2H), 3.65–3.65 (m, 2H), 3.53 (s, 6H), 3.41–3.31 (m, 2H), 2.97–2.98 (m, 4H), 2.44–2.48 (m, 2H), 2.16–2.14 (m, 2H), 2.09–1.87 (m, 8H), 1.62 (d, <i>J</i> = 5.5 Hz, 2H), 0.95–0.86 (m, 12H), 0.73 (t, <i>J</i> = 6.3 Hz, 2H), 0.04 (s, 6H); HPLC: 99.8% purity; HRMS (ESI) <i>m</i>/<i>z</i>: calcd for [M + H]<sup>+</sup> C<sub>52</sub>H<sub>71</sub>FN<sub>8</sub>O<sub>8</sub>Si: 983.5148, found 983.5158.</div></div><div id="sec5_4_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Dimethyl ((2<i>S</i>,2′<i>S</i>)-((2<i>S</i>,2′<i>S</i>)-(((((2<i>R</i>,5<i>R</i>)-1-(4-(4,4-Dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl))bis(carbonyl))bis (pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-1,2-diyl))dicarbamate (<b>6</b>)</h4><div class="NLM_p last">It was prepared from <b>20b</b> and (methoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-valyl-<span class="smallcaps smallerCapital">l</span>-proline (<b>21</b>) in the same method as <b>10</b>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 500 MHz) δ 9.98 (s, 2H), 7.51 (d, <i>J</i> = 8.0 Hz, 4H), 7.27 (d, <i>J</i> = 8.5 Hz, 2H), 7.13 (d, <i>J</i> = 8.0 Hz, 4H), 5.89–6.09 (m, 3H), 5.15–5.21 (m, 2H), 4.44 (dd, <i>J</i> = 5.0 Hz, 8.0 Hz, 2H), 4.04 (t, <i>J</i> = 8.5 Hz, 2H), 3.75–3.85 (m, 2H), 3.63–3.69 (m, 2H), 3.63–3.58 (m, 3H), 3.53 (s, 6H), 3.10–2.95 (m, 1H), 2.51–2.44 (m, 2H), 2.15–1.86 (m, 10H), 1.65–1.55 (m, 2H), 0.94–0.86 (m, 16H), 0.06 (s, 6H); HPLC: 99.7% purity; HRMS (ESI) <i>m</i>/<i>z</i>: calcd for [M + H]<sup>+</sup> C<sub>52</sub>H<sub>71</sub>FN<sub>8</sub>O<sub>8</sub>Si: 983.5148, found 983.5143.</div></div><div id="sec5_4_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Dimethyl ((2<i>S</i>,2′<i>S</i>)-((2<i>S</i>,2′<i>S</i>)-(((((2<i>S</i>,5<i>S</i>)-1-(4-(4,4-Dimethyl-1,4-azasilinan-1-yl)-3,5-difluorophenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl))bis(carbonyl))bis (pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-1,2-diyl))dicarbamate (<b>7</b>)</h4><div class="NLM_p last">It was prepared from <b>20c</b> and (methoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-valyl-<span class="smallcaps smallerCapital">l</span>-proline (<b>21</b>) in the same method as <b>11</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.98 (s, 2H), 7.52 (d, <i>J</i> = 8.5 Hz, 4H), 7.28 (d, <i>J</i> = 8.5 Hz, 2H), 7.13 (d, <i>J</i> = 8.5 Hz, 4H), 5.95–6.05 (m, 2H), 5.15 (d, <i>J</i> = 6.5 Hz, 2H), 4.45–4.43 (m, 2H), 4.11–4.07 (m, 2H), 3.82–3.75 (m, 2H), 3.65–3.63 (m, 2H), 3.53 (s, 6H), 3.41–3.31 (m, 2H), 2.97–2.98 (m, 4H), 2.44–2.48 (m, 2H), 2.16–2.14 (m, 2H), 2.09–1.87 (m, 8H), 1.62 (d, <i>J</i> = 5.5 Hz, 2H), 0.95–0.86 (m, 12H), 0.73 (t, <i>J</i> = 6.3 Hz, 2H), 0.04 (s, 6H); HPLC: 99.6% purity; HRMS (ESI) <i>m</i>/<i>z</i>: calcd for [M + H]<sup>+</sup> C<sub>52</sub>H<sub>70</sub>F<sub>2</sub>N<sub>8</sub>O<sub>8</sub>Si: 1001.5054, found 1001.5092.</div></div><div id="sec5_4_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Dimethyl ((2<i>S</i>,2′<i>S</i>)-((2<i>S</i>,2′<i>S</i>)-(((((2<i>R</i>,5<i>R</i>)-1-(4-(4,4-Dimethyl-1,4-azasilinan-1-yl)-3,5-difluorophenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl))bis(carbonyl))bis (pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-1,2-diyl))dicarbamate (<b>8</b>)</h4><div class="NLM_p last">It was prepared from <b>20d</b> and (methoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-valyl-<span class="smallcaps smallerCapital">l</span>-proline (<b>21</b>) in the same method as <b>12</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.99 (s, 2H), 7.53 (d, <i>J</i> = 8.5 Hz, 4H), 7.28 (d, <i>J</i> = 8.5 Hz, 2H), 7.13 (d, <i>J</i> = 8.5 Hz, 4H), 5.80 (d, <i>J</i> = 7.0 Hz, 2H), 5.15 (d, <i>J</i> = 6.5 Hz, 2H), 4.45–4.43 (m, 2H), 4.04 (t, <i>J</i> = 8.5 Hz, 2H), 3.82–3.75 (m, 2H), 3.65–3.63 (m, 2H), 3.53 (s, 6H), 3.12–3.02 (m, 6H), 2.97–2.98 (m, 4H), 2.20–1.87 (m, 14H), 1.62 (d, <i>J</i> = 5.5 Hz, 2H), 0.94–0.84 (m, 12H), 0.73 (t, <i>J</i> = 6.3 Hz, 2H), 0.04 (s, 6H); HPLC: 99.4% purity; HRMS (ESI) <i>m</i>/<i>z</i>: calcd for [M + H]<sup>+</sup> C<sub>52</sub>H<sub>70</sub>F<sub>2</sub>N<sub>8</sub>O<sub>8</sub>Si: 1001.5054, found 1001.5083.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00082" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48831" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48831" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00082?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00082</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings, HPLC spectrum of targeted compounds; <sup>1</sup>H and <sup>13</sup>C NMR spectra for compound <b>11</b>; body and organ weights; hematology data for mouse orally treated with <b>11</b> for 14 days; blood chemistry data for mouse orally treated with <b>11</b> for 14 days (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00082/suppl_file/jm0c00082_si_001.zip" class="ext-link">ZIP</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00082/suppl_file/jm0c00082_si_001.zip">jm0c00082_si_001.zip (1.43 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00082" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14404" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14404" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yinsheng Zhang</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 1099 Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5390-671X" title="Orcid link">http://orcid.org/0000-0001-5390-671X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6913101a290a1d1d18470a0604"><span class="__cf_email__" data-cfemail="502a292310332424217e333f3d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Baomin Liu</span> - <span class="hlFld-Affiliation affiliation">Institute
for Innovative Drug Discovery, Jiangsu Key Laboratory of Targeted
Antiviral Research, Chia Tai Tianqing Pharmaceutical
Group Co., Ltd., 1099
Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kuo Gai</span> - <span class="hlFld-Affiliation affiliation">Institute
for Innovative Drug Discovery, Jiangsu Key Laboratory of Targeted
Antiviral Research, Chia Tai Tianqing Pharmaceutical
Group Co., Ltd., 1099
Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui Qin</span> - <span class="hlFld-Affiliation affiliation">Institute
for Innovative Drug Discovery, Jiangsu Key Laboratory of Targeted
Antiviral Research, Chia Tai Tianqing Pharmaceutical
Group Co., Ltd., 1099
Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jie Wang</span> - <span class="hlFld-Affiliation affiliation">Institute
for Innovative Drug Discovery, Jiangsu Key Laboratory of Targeted
Antiviral Research, Chia Tai Tianqing Pharmaceutical
Group Co., Ltd., 1099
Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xushi Liu</span> - <span class="hlFld-Affiliation affiliation">Institute
for Innovative Drug Discovery, Jiangsu Key Laboratory of Targeted
Antiviral Research, Chia Tai Tianqing Pharmaceutical
Group Co., Ltd., 1099
Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuan Cao</span> - <span class="hlFld-Affiliation affiliation">Institute
of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted
Antiviral Research, Chia Tai Tianqing Pharmaceutical
Group Co., Ltd., 1099
Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qin Lu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted
Antiviral Research, Chia Tai Tianqing Pharmaceutical
Group Co., Ltd., 1099
Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dandan Lu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted
Antiviral Research, Chia Tai Tianqing Pharmaceutical
Group Co., Ltd., 1099
Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deyang Chen</span> - <span class="hlFld-Affiliation affiliation">Institute
of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted
Antiviral Research, Chia Tai Tianqing Pharmaceutical
Group Co., Ltd., 1099
Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hengqiao Shen</span> - <span class="hlFld-Affiliation affiliation">Institute
of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted
Antiviral Research, Chia Tai Tianqing Pharmaceutical
Group Co., Ltd., 1099
Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Song</span> - <span class="hlFld-Affiliation affiliation">Institute
of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted
Antiviral Research, Chia Tai Tianqing Pharmaceutical
Group Co., Ltd., 1099
Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jia Mei</span> - <span class="hlFld-Affiliation affiliation">Institute
of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted
Antiviral Research, Chia Tai Tianqing Pharmaceutical
Group Co., Ltd., 1099
Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaojin Wang</span> - <span class="hlFld-Affiliation affiliation">Institute
of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted
Antiviral Research, Chia Tai Tianqing Pharmaceutical
Group Co., Ltd., 1099
Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongjiang Xu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Drug Screening and Evaluation, Jiangsu Key Laboratory of Targeted
Antiviral Research, Chia Tai Tianqing Pharmaceutical
Group Co., Ltd., 1099
Fuying Road, Jiangning District, Nanjing 211122, Jiangsu Province, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e3992-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04720" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04720" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This study was partially supported by the Natural Science Foundation of Jiangsu Province (Grant No. BK20170454), China Postdoctoral Science Foundation (Grant No. 2019M651989), and Department of Science and Technology of Jiangsu Province (Sukyyz [2019] No. 1627).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">GT</td><td class="NLM_def"><p class="first last">genotype</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">CLp</td><td class="NLM_def"><p class="first last">systemic clearance</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06205" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06205" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 24 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">World
Health Organization</span>,  <i>Global Hepatitis Report 2017</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=World%0AHealth+Organization&title=Global+Hepatitis+Report+2017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26btitle%3DGlobal%2520Hepatitis%2520Report%25202017%26pub%3DWorld%2520Health%2520Organization%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hajarizadeh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grebely, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, G. J.</span></span> <span> </span><span class="NLM_article-title">Epidemiology and natural history of HCV infection</span>. <i>Nat. Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">553</span>, <span class="refDoi"> DOI: 10.1038/nrgastro.2013.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1038%2Fnrgastro.2013.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=23817321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWru77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=553&author=B.+Hajarizadehauthor=J.+Grebelyauthor=G.+J.+Dore&title=Epidemiology+and+natural+history+of+HCV+infection&doi=10.1038%2Fnrgastro.2013.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology and natural history of HCV infection</span></div><div class="casAuthors">Hajarizadeh, Behzad; Grebely, Jason; Dore, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">553-562</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Worldwide, an estd. 130-170 million people have HCV infection.  HCV prevalence is highest in Egypt at >10% of the general population and China has the most people with HCV (29.8 million).  Differences in past HCV incidence and current HCV prevalence, together with the generally protracted nature of HCV disease progression, has led to considerable diversity in the burden of advanced liver disease in different countries.  Countries with a high incidence of HCV or peak incidence in the recent past will have further escalations in HCV-related cirrhosis and hepatocellular carcinoma (HCC) over the next two decades.  Acute HCV infection is difficult to detect because of the generally asymptomatic nature of the disease and the marginalization of at-risk populations.  Around 25% of patients with acute HCV infection undergo spontaneous clearance, with increased rates among those with favorable IL28B genotypes, acute symptoms and in women.  The remaining 75% of patients progress to chronic HCV infection and are subsequently at risk of progression to hepatic fibrosis, cirrhosis and HCC.  Chronic hepatitis C generally progresses slowly in the initial two decades, but can be accelerated during this time as a result of advancing age and co-factors such as heavy alc. intake and HIV co-infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAGJrt4DO4BLVg90H21EOLACvtfcHk0lia5EadrEI2Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWru77F&md5=1542a3394c3bd84018527b88232950d4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2013.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2013.107%26sid%3Dliteratum%253Aachs%26aulast%3DHajarizadeh%26aufirst%3DB.%26aulast%3DGrebely%26aufirst%3DJ.%26aulast%3DDore%26aufirst%3DG.%2BJ.%26atitle%3DEpidemiology%2520and%2520natural%2520history%2520of%2520HCV%2520infection%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2013%26volume%3D10%26spage%3D553%26doi%3D10.1038%2Fnrgastro.2013.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. J.</span></span> <span> </span><span class="NLM_article-title">Interferon-free combination therapies for the treatment of hepatitis C: current insights</span>. <i>Hepatic Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">51</span>, <span class="refDoi"> DOI: 10.2147/HMER.S55864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.2147%2FHMER.S55864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=26586968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A280%3ADC%252BC28rgsVSqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=51&author=J.+A.+Holmesauthor=A.+J.+Thompson&title=Interferon-free+combination+therapies+for+the+treatment+of+hepatitis+C%3A+current+insights&doi=10.2147%2FHMER.S55864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon-free combination therapies for the treatment of hepatitis C: current insights</span></div><div class="casAuthors">Holmes Jacinta A; Thompson Alexander J</div><div class="citationInfo"><span class="NLM_cas:title">Hepatic medicine : evidence and research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-70</span>
        ISSN:<span class="NLM_cas:issn">1179-1535</span>.
    </div><div class="casAbstract">The hepatitis C virus (HCV) treatment landscape has rapidly changed over the past 5 years.  The development of direct-acting antiviral (DAA) agents that specifically target various steps in the HCV lifecycle has revolutionized therapeutic options for patients with HCV, with the development of highly effective and well-tolerated oral interferon-free regimens.  There are many DAAs that are currently in development or have recently been approved, which target different nonstructural HCV proteins and host targets that are essential for HCV replication.  This review will focus on the different classes of DAAs and the various combinations that are in advanced development for the treatment of chronic HCV infection and will focus on the different regimens in specific patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSaWQI_kNsvcFvAgqb2vdc5fW6udTcc2ealHHbtwBq9Rrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgsVSqtg%253D%253D&md5=132f4de5a7104defd164235b90711976</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2147%2FHMER.S55864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FHMER.S55864%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DJ.%2BA.%26aulast%3DThompson%26aufirst%3DA.%2BJ.%26atitle%3DInterferon-free%2520combination%2520therapies%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%253A%2520current%2520insights%26jtitle%3DHepatic%2520Med.%26date%3D2015%26volume%3D7%26spage%3D51%26doi%3D10.2147%2FHMER.S55864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talwani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temesgen, Z.</span></span> <span> </span><span class="NLM_article-title">Simeprevir: a macrocyclic HCV protease inhibitor</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1358/dot.2013.49.12.2067249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1358%2Fdot.2013.49.12.2067249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A280%3ADC%252BC2cvkvValsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=769-779&author=R.+Talwaniauthor=E.+Heilauthor=B.+Gilliamauthor=Z.+Temesgen&title=Simeprevir%3A+a+macrocyclic+HCV+protease+inhibitor&doi=10.1358%2Fdot.2013.49.12.2067249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Simeprevir: a macrocyclic HCV protease inhibitor</span></div><div class="casAuthors">Talwani R; Gilliam B L; Heil E L; Temesgen Z</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">769-79</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Simeprevir is a macrocyclic NS3/4A HCV protease inhibitor with potent activity against genotypes 1, 2, 4, 5 and 6 of the hepatitis C virus (HCV).  Phase II and III studies of simeprevir combined with pegylated interferon (peg-IFN) and ribavirin (RBV) demonstrated that the combination was safe and effective in HCV genotype 1 patients, with more than 75% of treatment-naive patients attaining a sustained virological response (SVR).  Simeprevir is administered once daily as a single 150-mg capsule.  It has a moderate drug interaction potential, but less than that of the first-generation HCV protease inhibitors.  Based on positive results from the product's phase III clinical program, simeprevir was approved and launched in Japan, the U.S. and Canada in late 2013 for use in combination with peg-IFN/RBV in HCV genotype 1 infections.  Phase II interferon-free studies of simeprevir are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPRn_AgMrD_MrRqEXsZufAfW6udTcc2ealHHbtwBq9Rrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvkvValsQ%253D%253D&md5=8a51a1cd0c0c4ced80310cf70ea62d3b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1358%2Fdot.2013.49.12.2067249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2013.49.12.2067249%26sid%3Dliteratum%253Aachs%26aulast%3DTalwani%26aufirst%3DR.%26aulast%3DHeil%26aufirst%3DE.%26aulast%3DGilliam%26aufirst%3DB.%26aulast%3DTemesgen%26aufirst%3DZ.%26atitle%3DSimeprevir%253A%2520a%2520macrocyclic%2520HCV%2520protease%2520inhibitor%26jtitle%3DDrugs%2520Today%26date%3D2013%26volume%3D49%26spage%3D769%26epage%3D779%26doi%3D10.1358%2Fdot.2013.49.12.2067249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardo
Buonomo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zappulo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaldo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, G.</span></span> <span> </span><span class="NLM_article-title">ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3261</span>– <span class="NLM_lpage">3270</span>, <span class="refDoi"> DOI: 10.2174/0929867321666140706125950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.2174%2F0929867321666140706125950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=25005190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCqsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=3261-3270&author=I.+Gentileauthor=F.+Borgiaauthor=A.+Riccardo%0ABuonomoauthor=E.+Zappuloauthor=G.+Castaldoauthor=G.+Borgia&title=ABT-450%3A+a+novel+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.2174%2F0929867321666140706125950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Gentile, Ivan; Borgia, Federico; Buonomo, Antonio Riccardo; Zappulo, Emanuela; Castaldo, Giuseppe; Borgia, Guglielmo</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3261-3270</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">About 2.3% of the world's population is infected with hepatitis C virus (HCV) and patients have a high risk of developing liver cirrhosis and its complications.  Current therapeutic strategies are based on a combination of pegylated interferon, ribavirin and (only for patients with genotype 1 infection) a protease inhibitor (boceprevir or telaprevir).  Consequently, all these combinations have the limitations of interferon.  In fact, they are contraindicated in decompensated disease and in subjects with severe comorbidities, and are assocd. with a high rate of side effects.  Moreover, they are poorly effective in advanced disease.  As complete viral eradication is assocd. with improved disease-free survival, several mols. are under clin. development for their potential to overcome the drawbacks of currently available treatments.  This review focuses on the pharmacodynamics, pharmacokinetics, safety and tolerability of ABT-450, a potent inhibitor of non-structural 3 protease.  ABT-450 is a substrate of cytochrome P 450; hence its co-administration with ritonavir, a cytochrome P 450 inhibitor, dramatically increases the plasma concn. and half-life of ABT-450 and allows once-daily administration.  Given in monotherapy for 3 days at different doses, ABT-450 causes a mean max. viral decline of about 4 logs.  Interestingly, high doses of ABT-450 are assocd. with a reduced and delayed development of resistance-conferring mutations.  Given in combination with other direct antiviral drugs, the sustained response rate reaches 90-95% in both naive and treatment-experienced genotype 1 patients, and tolerability is good.  In conclusion, ABT-450 is an excellent component of interferon-free combinations for the treatment of chronic HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR_Au_8lnB9rVg90H21EOLACvtfcHk0ljB3kUaFgi8Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCqsrzL&md5=e2f8c94407cd48efccb0d480acb5ad1a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F0929867321666140706125950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867321666140706125950%26sid%3Dliteratum%253Aachs%26aulast%3DGentile%26aufirst%3DI.%26aulast%3DBorgia%26aufirst%3DF.%26aulast%3DRiccardo%2BBuonomo%26aufirst%3DA.%26aulast%3DZappulo%26aufirst%3DE.%26aulast%3DCastaldo%26aufirst%3DG.%26aulast%3DBorgia%26aufirst%3DG.%26atitle%3DABT-450%253A%2520a%2520novel%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2014%26volume%3D21%26spage%3D3261%26epage%3D3270%26doi%3D10.2174%2F0929867321666140706125950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben Ari, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollison, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuckerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baruch, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhanja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, M. N.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of grazoprevir+ ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection</span>. <i>J. Viral Hepatitis</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1111/jvh.12552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1111%2Fjvh.12552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=27291249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWmtbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=789-797&author=E.+Ganeauthor=Z.+Ben+Ariauthor=L.+Mollisonauthor=E.+Zuckermanauthor=R.+Bruckauthor=Y.+Baruchauthor=A.+Howeauthor=J.+Wahlauthor=S.+Bhanjaauthor=P.+Hwangauthor=Y.+Zhaoauthor=M.+N.+Robertson&title=Efficacy+and+safety+of+grazoprevir%2B+ribavirin+for+12+or+24+weeks+in+treatment-na%C3%AFve+patients+with+hepatitis+C+virus+genotype+1+infection&doi=10.1111%2Fjvh.12552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naive patients with hepatitis C virus genotype 1 infection</span></div><div class="casAuthors">Gane, E.; Ben Ari, Z.; Mollison, L.; Zuckerman, E.; Bruck, R.; Baruch, Y.; Howe, A. Y. M.; Wahl, J.; Bhanja, S.; Hwang, P.; Zhao, Y.; Robertson, M. N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Viral Hepatitis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">789-797</span>CODEN:
                <span class="NLM_cas:coden">JVHEER</span>;
        ISSN:<span class="NLM_cas:issn">1365-2893</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Summary : Grazoprevir (GZR) is a second-generation hepatitis C virus NS3/4A protease inhibitor.  The aim of this study was to evaluate GZR plus ribavirin (RBV) in patients with HCV GT1 infection.  Noncirrhotic, IL28BCC patients with HCV genotype 1 infection were randomized to GZR 100 mg once daily and RBV for 12 or 24 wk.  Patients in the 12-wk arm with detectable HCV RNA at treatment week 4 (TW4) had treatment extended to 24 wk (response-guided therapy, RGT).  The primary endpoint was sustained virol. response (SVR12) at follow-up week 12 (HCV RNA <25 IU/mL) in the per-protocol (PP) population (excluding patients with important protocol deviations).  Twenty-six patients were randomized and 22 were included in the PP population.  SVR12 was 58.3% (7 of 12) and 90% (9 of 10) in the RGT and 24-wk arms, resp.  Seven PP patients had virol. failure, including one patient in the 24-wk arm who relapsed after follow-up week 12.  All three breakthrough patients had wild-type (WT) virus at baseline and developed breakthrough at TW6 or TW12 with Y56H, A156T and D168A/N mutations.  Of the five relapse patients, four had WT at baseline (at relapse three had WT and one had V55A and D168A), and one had S122A/T at baseline and S122T at relapse.  There were no serious adverse events (AEs), discontinuations due to AEs or grade 3/4 elevations in total and/or direct bilirubin.  Grazoprevir plus RBV was assocd. with a rapid and sustained suppression of HCV RNA.  These results support further evaluation of grazoprevir-based regimens (NCT01716156; protocol P039).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM823BVjHI_7Vg90H21EOLACvtfcHk0ljB3kUaFgi8Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWmtbfO&md5=701c82ed6412de104bb737882c7b1cf9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fjvh.12552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.12552%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%26aulast%3DBen%2BAri%26aufirst%3DZ.%26aulast%3DMollison%26aufirst%3DL.%26aulast%3DZuckerman%26aufirst%3DE.%26aulast%3DBruck%26aufirst%3DR.%26aulast%3DBaruch%26aufirst%3DY.%26aulast%3DHowe%26aufirst%3DA.%26aulast%3DWahl%26aufirst%3DJ.%26aulast%3DBhanja%26aufirst%3DS.%26aulast%3DHwang%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DRobertson%26aufirst%3DM.%2BN.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520grazoprevir%252B%2520ribavirin%2520for%252012%2520or%252024%2520weeks%2520in%2520treatment-na%25C3%25AFve%2520patients%2520with%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2016%26volume%3D23%26spage%3D789%26epage%3D797%26doi%3D10.1111%2Fjvh.12552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeuzem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asatryan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feld, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asselah, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourlière, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruane, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedemeyer, H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1702417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1056%2FNEJMoa1702417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=29365309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFSgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=354-369&author=S.+Zeuzemauthor=G.+R.+Fosterauthor=S.+Wangauthor=A.+Asatryanauthor=E.+Ganeauthor=J.+J.+Feldauthor=T.+Asselahauthor=M.+Bourli%C3%A8reauthor=P.+J.+Ruaneauthor=H.+Wedemeyer&title=Glecaprevir%E2%80%93pibrentasvir+for+8+or+12+weeks+in+HCV+genotype+1+or+3+infection&doi=10.1056%2FNEJMoa1702417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection</span></div><div class="casAuthors">Zeuzem, S.; Foster, G. R.; Wang, S.; Asatryan, A.; Gane, E.; Feld, J. J.; Asselah, T.; Bourliere, M.; Ruane, P. J.; Wedemeyer, H.; Pol, S.; Flisiak, R.; Poordad, F.; Chuang, W.-L.; Stedman, C. A.; Flamm, S.; Kwo, P.; Dore, G. J.; Sepulveda-Arzola, G.; Roberts, S. K.; Soto-Malave, R.; Kaita, K.; Puoti, M.; Vierling, J.; Tam, E.; Vargas, H. E.; Bruck, R.; Fuster, F.; Paik, S.-W.; Felizarta, F.; Kort, J.; Fu, B.; Liu, R.; Ng, T. I.; Pilot-Matias, T.; Lin, C.-W.; Trinh, R.; Mensa, F. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">354-369</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Glecaprevir and pibrentasvir are direct-acting antiviral agents with pangenotypic activity and a high barrier to resistance.  We evaluated the efficacy and safety of 8-wk and 12-wk courses of treatment with 300 mg of glecaprevir plus 120 mg of pibrentasvir in patients without cirrhosis who had hepatitis C virus (HCV) genotype 1 or 3 infection. methods We conducted two phase 3, randomized, open-label, multicenter trials.  Patients with genotype 1 infection were randomly assigned in a 1:1 ratio to receive once-daily glecaprevir-pibrentasvir for either 8 or 12 wk.  Patients with genotype 3 infection were randomly assigned in a 2:1 ratio to receive 12 wk of treatment with either glecaprevir-pibrentasvir or sofosbuvir-daclatasvir.  Addnl. patients with genotype 3 infection were subsequently enrolled and nonrandomly assigned to receive 8 wk of treatment with glecaprevir-pibrentasvir.  The primary end point was the rate of sustained virol. response 12 wk after the end of treatment. results In total, 1208 patients were treated.  The rate of sustained virol. response at 12 wk among genotype 1-infected patients was 99.1% (95% confidence interval [CI], 98 to 100) in the 8-wk group and 99.7% (95% CI, 99 to 100) in the 12-wk group.  Genotype 3-infected patients who were treated for 12 wk had a rate of sustained virol. response at 12 wk of 95% (95% CI, 93 to 98; 222 of 233 patients) with glecaprevir-pibrentasvir and 97% (95% CI, 93 to 99.9; 111 of 115) with sofosbuvir-daclatasvir; 8 wk of treatment with glecaprevir-pibrentasvir yielded a rate of 95% (95% CI, 91 to 98; 149 of 157 patients).  Adverse events led to discontinuation of treatment in no more than 1% of patients in any treatment group. conclusions Once-daily treatment with glecaprevir-pibrentasvir for either 8 wk or 12 wk achieved high rates of sustained virol. response among patients with HCV genotype 1 or 3 infection who did not have cirrhosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpODsBNSDJYN7Vg90H21EOLACvtfcHk0ljB3kUaFgi8Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFSgsrs%253D&md5=29bb370c8a59263f9f6a56406c20ef2d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1702417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1702417%26sid%3Dliteratum%253Aachs%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DAsatryan%26aufirst%3DA.%26aulast%3DGane%26aufirst%3DE.%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DRuane%26aufirst%3DP.%2BJ.%26aulast%3DWedemeyer%26aufirst%3DH.%26atitle%3DGlecaprevir%25E2%2580%2593pibrentasvir%2520for%25208%2520or%252012%2520weeks%2520in%2520HCV%2520genotype%25201%2520or%25203%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D354%26epage%3D369%26doi%3D10.1056%2FNEJMoa1702417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feld, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hézode, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asselah, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruane, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruener, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abergel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. L.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">2599</span>– <span class="NLM_lpage">2607</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1512610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1056%2FNEJMoa1512610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=26571066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2599-2607&author=J.+J.+Feldauthor=I.+M.+Jacobsonauthor=C.+H%C3%A9zodeauthor=T.+Asselahauthor=P.+J.+Ruaneauthor=N.+Gruenerauthor=A.+Abergelauthor=A.+Mangiaauthor=C.-L.+Laiauthor=H.+L.+Chan&title=Sofosbuvir+and+velpatasvir+for+HCV+genotype+1%2C+2%2C+4%2C+5%2C+and+6+infection&doi=10.1056%2FNEJMoa1512610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection</span></div><div class="casAuthors">Feld, J. J.; Jacobson, I. M.; Hezode, C.; Asselah, T.; Ruane, P. J.; Gruener, N.; Abergel, A.; Mangia, A.; Lai, C.-L.; Chan, H. L. Y.; Mazzotta, F.; Moreno, C.; Yoshida, E.; Shafran, S. D.; Towner, W. J.; Tran, T. T.; McNally, J.; Osinusi, A.; Svarovskaia, E.; Zhu, Y.; Brainard, D. M.; McHutchison, J. G.; Agarwal, K.; Zeuzem, S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">2599-2607</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A simple treatment regimen that is effective in a broad range of patients who are chronically infected with the hepatitis C virus (HCV) remains an unmet medical need.  We conducted a phase 3, double-blind, placebo-controlled study involving untreated and previously treated patients with chronic HCV genotype 1, 2, 4, 5, or 6 infection, including those with compensated cirrhosis.  Patients with HCV genotype 1, 2, 4, or 6 were randomly assigned in a 5:1 ratio to receive the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir in a once-daily, fixed-dose combination tablet or matching placebo for 12 wk.  Because of the low prevalence of genotype 5 in the study regions, patients with genotype 5 did not undergo randomization but were assigned to the sofosbuvir-velpatasvir group.  The primary end point was a sustained virol. response at 12 wk after the end of therapy.  Of the 624 patients who received treatment with sofosbuvir-velpatasvir, 34% had HCV genotype 1a, 19% genotype 1b, 17% genotype 2, 19% genotype 4, 6% genotype 5, and 7% genotype 6.  A total of 8% of patients were black, 19% had cirrhosis, and 32% had been previously treated for HCV.  The rate of sustained virol. response among patients receiving sofosbuvir-velpatasvir was 99% (95% confidence interval, 98 to >99).  Two patients receiving sofosbuvir-velpatasvir, both with HCV genotype 1, had a virol. relapse.  None of the 116 patients receiving placebo had a sustained virol. response.  Serious adverse events were reported in 15 patients (2%) in the sofosbuvir-velpatasvir group and none in the placebo group.  Once-daily sofosbuvir-velpatasvir for 12 wk provided high rates of sustained virol. response among both previously treated and untreated patients infected with HCV genotype 1, 2, 4, 5, or 6, including those with compensated cirrhosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIaLSuQe4dW7Vg90H21EOLACvtfcHk0ljm-rZtT9vHUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlurjO&md5=cb66c57f7845aff86567d3b59705faf6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1512610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1512610%26sid%3Dliteratum%253Aachs%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DRuane%26aufirst%3DP.%2BJ.%26aulast%3DGruener%26aufirst%3DN.%26aulast%3DAbergel%26aufirst%3DA.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DC.-L.%26aulast%3DChan%26aufirst%3DH.%2BL.%26atitle%3DSofosbuvir%2520and%2520velpatasvir%2520for%2520HCV%2520genotype%25201%252C%25202%252C%25204%252C%25205%252C%2520and%25206%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2599%26epage%3D2607%26doi%3D10.1056%2FNEJMoa1512610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">R Buonomo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, G.</span></span> <span> </span><span class="NLM_article-title">Dasabuvir: a non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infection</span>. <i>Rev. Recent Clin. Trials</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.2174/1574887109666140529222602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.2174%2F1574887109666140529222602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=24882169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGqu7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=115-123&author=I.+Gentileauthor=A.+R+Buonomoauthor=G.+Borgia&title=Dasabuvir%3A+a+non-nucleoside+inhibitor+of+NS5B+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.2174%2F1574887109666140529222602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Gentile, Ivan; Buonomo, Antonio R.; Borgia, Guglielmo</div><div class="citationInfo"><span class="NLM_cas:title">Reviews on Recent Clinical Trials</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-123</span>CODEN:
                <span class="NLM_cas:coden">RRCTB2</span>;
        ISSN:<span class="NLM_cas:issn">1574-8871</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) chronically infects about 2% of the world's population.  Approx. a quarter of these patients will develop, during their life, liver cirrhosis, which entails a high risk of complications and death.  Successful antiviral therapy can reduce the risk of disease progression, but it is feasible only in a minority of patients because it includes interferon which is contraindicated in the most advanced stages of the disease and in patients with severe impairment of other organs.  Consequent to the launch of the first direct antiviral agents (DAA), namely the protease inhibitors telaprevir and boceprevir, several mols. are in an advanced phase of clin. development to be used in assocn. with interferon or with other DAA (in interferon-free combinations).  This review focuses on the mechanism of action, pharmacokinetics, efficacy, safety and resistance of dasabuvir, a non-nucleoside inhibitor of NS5B viral RNA-dependent RNA polymerase.  Thanks to its pharmacokinetics, dasabuvir can be administered twice daily.  In combinations with other oral DAAs, dasabuvir results in very high rates of SVR (about 95%) in patients with HCV genotype 1 infection with a good tolerability and safety.  In conclusion, dasabuvir is a good agent to be used in interferon-free combinations for the treatment of chronic hepatitis C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUMZrbnwVJvrVg90H21EOLACvtfcHk0ljm-rZtT9vHUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGqu7vJ&md5=75f136bd5bccdf288697d8aba73ba037</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F1574887109666140529222602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1574887109666140529222602%26sid%3Dliteratum%253Aachs%26aulast%3DGentile%26aufirst%3DI.%26aulast%3DR%2BBuonomo%26aufirst%3DA.%26aulast%3DBorgia%26aufirst%3DG.%26atitle%3DDasabuvir%253A%2520a%2520non-nucleoside%2520inhibitor%2520of%2520NS5B%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DRev.%2520Recent%2520Clin.%2520Trials%26date%3D2014%26volume%3D9%26spage%3D115%26epage%3D123%26doi%3D10.2174%2F1574887109666140529222602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pol, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghalib, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustgi, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martorell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everson, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatum, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hézode, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronowicki, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, G. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(12)70138-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1016%2FS1473-3099%2812%2970138-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=22714001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GlsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=671-677&author=S.+Polauthor=R.+H.+Ghalibauthor=V.+K.+Rustgiauthor=C.+Martorellauthor=G.+T.+Eversonauthor=H.+A.+Tatumauthor=C.+H%C3%A9zodeauthor=J.+K.+Limauthor=J.-P.+Bronowickiauthor=G.+A.+Abrams&title=Daclatasvir+for+previously+untreated+chronic+hepatitis+C+genotype-1+infection%3A+a+randomised%2C+parallel-group%2C+double-blind%2C+placebo-controlled%2C+dose-finding%2C+phase+2a+trial&doi=10.1016%2FS1473-3099%2812%2970138-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial</span></div><div class="casAuthors">Pol, Stanislas; Ghalib, Reem H.; Rustgi, Vinod K.; Martorell, Claudia; Everson, Greg T.; Tatum, Harvey A.; Hezode, Christophe; Lim, Joseph K.; Bronowicki, Jean-Pierre; Abrams, Gary A.; Braeu, Norbert; Morris, David W.; Thuluvath, Paul J.; Reindollar, Robert W.; Yin, Philip D.; Diva, Ulysses; Hindes, Robert; McPhee, Fiona; Hernandez, Dennis; Wind-Rotolo, Megan; Hughes, Eric A.; Schnittman, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">671-677</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Several direct-acting antivirals for chronic hepatitis C virus (HCV) infection are available, but they are limited by tolerability and dosing schedules.  Once-daily daclatasvir, a potent NS5A replication complex inhibitor, was generally well tolerated in phase 1 studies.  We assessed daclatasvir in combination with pegylated interferon (peginterferon) and ribavirin for chronic HCV.  Methods: In this double-blind, parallel-group, dose-finding, phase 2a study, treatment-naive patients with HCV genotype-1 infection (without cirrhosis) from 14 centers in the USA and France were randomly assigned (1:1:1:1) to receive peginterferon alfa-2a (180 μg per wk) and ribavirin (1000-1200 mg daily) plus placebo or 3 mg, 10 mg, or 60 mg of daclatasvir taken once daily, for 48 wk.  The primary efficacy endpoint was undetectable HCV RNA at 4 wk and 12 wk after start of treatment (extended rapid virol. response, eRVR).  Anal. was of all participants who received one dose of study drug.  We used descriptive analyses to compare results.  This study is registered with ClinicalTrials.gov, no. NCT00874770.  Findings: 48 patients were randomly assigned (12 per group); all received at least one dose of study drug. 15 patients discontinued treatment before week 48.  Five of 12 patients (42%, 80% CI 22-64%) who received 3 mg daclatasvir achieved eRVR, compared with ten of 12 (83%, 61-96%) who received 10 mg daclatasvir, nine of 12 (75%, 53-90%) who received 60 mg daclatasvir, and one of 12 (8%, 1-29%) who received placebo.  Adverse events and discontinuations as a result of adverse events occurred with similar frequency across groups.  Interpretation: Daclatasvir seems to be a potent NS5A replication complex inhibitor that increases the antiviral potency of peginterferon and ribavirin.  Our findings support the further development of regimens contg. 60 mg daclatasvir for the treatment of chronic genotype-1 HCV infection.  Funding: Bristol-Myers Squibb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0jrF6ixurObVg90H21EOLACvtfcHk0ljm-rZtT9vHUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GlsL%252FJ&md5=fb310d15629ecd376196a92faa8291ba</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2812%2970138-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252812%252970138-X%26sid%3Dliteratum%253Aachs%26aulast%3DPol%26aufirst%3DS.%26aulast%3DGhalib%26aufirst%3DR.%2BH.%26aulast%3DRustgi%26aufirst%3DV.%2BK.%26aulast%3DMartorell%26aufirst%3DC.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DTatum%26aufirst%3DH.%2BA.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DBronowicki%26aufirst%3DJ.-P.%26aulast%3DAbrams%26aufirst%3DG.%2BA.%26atitle%3DDaclatasvir%2520for%2520previously%2520untreated%2520chronic%2520hepatitis%2520C%2520genotype-1%2520infection%253A%2520a%2520randomised%252C%2520parallel-group%252C%2520double-blind%252C%2520placebo-controlled%252C%2520dose-finding%252C%2520phase%25202a%2520trial%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2012%26volume%3D12%26spage%3D671%26epage%3D677%26doi%3D10.1016%2FS1473-3099%2812%2970138-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feld, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowdley, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coakley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiland, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilot-Matias, T.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Treatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">1594</span>– <span class="NLM_lpage">1603</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1315722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1056%2FNEJMoa1315722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=24720703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnt1Grsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1594-1603&author=J.+J.+Feldauthor=K.+V.+Kowdleyauthor=E.+Coakleyauthor=S.+Sigalauthor=D.+R.+Nelsonauthor=D.+Crawfordauthor=O.+Weilandauthor=H.+Aguilarauthor=J.+Xiongauthor=T.+Pilot-Matias&title=Treatment+of+HCV+with+ABT-450%2Fr%E2%80%93ombitasvir+and+dasabuvir+with+ribavirin&doi=10.1056%2FNEJMoa1315722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin</span></div><div class="casAuthors">Feld, Jordan J.; Kowdley, Kris V.; Coakley, Eoin; Sigal, Samuel; Nelson, David R.; Crawford, Darrell; Weiland, Ola; Aguilar, Humberto; Xiong, Junyuan; Pilot-Matias, Tami; Da Silva-Tillmann, Barbara; Larsen, Lois; Podsadecki, Thomas; Bernstein, Barry</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1594-1603</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The interferon-free combination of the protease inhibitor ABT-450 With ritonavir (ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the non-nucleoside polymerase inhibitor dasabuvir (also known as ABT-333) and ribavirin has shown efficacy against the hepatitis C virus (HCV) in patients with HCV genotype 1 infection.  In this phase 3 trial, we evaluated this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis.  METHODS In this multicenter, randomized, double-blind, placebo-controlled trial, we assigned previously untreated patients with HCV genotype 1 infection, in a 3:1 ratio, to an active regimen consisting of a single-tablet coformulation of ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), and dasabuvir (250 mg twice daily) with ribavirin (in doses detd. according to body wt.) (group A) or matching placebos (group B).  The patients received the study treatment during a 12-wk double-blind period.  The primary end point was sustained virol. response at 12 wk after the end of treatment.  The primary anal. compared the response rate in group A with the response rate (78%) in a historical control group of previously untreated patients without cirrhosis who received telaprevir with peginterferon and ribavirin.  Adverse events occurring during the double-blind period were compared between group A and group B.  RESULTS A total of 631 patients received at least one dose of the study drugs.  The rate of sustained virol. response in group A was 96.2% (95% confidence interval, 94.5 to 97.9), which was superior to the historical control rate.  Virol. failure during treatment and relapse after treatment occurred in 0.2% and 1.5%, resp., of the patients in group A.  The response rates in group A were 95.3% among patients with HCV genotype 1a infection and 98.0% among those with HCV genotype 1b infection.  The rate of discontinuation due to adverse events was 0.6% in each study group.  Nausea, pruritus, insomnia, diarrhea, and asthenia occurred in significantly more patients in group A than in group B (P < 0.05 for all comparisons).  Redns. in the Hb level were all of grade 1 or 2; redns. of grade 1 and 2 occurred in 47.5% and 5.8%, resp., of the patients in group A, whereas grade 1 redns. occurred in 2.5% of the patients in group B.  CONCLUSIONS In previously untreated patients with HCV genotype 1 infection and no cirrhosis, a 12-wk multitargeted regimen of ABT-450/r-ombitasvir and dasabuvir with ribavirin was highly effective and was assocd. with a low rate of treatment discontinuation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGvK9K2P4sJ7Vg90H21EOLACvtfcHk0lgnXPvHIpHCzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnt1Grsrg%253D&md5=0e5e8ff9c7ebd43fe755c3d3c77f3462</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1315722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1315722%26sid%3Dliteratum%253Aachs%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DCoakley%26aufirst%3DE.%26aulast%3DSigal%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DCrawford%26aufirst%3DD.%26aulast%3DWeiland%26aufirst%3DO.%26aulast%3DAguilar%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.%26aulast%3DPilot-Matias%26aufirst%3DT.%26atitle%3DTreatment%2520of%2520HCV%2520with%2520ABT-450%252Fr%25E2%2580%2593ombitasvir%2520and%2520dasabuvir%2520with%2520ribavirin%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1594%26epage%3D1603%26doi%3D10.1056%2FNEJMoa1315722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Afdhal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeuzem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chojkier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitlin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puoti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero-Gomez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarski, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggisch, P.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">1889</span>– <span class="NLM_lpage">1898</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1402454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1056%2FNEJMoa1402454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=24725239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1889-1898&author=N.+Afdhalauthor=S.+Zeuzemauthor=P.+Kwoauthor=M.+Chojkierauthor=N.+Gitlinauthor=M.+Puotiauthor=M.+Romero-Gomezauthor=J.-P.+Zarskiauthor=K.+Agarwalauthor=P.+Buggisch&title=Ledipasvir+and+sofosbuvir+for+untreated+HCV+genotype+1+infection&doi=10.1056%2FNEJMoa1402454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</span></div><div class="casAuthors">Afdhal, Nezam; Zeuzem, Stefan; Kwo, Paul; Chojkier, Mario; Gitlin, Norman; Puoti, Massimo; Romero-Gomez, Manuel; Zarski, Jean-Pierre; Agarwal, Kosh; Buggisch, Peter; Foster, Graham R.; Brau, Norbert; Buti, Maria; Jacobson, Ira M.; Subramanian, G. Mani; Ding, Xiao; Mo, Hongmei; Yang, Jenny C.; Pang, Phillip S.; Symonds, William T.; McHutchison, John G.; Muir, Andrew J.; Mangia, Alessandra; Marcellin, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1889-1898, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virol. response among previously untreated patients with hepatitis C virus (HCV) genotype 1 infection.  Methods: We conducted a phase 3, open-label study involving previously untreated patients with chronic HCV genotype 1 infection.  Patients were randomly assigned in a 1:1:1:1 ratio to receive ledipasvir and sofosbuvir in a fixed-dose combination tablet once daily for 12 wk, ledipasvir-sofosbuvir plus ribavirin for 12 wk, ledipasvir- sofosbuvir for 24 wk, or ledipasvir-sofosbuvir plus ribavirin for 24 wk.  The primary end point was a sustained virol. response at 12 wk after the end of therapy.  Results: Of the 865 patients who underwent randomization and were treated, 16% had cirrhosis, 12% were black, and 67% had HCV genotype 1a infection.  The rates of sustained virol. response were 99% (95% confidence interval [CI], 96 to 100) in the group that received 12 wk of ledipasvir-sofosbuvir; 97% (95% CI, 94 to 99) in the group that received 12 wk of ledipasvir-sofosbuvir plus ribavirin; 98% (95% CI, 95 to 99) in the group that received 24 wk of ledipasvir-sofosbuvir; and 99% (95% CI, 97 to 100) in the group that received 24 wk of ledipasvir-sofosbuvir plus ribavirin.  No patient in either 12-wk group discontinued ledipasvir-sofosbuvir owing to an adverse event.  The most common adverse events were fatigue, headache, insomnia, and nausea.  Conculsions: Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 wk was highly effective in previously untreated patients with HCV genotype 1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroadkxw2jRR7Vg90H21EOLACvtfcHk0lgnXPvHIpHCzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnM&md5=e433fd7d493c1c0f9dfef37c1527388f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402454%26sid%3Dliteratum%253Aachs%26aulast%3DAfdhal%26aufirst%3DN.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DKwo%26aufirst%3DP.%26aulast%3DChojkier%26aufirst%3DM.%26aulast%3DGitlin%26aufirst%3DN.%26aulast%3DPuoti%26aufirst%3DM.%26aulast%3DRomero-Gomez%26aufirst%3DM.%26aulast%3DZarski%26aufirst%3DJ.-P.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DBuggisch%26aufirst%3DP.%26atitle%3DLedipasvir%2520and%2520sofosbuvir%2520for%2520untreated%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1889%26epage%3D1898%26doi%3D10.1056%2FNEJMoa1402454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMonagle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludmerer, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jumes, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingravallo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6922</span>– <span class="NLM_lpage">6929</span>, <span class="refDoi"> DOI: 10.1128/AAC.01390-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1128%2FAAC.01390-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=26303801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtVynt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=6922-6929&author=R.+Liuauthor=S.+Curryauthor=P.+McMonagleauthor=W.+W.+Yehauthor=S.+W.+Ludmererauthor=P.+A.+Jumesauthor=W.+L.+Marshallauthor=S.+Kongauthor=P.+Ingravalloauthor=S.+Black&title=Susceptibilities+of+genotype+1a%2C+1b%2C+and+3+hepatitis+C+virus+variants+to+the+NS5A+inhibitor+elbasvir&doi=10.1128%2FAAC.01390-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir</span></div><div class="casAuthors">Liu, Rong; Curry, Stephanie; McMonagle, Patricia; Yeh, Wendy W.; Ludmerer, Steven W.; Jumes, Patricia A.; Marshall, William L.; Kong, Stephanie; Ingravallo, Paul; Black, Stuart; Pak, Irene; Di Nubile, Mark J.; Howe, Anita Y. M.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6922-6929</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Elbasvir is an investigational NS5A inhibitor with in vitro activity against multiple HCV genotypes.  Antiviral activity of elbasvir was measured in replicons derived from wild-type or resistant variants of genotypes 1a, 1b, and 3.  The barrier to resistance was assessed by the no. of resistant colonies selected by exposure to various elbasvir concns.  In a phase 1b dose-escalating study, virol. responses were detd. in 48 noncirrhotic adult men with chronic genotype 1 or 3 infections randomized to placebo or elbasvir from 5 to 50 mg (genotype 1) or 10 to 100 mg (genotype 3) once daily for 5 days.  The NS5A gene was sequenced from plasma specimens obtained before, during, and after treatment.  Elbasvir suppressed the emergence of resistance-assocd. variants (RAVs) in vitro in a dose-dependent manner.  Variants selected by exposure to high elbasvir concns. typically encoded multiple amino acid substitutions (most commonly involving loci 30, 31, and 93), conferring high-level elbasvir resistance.  In the monotherapy study, patients with genotype 1b had greater redns. in HCV RNA levels than patients with genotype 1a at all elbasvir doses; responses in patients with genotype 3 were generally less pronounced than for genotype 1, particularly at lower elbasvir doses.  M28T, Q30R, L31V, and Y93H in genotype 1a, L31V and Y93H in genotype 1b, and A30K, L31F, and Y93H in genotype 3 were the predominant RAVs selected by elbasvir monotherapy.  Virol. findings in patients were consistent with the preclin. observations.  NS5A-RAVs emerged most often at amino acid positions 28, 30, 31, and 93 in both the lab. and clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqww8cEyKUq57Vg90H21EOLACvtfcHk0lgnXPvHIpHCzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtVynt7w%253D&md5=c112597ce683add1024b594b502a8c4c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FAAC.01390-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01390-15%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DCurry%26aufirst%3DS.%26aulast%3DMcMonagle%26aufirst%3DP.%26aulast%3DYeh%26aufirst%3DW.%2BW.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DJumes%26aufirst%3DP.%2BA.%26aulast%3DMarshall%26aufirst%3DW.%2BL.%26aulast%3DKong%26aufirst%3DS.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DBlack%26aufirst%3DS.%26atitle%3DSusceptibilities%2520of%2520genotype%25201a%252C%25201b%252C%2520and%25203%2520hepatitis%2520C%2520virus%2520variants%2520to%2520the%2520NS5A%2520inhibitor%2520elbasvir%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D6922%26epage%3D6929%26doi%3D10.1128%2FAAC.01390-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwo, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poordad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asatryan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyles, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassanein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felizarta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulkowski, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maliakkal, B.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">271</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2017.03.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1016%2Fj.jhep.2017.03.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=28412293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFeks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2017&pages=263-271&author=P.+Y.+Kwoauthor=F.+Poordadauthor=A.+Asatryanauthor=S.+Wangauthor=D.+L.+Wylesauthor=T.+Hassaneinauthor=F.+Felizartaauthor=M.+S.+Sulkowskiauthor=E.+Ganeauthor=B.+Maliakkal&title=Glecaprevir+and+pibrentasvir+yield+high+response+rates+in+patients+with+HCV+genotype+1%E2%80%936+without+cirrhosis&doi=10.1016%2Fj.jhep.2017.03.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis</span></div><div class="casAuthors">Kwo, Paul Y.; Poordad, Fred; Asatryan, Armen; Wang, Stanley; Wyles, David L.; Hassanein, Tarek; Felizarta, Franco; Sulkowski, Mark S.; Gane, Edward; Maliakkal, Benedict; Overcash, J. Scott; Gordon, Stuart C.; Muir, Andrew J.; Aguilar, Humberto; Agarwal, Kosh; Dore, Gregory J.; Lin, Chih-Wei; Liu, Ran; Lovell, Sandra S.; Ng, Teresa I.; Kort, Jens; Mensa, Federico J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-271</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) therapy that is highly efficacious, pangenotypic, with a high barrier to resistance and short treatment duration is desirable.  The efficacy and safety of 8- and 12-wk treatments with glecaprevir (ABT-493; NS3/4 A protease inhibitor) and pibrentasvir (ABT-530; NS5A inhibitor) were evaluated in non-cirrhotic patients with chronic HCV genotype 1-6 infection.  SURVEYOR-I and SURVEYOR-II were phase II, open-label, multicenter, dose-ranging trials including patients with chronic HCV genotype 1-6 infection who were either previously untreated or treated with pegylated interferon plus ribavirin.  Patients received once-daily glecaprevir plus pibrentasvir at varying doses with or without ribavirin for 8 or 12 wk.  The primary efficacy endpoint was the percentage of patients with a sustained virol. response at post-treatment week 12 (SVR12).  Of the 449 patients who received varying doses of glecaprevir plus pibrentasvir, 25%, 29%, 39%, and 8% had HCV genotype 1, 2, 3, and 4-6 infection, resp.  Twelve-week treatment achieved SVR12 in 97-100%, 96-100%, 83-94%, and 100% in genotypes 1, 2, 3, and 4-6, resp.  Eight-week treatment with 300 mg glecaprevir plus 120 mg pibrentasvir in genotype 1-, 2-, or 3-infected patients yielded 97-98% SVR12 with no virol. failures.  Three (0.7%) patients discontinued treatment due to adverse events; most events were mild (grade 1) in severity.  No post-nadir alanine aminotransferase elevations were obsd.  Glecaprevir plus pibrentasvir was well tolerated and achieved high sustained virol. response rates in HCV genotypes 1-6-infected patients without cirrhosis following 8- or 12-wk treatment durations.  The combination of direct-acting antivirals glecaprevir and pibrentasvir comprise a once-daily, all-oral, pangenotypic treatment for HCV genotype 1-6 infection.  This article describes results from two phase II trials investigating a range of doses at treatment durations of 8 or 12 wk in 449 patients without cirrhosis.  Efficacy of the optimal dose, as detd. by rates of sustained virol. response at post-treatment week 12, ranged from 92%-100%; treatment was well tolerated and significant lab. abnormalities were rare.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY1_YC2ck4e7Vg90H21EOLACvtfcHk0lhPPLXwkTEAqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFeks70%253D&md5=33971ab16202fe91408b866cc8b02490</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2017.03.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2017.03.039%26sid%3Dliteratum%253Aachs%26aulast%3DKwo%26aufirst%3DP.%2BY.%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DAsatryan%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWyles%26aufirst%3DD.%2BL.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DFelizarta%26aufirst%3DF.%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DGane%26aufirst%3DE.%26aulast%3DMaliakkal%26aufirst%3DB.%26atitle%3DGlecaprevir%2520and%2520pibrentasvir%2520yield%2520high%2520response%2520rates%2520in%2520patients%2520with%2520HCV%2520genotype%25201%25E2%2580%25936%2520without%2520cirrhosis%26jtitle%3DJ.%2520Hepatol.%26date%3D2017%26volume%3D67%26spage%3D263%26epage%3D271%26doi%3D10.1016%2Fj.jhep.2017.03.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eisenman, T.</span></span> <span> </span><span class="NLM_article-title">FDA Approves Epclusa for Treatment of Chronic Hepatitis C Virus Infection</span>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-epclusa-treatment-chronic-hepatitis-c-virus-infection" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-epclusa-treatment-chronic-hepatitis-c-virus-infection</a> (accessed March 11, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=T.+Eisenman&title=FDA+Approves+Epclusa+for+Treatment+of+Chronic+Hepatitis+C+Virus+Infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DEisenman%26aufirst%3DT.%26atitle%3DFDA%2520Approves%2520Epclusa%2520for%2520Treatment%2520of%2520Chronic%2520Hepatitis%2520C%2520Virus%2520Infection%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">US
Food and Drug Administration</span>, <span> </span><span class="NLM_article-title">FDA Approves
Zepatier for Treatment of Chronic Hepatitis C Genotypes 1 and 4</span>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-zepatier-treatment-chronic-hepatitis-c-genotypes-1-and-4" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-zepatier-treatment-chronic-hepatitis-c-genotypes-1-and-4</a> (accessed March 11, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=US%0AFood+and+Drug+Administration&title=FDA+Approves%0AZepatier+for+Treatment+of+Chronic+Hepatitis+C+Genotypes+1+and+4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DFDA%2520Approves%250AZepatier%2520for%2520Treatment%2520of%2520Chronic%2520Hepatitis%2520C%2520Genotypes%25201%2520and%25204%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlich, D. R.</span></span> <span> </span><span class="NLM_article-title">Glecaprevir/pibrentasvir (Mavyret) for the treatment of chronic hepatitis C</span>. <i>Am. Fam. Physician</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">601</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=30365290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A280%3ADC%252BB3cvjslaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2018&pages=601&author=A.+Groverauthor=D.+R.+Erlich&title=Glecaprevir%2Fpibrentasvir+%28Mavyret%29+for+the+treatment+of+chronic+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Glecaprevir/Pibrentasvir (Mavyret) for the Treatment of Chronic Hepatitis C</span></div><div class="casAuthors">Grover Anupriya; Erlich Deborah R</div><div class="citationInfo"><span class="NLM_cas:title">American family physician</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">601-602</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSR2DQeGejR8JQHPYJuLg8TfW6udTcc2ebq7WXekWXYDrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvjslaqsg%253D%253D&md5=98c24218c245c109d2b0c3006fd9f842</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrover%26aufirst%3DA.%26aulast%3DErlich%26aufirst%3DD.%2BR.%26atitle%3DGlecaprevir%252Fpibrentasvir%2520%2528Mavyret%2529%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2018%26volume%3D98%26spage%3D601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheel, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, C. M.</span></span> <span> </span><span class="NLM_article-title">Understanding the hepatitis C virus life cycle paves the way for highly effective therapies</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">837</span>, <span class="refDoi"> DOI: 10.1038/nm.3248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1038%2Fnm.3248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=23836234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKru7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=837&author=T.+K.+Scheelauthor=C.+M.+Rice&title=Understanding+the+hepatitis+C+virus+life+cycle+paves+the+way+for+highly+effective+therapies&doi=10.1038%2Fnm.3248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the hepatitis C virus life cycle paves the way for highly effective therapies</span></div><div class="casAuthors">Scheel, Troels K. H.; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">837-849</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  More than two decades of intense research has provided a detailed understanding of hepatitis C virus (HCV), which chronically infects 2% of the world's population.  This effort has paved the way for the development of antiviral compds. to spare patients from life-threatening liver disease.  An exciting new era in HCV therapy dawned with the recent approval of two viral protease inhibitors, used in combination with pegylated interferon-α and ribavirin; however, this is just the beginning.  Multiple classes of antivirals with distinct targets promise highly efficient combinations, and interferon-free regimens with short treatment duration and fewer side effects are the future of HCV therapy.  Ongoing and future trials will det. the best antiviral combinations and whether the current seemingly rich pipeline is sufficient for successful treatment of all patients in the face of major challenges, such as HCV diversity, viral resistance, the influence of host genetics, advanced liver disease and other co-morbidities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpde8altGxkeLVg90H21EOLACvtfcHk0ljcbGeLmap01w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKru7rI&md5=dabc9fbc7dc0bc56115d5ede0d8ae072</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnm.3248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3248%26sid%3Dliteratum%253Aachs%26aulast%3DScheel%26aufirst%3DT.%2BK.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DUnderstanding%2520the%2520hepatitis%2520C%2520virus%2520life%2520cycle%2520paves%2520the%2520way%2520for%2520highly%2520effective%2520therapies%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D837%26doi%3D10.1038%2Fnm.3248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D. R.,  II</span></span> <span> </span><span class="NLM_article-title">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>465</i></span>,  <span class="NLM_fpage">96</span>, <span class="refDoi"> DOI: 10.1038/nature08960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1038%2Fnature08960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=20410884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=96&author=M.+Gaoauthor=R.+E.+Nettlesauthor=M.+Belemaauthor=L.+B.+Snyderauthor=V.+N.+Nguyenauthor=R.+A.+Fridellauthor=M.+H.+Serrano-Wuauthor=D.+R.+Langleyauthor=J.-H.+Sunauthor=D.+R.+O%E2%80%99Boyle&title=Chemical+genetics+strategy+identifies+an+HCV+NS5A+inhibitor+with+a+potent+clinical+effect.&doi=10.1038%2Fnature08960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span></div><div class="casAuthors">Gao, Min; Nettles, Richard E.; Belema, Makonen; Snyder, Lawrence B.; Nguyen, Van N.; Fridell, Robert A.; Serrano-Wu, Michael H.; Langley, David R.; Sun, Jin-Hua; O'Boyle, Donald R., II; Lemm, Julie A.; Wang, Chunfu; Knipe, Jay O.; Chien, Caly; Colonno, Richard J.; Grasela, Dennis M.; Meanwell, Nicholas A.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7294</span>),
    <span class="NLM_cas:pages">96-100</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estd. to be approaching 200 million people.  Current therapy relies upon a combination of pegylated interferon-α and ribavirin, a poorly tolerated regimen typically assocd. with less than 50% sustained virol. response rate in those infected with genotype 1 virus.  The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B.  Here we describe the profile of BMS-790052, a small mol. inhibitor of the HCV NS5A protein that exhibits picomolar half-max. effective concns. (EC50) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture.  In a phase I clin. trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was assocd. with a 3.3 log10 redn. in mean viral load measured 24 h post-dose that was sustained for an addnl. 120 h in two patients infected with genotype 1b virus.  Genotypic anal. of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants obsd. had substitutions at amino-acid positions identified using the in vitro replicon system.  These results provide the first clin. validation of an inhibitor of HCV NS5A, a protein with no known enzymic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAY7Lig0xT9LVg90H21EOLACvtfcHk0ljcbGeLmap01w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D&md5=620427e987f2bccd153270cde2ef5027</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnature08960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08960%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26atitle%3DChemical%2520genetics%2520strategy%2520identifies%2520an%2520HCV%2520NS5A%2520inhibitor%2520with%2520a%2520potent%2520clinical%2520effect.%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D96%26doi%3D10.1038%2Fnature08960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S. O.</span></span> <span> </span><span class="NLM_article-title">Organosilicon molecules with medicinal applications</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.1021/jm3010114</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3010114" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSgs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=388-405&author=A.+K.+Franzauthor=S.+O.+Wilson&title=Organosilicon+molecules+with+medicinal+applications&doi=10.1021%2Fjm3010114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Organosilicon Molecules with Medicinal Applications</span></div><div class="casAuthors">Franz, Annaliese K.; Wilson, Sean O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">388-405</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The incorporation of silicon and synthesis of organosilicon small mols. provide unique opportunities for medicinal applications.  The biol. investigation of organosilicon small mols. is particularly interesting because of differences in their chem. properties that can contribute to enhanced potency and improved pharmacol. attributes.  Applications such as inhibitor design, imaging, drug release technol., and mapping inhibitor binding are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVagNko6ifK7Vg90H21EOLACvtfcHk0ljcbGeLmap01w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSgs7bJ&md5=ffca8660a9a619e474b64624ad5705d0</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm3010114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3010114%26sid%3Dliteratum%253Aachs%26aulast%3DFranz%26aufirst%3DA.%2BK.%26aulast%3DWilson%26aufirst%3DS.%2BO.%26atitle%3DOrganosilicon%2520molecules%2520with%2520medicinal%2520applications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D388%26epage%3D405%26doi%3D10.1021%2Fjm3010114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, D. S.</span></span> <span> </span><span class="NLM_article-title">Quest for novel chemical entities through incorporation of silicon in drug scaffolds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3779</span>– <span class="NLM_lpage">3798</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00718</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00718" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1KnsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3779-3798&author=R.+Rameshauthor=D.+S.+Reddy&title=Quest+for+novel+chemical+entities+through+incorporation+of+silicon+in+drug+scaffolds&doi=10.1021%2Facs.jmedchem.7b00718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Quest for Novel Chemical Entities through Incorporation of Silicon in Drug Scaffolds</span></div><div class="casAuthors">Ramesh, Remya; Reddy, D. Srinivasa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3779-3798</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to optimize a lead mol. for further development, bioisosteric replacements are generally adopted as one of the strategies.  Silicon appears to be the right choice as a carbon isostere because of the similarity in chem. properties.  Silicon can be strategically introduced in a mol. to modulate its druglike properties, providing medicinal chemists with an unconventional strategy for replacing a carbon atom.  Silicon can also be introduced to replace other heteroatoms and can act as a surrogate of functional groups such as olefin and amide as well.  The present Perspective focuses on the opportunities that silicon incorporation offers in drug discovery, with an emphasis on case studies where introduction of silicon has created a benefit over its analog.  We have tried to highlight all the recent developments in the field and briefly discuss the challenges assocd. with them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjk4JZC1BTKLVg90H21EOLACvtfcHk0ljcbGeLmap01w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1KnsbvM&md5=fa3da0fddb955d156d410eb68030e78a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00718%26sid%3Dliteratum%253Aachs%26aulast%3DRamesh%26aufirst%3DR.%26aulast%3DReddy%26aufirst%3DD.%2BS.%26atitle%3DQuest%2520for%2520novel%2520chemical%2520entities%2520through%2520incorporation%2520of%2520silicon%2520in%2520drug%2520scaffolds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3779%26epage%3D3798%26doi%3D10.1021%2Facs.jmedchem.7b00718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1016%2Fj.ejmech.2018.02.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=29454920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtVWru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=95-105&author=B.+Liuauthor=K.+Gaiauthor=H.+Qinauthor=X.+Liuauthor=Y.+Caoauthor=Q.+Luauthor=D.+Luauthor=D.+Chenauthor=H.+Shenauthor=W.+Songauthor=Y.+Zhangauthor=X.+Wangauthor=H.+Xuauthor=Y.+Zhang&title=Design%2C+synthesis+and+identification+of+silicon-containing+HCV+NS5A+inhibitors+with+pan-genotype+activity&doi=10.1016%2Fj.ejmech.2018.02.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity</span></div><div class="casAuthors">Liu, Baomin; Gai, Kuo; Qin, Hui; Liu, Xushi; Cao, Yuan; Lu, Qin; Lu, Dandan; Chen, Deyang; Shen, Hengqiao; Song, Wei; Zhang, Yang; Wang, Xiaojin; Xu, Hongjiang; Zhang, Yinsheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">95-105</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Modification of a HCV NS5A inhibitor, ombitasvir, led to the identification of 10d with improved pan-genotype NS5A inhibition and better pharmacokinetic properties.  The key structural changes to ombitasvir include bioisosteric replacement of carbon with silicon atom.  Compared with ombitasvir, the activity of anti-HCV genotypes (GT 1 to 6) of 10d is increased to some extent, esp. the inhibitory activity against genotype 3a and 6a is increased by more than seven times, and the dog's in vivo pharmacokinetics properties were also superior to ombitasvir.  Further drug evaluation showed that 10d was similar to ombitasvir on plasma protein binding and liver distribution profiles, with no cytotoxicity and no inhibitory effect on both CYP 450 and hERG ligand binding.  However, permeability assay results indicated that 10d was not the substrate of P-gp or BCRP transporter, which is different from that of ombitasvir.  The results of a 14-day repeat-dose toxicity study identified no toxicity with 10d.  Our findings in preclin. tests suggest that the silicon-contg. compd. 10d could be worthy of continued study as a potential drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPr6ylPm7KrLVg90H21EOLACvtfcHk0lgfjybMMv9Eyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtVWru7g%253D&md5=a48300812980be663870fa1cf54793ac</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DGai%26aufirst%3DK.%26aulast%3DQin%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%2520and%2520identification%2520of%2520silicon-containing%2520HCV%2520NS5A%2520inhibitors%2520with%2520pan-genotype%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D148%26spage%3D95%26epage%3D105%26doi%3D10.1016%2Fj.ejmech.2018.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeGoey, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randolph, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulenko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motter, C. E.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2047</span>– <span class="NLM_lpage">2057</span>, <span class="refDoi"> DOI: 10.1021/jm401398x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401398x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2047-2057&author=D.+A.+DeGoeyauthor=J.+T.+Randolphauthor=D.+Liuauthor=J.+Prattauthor=C.+Hutchinsauthor=P.+Donnerauthor=A.+C.+Kruegerauthor=M.+Matulenkoauthor=S.+Patelauthor=C.+E.+Motter&title=Discovery+of+ABT-267%2C+a+pan-genotypic+inhibitor+of+HCV+NS5A&doi=10.1021%2Fjm401398x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A</span></div><div class="casAuthors">DeGoey, David A.; Randolph, John T.; Liu, Dachun; Pratt, John; Hutchins, Charles; Donner, Pamela; Krueger, A. Chris; Matulenko, Mark; Patel, Sachin; Motter, Christopher E.; Nelson, Lissa; Keddy, Ryan; Tufano, Michael; Caspi, Daniel D.; Krishnan, Preethi; Mistry, Neeta; Koev, Gennadiy; Reisch, Thomas J.; Mondal, Rubina; Pilot-Matias, Tami; Gao, Yi; Beno, David W. A.; Maring, Clarence J.; Molla, Akhter; Dumas, Emily; Campbell, Andrew; Williams, Laura; Collins, Christine; Wagner, Rolf; Kati, Warren M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2047-2057</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe here N-phenylpyrrolidine-based inhibitors of HCV NS5A with excellent potency, metabolic stability, and pharmacokinetics.  Compds. with 2S,5S stereochem. at the pyrrolidine ring provided improved genotype 1 (GT1) potency compared to the 2R,5R analogs.  Furthermore, the attachment of substituents at the 4-position of the central N-Ph group resulted in compds. with improved potency.  Substitution with tert-Bu, as in compd. 38 (ABT-267)(I), provided compds. with low-picomolar EC50 values and superior pharmacokinetics.  It was discovered that compd. 38 was a pan-genotypic HCV inhibitor, with an EC50 range of 1.7-19.3 pM against GT1a, -1b, -2a, -2b, -3a, -4a, and -5a and 366 pM against GT6a.  Compd. 38 decreased HCV RNA up to 3.10 log10 IU/mL during 3-day monotherapy in treatment-naive HCV GT1-infected subjects and is currently in phase 3 clin. trials in combination with an NS3 protease inhibitor with ritonavir (r) (ABT-450/r) and an NS5B non-nucleoside polymerase inhibitor (ABT-333), with and without ribavirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQLXZPjB144rVg90H21EOLACvtfcHk0lgfjybMMv9Eyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKhsQ%253D%253D&md5=70f0d0f8e9751b533617fecc1b4a8016</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm401398x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401398x%26sid%3Dliteratum%253Aachs%26aulast%3DDeGoey%26aufirst%3DD.%2BA.%26aulast%3DRandolph%26aufirst%3DJ.%2BT.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DPratt%26aufirst%3DJ.%26aulast%3DHutchins%26aufirst%3DC.%26aulast%3DDonner%26aufirst%3DP.%26aulast%3DKrueger%26aufirst%3DA.%2BC.%26aulast%3DMatulenko%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DMotter%26aufirst%3DC.%2BE.%26atitle%3DDiscovery%2520of%2520ABT-267%252C%2520a%2520pan-genotypic%2520inhibitor%2520of%2520HCV%2520NS5A%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2047%26epage%3D2057%26doi%3D10.1021%2Fjm401398x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randolph, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulenko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keddy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donner, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flentge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betebenner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockway, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maring, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilot-Matias, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekhtyar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolarik, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beno, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kati, W. M.</span></span> <span> </span><span class="NLM_article-title">Highlights of the structure-activity relationships of benzimidazole linked pyrrolidines leading to the discovery of the hepatitis C virus NS5A inhibitor pibrentasvir (ABT-530)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4052</span>– <span class="NLM_lpage">4066</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00082</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00082" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsF2rsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4052-4066&author=R.+Wagnerauthor=J.+T.+Randolphauthor=S.+V.+Patelauthor=L.+Nelsonauthor=M.+A.+Matulenkoauthor=R.+Keddyauthor=J.+K.+Prattauthor=D.+Liuauthor=A.+C.+Kruegerauthor=P.+L.+Donnerauthor=D.+K.+Hutchinsonauthor=C.+Flentgeauthor=D.+Betebennerauthor=T.+Rockwayauthor=C.+J.+Maringauthor=T.+I.+Ngauthor=P.+Krishnanauthor=T.+Pilot-Matiasauthor=C.+Collinsauthor=N.+Panchalauthor=T.+Reischauthor=T.+Dekhtyarauthor=R.+Mondalauthor=D.+F.+Stolarikauthor=Y.+Gaoauthor=W.+Gaoauthor=D.+A.+Benoauthor=W.+M.+Kati&title=Highlights+of+the+structure-activity+relationships+of+benzimidazole+linked+pyrrolidines+leading+to+the+discovery+of+the+hepatitis+C+virus+NS5A+inhibitor+pibrentasvir+%28ABT-530%29&doi=10.1021%2Facs.jmedchem.8b00082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530)</span></div><div class="casAuthors">Wagner, Rolf; Randolph, John T.; Patel, Sachin V.; Nelson, Lissa; Matulenko, Mark A.; Keddy, Ryan; Pratt, John K.; Liu, Dachun; Krueger, A. Chris; Donner, Pamela L.; Hutchinson, Douglas K.; Flentge, Charles; Betebenner, David; Rockway, Todd; Maring, Clarence J.; Ng, Teresa I.; Krishnan, Preethi; Pilot-Matias, Tami; Collins, Christine; Panchal, Neeta; Reisch, Thomas; Dekhtyar, Tatyana; Mondal, Rubina; Stolarik, DeAnne F.; Gao, Yi; Gao, Wenqing; Beno, David A.; Kati, Warren M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4052-4066</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Curative interferon and ribavirin sparing treatments for hepatitis C virus (HCV)-infected patients require a combination of mechanistically orthogonal direct acting antivirals.  A shared component of these treatments is usually an HCV NS5A inhibitor.  First generation FDA approved treatments, including the component NS5A inhibitors, do not exhibit equiv. efficacy against HCV virus genotypes 1-6.  In particular, these first generation NS5A inhibitors tend to select for viral drug resistance.  Ombitasvir is a first generation HCV NS5A inhibitor included as a key component of Viekira Pak for the treatment of patients with HCV genotype 1 infection.  Since the launch of next generation HCV treatments, functional cure for genotype 1-6 HCV infections has been achieved, as well as shortened treatment duration across a wider spectrum of genotypes.  In this paper, we show how we have modified the anchor, linker, and end-cap architecture of our NS5A inhibitor design template to discover a next generation NS5A inhibitor pibrentasvir (ABT-530), which exhibits potent inhibition of the replication of wild-type genotype 1-6 HCV replicons, as well as improved activity against replicon variants demonstrating resistance against first generation NS5A inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM7hUxmbEpArVg90H21EOLACvtfcHk0ljHzrTYb297hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsF2rsrw%253D&md5=450645ee6f484479478f549a0d07b7ae</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00082%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DR.%26aulast%3DRandolph%26aufirst%3DJ.%2BT.%26aulast%3DPatel%26aufirst%3DS.%2BV.%26aulast%3DNelson%26aufirst%3DL.%26aulast%3DMatulenko%26aufirst%3DM.%2BA.%26aulast%3DKeddy%26aufirst%3DR.%26aulast%3DPratt%26aufirst%3DJ.%2BK.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DKrueger%26aufirst%3DA.%2BC.%26aulast%3DDonner%26aufirst%3DP.%2BL.%26aulast%3DHutchinson%26aufirst%3DD.%2BK.%26aulast%3DFlentge%26aufirst%3DC.%26aulast%3DBetebenner%26aufirst%3DD.%26aulast%3DRockway%26aufirst%3DT.%26aulast%3DMaring%26aufirst%3DC.%2BJ.%26aulast%3DNg%26aufirst%3DT.%2BI.%26aulast%3DKrishnan%26aufirst%3DP.%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DPanchal%26aufirst%3DN.%26aulast%3DReisch%26aufirst%3DT.%26aulast%3DDekhtyar%26aufirst%3DT.%26aulast%3DMondal%26aufirst%3DR.%26aulast%3DStolarik%26aufirst%3DD.%2BF.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DBeno%26aufirst%3DD.%2BA.%26aulast%3DKati%26aufirst%3DW.%2BM.%26atitle%3DHighlights%2520of%2520the%2520structure-activity%2520relationships%2520of%2520benzimidazole%2520linked%2520pyrrolidines%2520leading%2520to%2520the%2520discovery%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitor%2520pibrentasvir%2520%2528ABT-530%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4052%26epage%3D4066%26doi%3D10.1021%2Facs.jmedchem.8b00082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Wanshu Wang, Song Zhou, Linjie Li, Yuanhang He, Xue Dong, Lu Gao, Qiantao Wang, <span class="NLM_string-name hlFld-ContribAuthor">Zhenlei Song</span>. </span><span class="cited-content_cbyCitation_article-title">3-Silaazetidine: An Unexplored yet Versatile Organosilane Species for Ring Expansion toward Silaazacycles. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (29)
                                     , 11141-11151. <a href="https://doi.org/10.1021/jacs.1c04667" title="DOI URL">https://doi.org/10.1021/jacs.1c04667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.1c04667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.1c04667%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3D3-Silaazetidine%25253A%252BAn%252BUnexplored%252Byet%252BVersatile%252BOrganosilane%252BSpecies%252Bfor%252BRing%252BExpansion%252Btoward%252BSilaazacycles%26aulast%3DWang%26aufirst%3DWanshu%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D10052021%26date%3D19072021%26volume%3D143%26issue%3D29%26spage%3D11141%26epage%3D11151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miguel Angel  Martinez</span>, <span class="hlFld-ContribAuthor ">Sandra  Franco</span>. </span><span class="cited-content_cbyCitation_article-title">Therapy Implications of Hepatitis C Virus Genetic Diversity. </span><span class="cited-content_cbyCitation_journal-name">Viruses</span><span> <strong>2021,</strong> <em>13 </em>
                                    (1)
                                     , 41. <a href="https://doi.org/10.3390/v13010041" title="DOI URL">https://doi.org/10.3390/v13010041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/v13010041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fv13010041%26sid%3Dliteratum%253Aachs%26jtitle%3DViruses%26atitle%3DTherapy%252BImplications%252Bof%252BHepatitis%252BC%252BVirus%252BGenetic%252BDiversity%26aulast%3DMartinez%26aufirst%3DMiguel%2BAngel%26date%3D2021%26date%3D2020%26volume%3D13%26issue%3D1%26spage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miguel Angel  Martinez</span>, <span class="hlFld-ContribAuthor ">Sandra  Franco</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 139-157. <a href="https://doi.org/10.1007/978-981-16-0267-2_6" title="DOI URL">https://doi.org/10.1007/978-981-16-0267-2_6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-16-0267-2_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-16-0267-2_6%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BAntiviral%252BTherapies%252Bfor%252BChronic%252BHepatitis%252BC%252BVirus%252BInfection%26aulast%3DMartinez%26aufirst%3DMiguel%2BAngel%26date%3D2021%26date%3D2021%26spage%3D139%26epage%3D157%26pub%3DSpringer%2520Singapore%26atitle%3DAntiviral%252BDrug%252BDiscovery%252Band%252BDevelopment%26aulast%3DLiu%26aufirst%3DXinyong%26date%3D2021%26volume%3D1322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00082&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structure of HCV NS5A inhibitors approved by FDA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00082&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structure of compound <b>1</b> and structural modification strategy for a novel NS5A inhibitor design.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00082&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. PK study of compound <b>11</b> in dog (PO 5 mpk).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00082&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0004.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Compounds <b>2–4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00082&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI), 1-hydroxybenzotriazole (HOBt), <i>N</i>-methylmorpholine (NMM), dimethylformamide (DMF), 60 °C, 2 h, 29–47% yield.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0005.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Compounds <b>5–8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00082&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) triethylamine, DMF, r.t., 12 h; (ii) H<sub>2</sub>, 10% Pd/C, tetrahydrofuran (THF), r.t., 12 h; (iii) (1<i>R</i>,4<i>R</i>)-1,4-bis(4-nitrophenyl)butane-1,4-diyl dimethanesulfonate (<b>19r</b>) or (1<i>S</i>,4<i>S</i>)-1,4-bis(4-nitrophenyl)butane-1,4-diyl dimethanesulfonate (<b>19s</b>), DMF, 60 °C, 24 h; (iv) H<sub>2</sub>, platinum dioxide, THF, r.t, 3 h; and (v) EDCI, HOBt, <i>N</i>-methylmorpholine, DMF, 55 °C, 2 h.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/medium/jm0c00082_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Compounds <b>9–12</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00082/20200520/images/large/jm0c00082_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00082&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: EDCI, HOBt, <i>N</i>-methylmorpholine, DMF, 60 °C, 2 h.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04406" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04406" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 24 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">World
Health Organization</span>,  <i>Global Hepatitis Report 2017</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=World%0AHealth+Organization&title=Global+Hepatitis+Report+2017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26btitle%3DGlobal%2520Hepatitis%2520Report%25202017%26pub%3DWorld%2520Health%2520Organization%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hajarizadeh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grebely, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, G. J.</span></span> <span> </span><span class="NLM_article-title">Epidemiology and natural history of HCV infection</span>. <i>Nat. Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">553</span>, <span class="refDoi"> DOI: 10.1038/nrgastro.2013.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1038%2Fnrgastro.2013.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=23817321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWru77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=553&author=B.+Hajarizadehauthor=J.+Grebelyauthor=G.+J.+Dore&title=Epidemiology+and+natural+history+of+HCV+infection&doi=10.1038%2Fnrgastro.2013.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology and natural history of HCV infection</span></div><div class="casAuthors">Hajarizadeh, Behzad; Grebely, Jason; Dore, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">553-562</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Worldwide, an estd. 130-170 million people have HCV infection.  HCV prevalence is highest in Egypt at >10% of the general population and China has the most people with HCV (29.8 million).  Differences in past HCV incidence and current HCV prevalence, together with the generally protracted nature of HCV disease progression, has led to considerable diversity in the burden of advanced liver disease in different countries.  Countries with a high incidence of HCV or peak incidence in the recent past will have further escalations in HCV-related cirrhosis and hepatocellular carcinoma (HCC) over the next two decades.  Acute HCV infection is difficult to detect because of the generally asymptomatic nature of the disease and the marginalization of at-risk populations.  Around 25% of patients with acute HCV infection undergo spontaneous clearance, with increased rates among those with favorable IL28B genotypes, acute symptoms and in women.  The remaining 75% of patients progress to chronic HCV infection and are subsequently at risk of progression to hepatic fibrosis, cirrhosis and HCC.  Chronic hepatitis C generally progresses slowly in the initial two decades, but can be accelerated during this time as a result of advancing age and co-factors such as heavy alc. intake and HIV co-infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAGJrt4DO4BLVg90H21EOLACvtfcHk0ljp1qHHXKb2bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWru77F&md5=1542a3394c3bd84018527b88232950d4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2013.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2013.107%26sid%3Dliteratum%253Aachs%26aulast%3DHajarizadeh%26aufirst%3DB.%26aulast%3DGrebely%26aufirst%3DJ.%26aulast%3DDore%26aufirst%3DG.%2BJ.%26atitle%3DEpidemiology%2520and%2520natural%2520history%2520of%2520HCV%2520infection%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2013%26volume%3D10%26spage%3D553%26doi%3D10.1038%2Fnrgastro.2013.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. J.</span></span> <span> </span><span class="NLM_article-title">Interferon-free combination therapies for the treatment of hepatitis C: current insights</span>. <i>Hepatic Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">51</span>, <span class="refDoi"> DOI: 10.2147/HMER.S55864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.2147%2FHMER.S55864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=26586968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A280%3ADC%252BC28rgsVSqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=51&author=J.+A.+Holmesauthor=A.+J.+Thompson&title=Interferon-free+combination+therapies+for+the+treatment+of+hepatitis+C%3A+current+insights&doi=10.2147%2FHMER.S55864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon-free combination therapies for the treatment of hepatitis C: current insights</span></div><div class="casAuthors">Holmes Jacinta A; Thompson Alexander J</div><div class="citationInfo"><span class="NLM_cas:title">Hepatic medicine : evidence and research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-70</span>
        ISSN:<span class="NLM_cas:issn">1179-1535</span>.
    </div><div class="casAbstract">The hepatitis C virus (HCV) treatment landscape has rapidly changed over the past 5 years.  The development of direct-acting antiviral (DAA) agents that specifically target various steps in the HCV lifecycle has revolutionized therapeutic options for patients with HCV, with the development of highly effective and well-tolerated oral interferon-free regimens.  There are many DAAs that are currently in development or have recently been approved, which target different nonstructural HCV proteins and host targets that are essential for HCV replication.  This review will focus on the different classes of DAAs and the various combinations that are in advanced development for the treatment of chronic HCV infection and will focus on the different regimens in specific patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSaWQI_kNsvcFvAgqb2vdc5fW6udTcc2eYgL5wuIFExerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgsVSqtg%253D%253D&md5=132f4de5a7104defd164235b90711976</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2147%2FHMER.S55864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FHMER.S55864%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DJ.%2BA.%26aulast%3DThompson%26aufirst%3DA.%2BJ.%26atitle%3DInterferon-free%2520combination%2520therapies%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%253A%2520current%2520insights%26jtitle%3DHepatic%2520Med.%26date%3D2015%26volume%3D7%26spage%3D51%26doi%3D10.2147%2FHMER.S55864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talwani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temesgen, Z.</span></span> <span> </span><span class="NLM_article-title">Simeprevir: a macrocyclic HCV protease inhibitor</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1358/dot.2013.49.12.2067249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1358%2Fdot.2013.49.12.2067249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A280%3ADC%252BC2cvkvValsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=769-779&author=R.+Talwaniauthor=E.+Heilauthor=B.+Gilliamauthor=Z.+Temesgen&title=Simeprevir%3A+a+macrocyclic+HCV+protease+inhibitor&doi=10.1358%2Fdot.2013.49.12.2067249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Simeprevir: a macrocyclic HCV protease inhibitor</span></div><div class="casAuthors">Talwani R; Gilliam B L; Heil E L; Temesgen Z</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">769-79</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Simeprevir is a macrocyclic NS3/4A HCV protease inhibitor with potent activity against genotypes 1, 2, 4, 5 and 6 of the hepatitis C virus (HCV).  Phase II and III studies of simeprevir combined with pegylated interferon (peg-IFN) and ribavirin (RBV) demonstrated that the combination was safe and effective in HCV genotype 1 patients, with more than 75% of treatment-naive patients attaining a sustained virological response (SVR).  Simeprevir is administered once daily as a single 150-mg capsule.  It has a moderate drug interaction potential, but less than that of the first-generation HCV protease inhibitors.  Based on positive results from the product's phase III clinical program, simeprevir was approved and launched in Japan, the U.S. and Canada in late 2013 for use in combination with peg-IFN/RBV in HCV genotype 1 infections.  Phase II interferon-free studies of simeprevir are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPRn_AgMrD_MrRqEXsZufAfW6udTcc2eYgL5wuIFExerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvkvValsQ%253D%253D&md5=8a51a1cd0c0c4ced80310cf70ea62d3b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1358%2Fdot.2013.49.12.2067249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2013.49.12.2067249%26sid%3Dliteratum%253Aachs%26aulast%3DTalwani%26aufirst%3DR.%26aulast%3DHeil%26aufirst%3DE.%26aulast%3DGilliam%26aufirst%3DB.%26aulast%3DTemesgen%26aufirst%3DZ.%26atitle%3DSimeprevir%253A%2520a%2520macrocyclic%2520HCV%2520protease%2520inhibitor%26jtitle%3DDrugs%2520Today%26date%3D2013%26volume%3D49%26spage%3D769%26epage%3D779%26doi%3D10.1358%2Fdot.2013.49.12.2067249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardo
Buonomo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zappulo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaldo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, G.</span></span> <span> </span><span class="NLM_article-title">ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3261</span>– <span class="NLM_lpage">3270</span>, <span class="refDoi"> DOI: 10.2174/0929867321666140706125950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.2174%2F0929867321666140706125950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=25005190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCqsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=3261-3270&author=I.+Gentileauthor=F.+Borgiaauthor=A.+Riccardo%0ABuonomoauthor=E.+Zappuloauthor=G.+Castaldoauthor=G.+Borgia&title=ABT-450%3A+a+novel+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.2174%2F0929867321666140706125950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Gentile, Ivan; Borgia, Federico; Buonomo, Antonio Riccardo; Zappulo, Emanuela; Castaldo, Giuseppe; Borgia, Guglielmo</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3261-3270</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">About 2.3% of the world's population is infected with hepatitis C virus (HCV) and patients have a high risk of developing liver cirrhosis and its complications.  Current therapeutic strategies are based on a combination of pegylated interferon, ribavirin and (only for patients with genotype 1 infection) a protease inhibitor (boceprevir or telaprevir).  Consequently, all these combinations have the limitations of interferon.  In fact, they are contraindicated in decompensated disease and in subjects with severe comorbidities, and are assocd. with a high rate of side effects.  Moreover, they are poorly effective in advanced disease.  As complete viral eradication is assocd. with improved disease-free survival, several mols. are under clin. development for their potential to overcome the drawbacks of currently available treatments.  This review focuses on the pharmacodynamics, pharmacokinetics, safety and tolerability of ABT-450, a potent inhibitor of non-structural 3 protease.  ABT-450 is a substrate of cytochrome P 450; hence its co-administration with ritonavir, a cytochrome P 450 inhibitor, dramatically increases the plasma concn. and half-life of ABT-450 and allows once-daily administration.  Given in monotherapy for 3 days at different doses, ABT-450 causes a mean max. viral decline of about 4 logs.  Interestingly, high doses of ABT-450 are assocd. with a reduced and delayed development of resistance-conferring mutations.  Given in combination with other direct antiviral drugs, the sustained response rate reaches 90-95% in both naive and treatment-experienced genotype 1 patients, and tolerability is good.  In conclusion, ABT-450 is an excellent component of interferon-free combinations for the treatment of chronic HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR_Au_8lnB9rVg90H21EOLACvtfcHk0lhugRqLD9cFRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCqsrzL&md5=e2f8c94407cd48efccb0d480acb5ad1a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F0929867321666140706125950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867321666140706125950%26sid%3Dliteratum%253Aachs%26aulast%3DGentile%26aufirst%3DI.%26aulast%3DBorgia%26aufirst%3DF.%26aulast%3DRiccardo%2BBuonomo%26aufirst%3DA.%26aulast%3DZappulo%26aufirst%3DE.%26aulast%3DCastaldo%26aufirst%3DG.%26aulast%3DBorgia%26aufirst%3DG.%26atitle%3DABT-450%253A%2520a%2520novel%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2014%26volume%3D21%26spage%3D3261%26epage%3D3270%26doi%3D10.2174%2F0929867321666140706125950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben Ari, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollison, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuckerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baruch, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhanja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, M. N.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of grazoprevir+ ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection</span>. <i>J. Viral Hepatitis</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1111/jvh.12552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1111%2Fjvh.12552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=27291249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWmtbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=789-797&author=E.+Ganeauthor=Z.+Ben+Ariauthor=L.+Mollisonauthor=E.+Zuckermanauthor=R.+Bruckauthor=Y.+Baruchauthor=A.+Howeauthor=J.+Wahlauthor=S.+Bhanjaauthor=P.+Hwangauthor=Y.+Zhaoauthor=M.+N.+Robertson&title=Efficacy+and+safety+of+grazoprevir%2B+ribavirin+for+12+or+24+weeks+in+treatment-na%C3%AFve+patients+with+hepatitis+C+virus+genotype+1+infection&doi=10.1111%2Fjvh.12552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naive patients with hepatitis C virus genotype 1 infection</span></div><div class="casAuthors">Gane, E.; Ben Ari, Z.; Mollison, L.; Zuckerman, E.; Bruck, R.; Baruch, Y.; Howe, A. Y. M.; Wahl, J.; Bhanja, S.; Hwang, P.; Zhao, Y.; Robertson, M. N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Viral Hepatitis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">789-797</span>CODEN:
                <span class="NLM_cas:coden">JVHEER</span>;
        ISSN:<span class="NLM_cas:issn">1365-2893</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Summary : Grazoprevir (GZR) is a second-generation hepatitis C virus NS3/4A protease inhibitor.  The aim of this study was to evaluate GZR plus ribavirin (RBV) in patients with HCV GT1 infection.  Noncirrhotic, IL28BCC patients with HCV genotype 1 infection were randomized to GZR 100 mg once daily and RBV for 12 or 24 wk.  Patients in the 12-wk arm with detectable HCV RNA at treatment week 4 (TW4) had treatment extended to 24 wk (response-guided therapy, RGT).  The primary endpoint was sustained virol. response (SVR12) at follow-up week 12 (HCV RNA <25 IU/mL) in the per-protocol (PP) population (excluding patients with important protocol deviations).  Twenty-six patients were randomized and 22 were included in the PP population.  SVR12 was 58.3% (7 of 12) and 90% (9 of 10) in the RGT and 24-wk arms, resp.  Seven PP patients had virol. failure, including one patient in the 24-wk arm who relapsed after follow-up week 12.  All three breakthrough patients had wild-type (WT) virus at baseline and developed breakthrough at TW6 or TW12 with Y56H, A156T and D168A/N mutations.  Of the five relapse patients, four had WT at baseline (at relapse three had WT and one had V55A and D168A), and one had S122A/T at baseline and S122T at relapse.  There were no serious adverse events (AEs), discontinuations due to AEs or grade 3/4 elevations in total and/or direct bilirubin.  Grazoprevir plus RBV was assocd. with a rapid and sustained suppression of HCV RNA.  These results support further evaluation of grazoprevir-based regimens (NCT01716156; protocol P039).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM823BVjHI_7Vg90H21EOLACvtfcHk0lhugRqLD9cFRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWmtbfO&md5=701c82ed6412de104bb737882c7b1cf9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fjvh.12552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.12552%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%26aulast%3DBen%2BAri%26aufirst%3DZ.%26aulast%3DMollison%26aufirst%3DL.%26aulast%3DZuckerman%26aufirst%3DE.%26aulast%3DBruck%26aufirst%3DR.%26aulast%3DBaruch%26aufirst%3DY.%26aulast%3DHowe%26aufirst%3DA.%26aulast%3DWahl%26aufirst%3DJ.%26aulast%3DBhanja%26aufirst%3DS.%26aulast%3DHwang%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DRobertson%26aufirst%3DM.%2BN.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520grazoprevir%252B%2520ribavirin%2520for%252012%2520or%252024%2520weeks%2520in%2520treatment-na%25C3%25AFve%2520patients%2520with%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2016%26volume%3D23%26spage%3D789%26epage%3D797%26doi%3D10.1111%2Fjvh.12552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeuzem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asatryan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feld, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asselah, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourlière, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruane, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedemeyer, H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1702417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1056%2FNEJMoa1702417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=29365309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFSgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=354-369&author=S.+Zeuzemauthor=G.+R.+Fosterauthor=S.+Wangauthor=A.+Asatryanauthor=E.+Ganeauthor=J.+J.+Feldauthor=T.+Asselahauthor=M.+Bourli%C3%A8reauthor=P.+J.+Ruaneauthor=H.+Wedemeyer&title=Glecaprevir%E2%80%93pibrentasvir+for+8+or+12+weeks+in+HCV+genotype+1+or+3+infection&doi=10.1056%2FNEJMoa1702417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection</span></div><div class="casAuthors">Zeuzem, S.; Foster, G. R.; Wang, S.; Asatryan, A.; Gane, E.; Feld, J. J.; Asselah, T.; Bourliere, M.; Ruane, P. J.; Wedemeyer, H.; Pol, S.; Flisiak, R.; Poordad, F.; Chuang, W.-L.; Stedman, C. A.; Flamm, S.; Kwo, P.; Dore, G. J.; Sepulveda-Arzola, G.; Roberts, S. K.; Soto-Malave, R.; Kaita, K.; Puoti, M.; Vierling, J.; Tam, E.; Vargas, H. E.; Bruck, R.; Fuster, F.; Paik, S.-W.; Felizarta, F.; Kort, J.; Fu, B.; Liu, R.; Ng, T. I.; Pilot-Matias, T.; Lin, C.-W.; Trinh, R.; Mensa, F. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">354-369</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Glecaprevir and pibrentasvir are direct-acting antiviral agents with pangenotypic activity and a high barrier to resistance.  We evaluated the efficacy and safety of 8-wk and 12-wk courses of treatment with 300 mg of glecaprevir plus 120 mg of pibrentasvir in patients without cirrhosis who had hepatitis C virus (HCV) genotype 1 or 3 infection. methods We conducted two phase 3, randomized, open-label, multicenter trials.  Patients with genotype 1 infection were randomly assigned in a 1:1 ratio to receive once-daily glecaprevir-pibrentasvir for either 8 or 12 wk.  Patients with genotype 3 infection were randomly assigned in a 2:1 ratio to receive 12 wk of treatment with either glecaprevir-pibrentasvir or sofosbuvir-daclatasvir.  Addnl. patients with genotype 3 infection were subsequently enrolled and nonrandomly assigned to receive 8 wk of treatment with glecaprevir-pibrentasvir.  The primary end point was the rate of sustained virol. response 12 wk after the end of treatment. results In total, 1208 patients were treated.  The rate of sustained virol. response at 12 wk among genotype 1-infected patients was 99.1% (95% confidence interval [CI], 98 to 100) in the 8-wk group and 99.7% (95% CI, 99 to 100) in the 12-wk group.  Genotype 3-infected patients who were treated for 12 wk had a rate of sustained virol. response at 12 wk of 95% (95% CI, 93 to 98; 222 of 233 patients) with glecaprevir-pibrentasvir and 97% (95% CI, 93 to 99.9; 111 of 115) with sofosbuvir-daclatasvir; 8 wk of treatment with glecaprevir-pibrentasvir yielded a rate of 95% (95% CI, 91 to 98; 149 of 157 patients).  Adverse events led to discontinuation of treatment in no more than 1% of patients in any treatment group. conclusions Once-daily treatment with glecaprevir-pibrentasvir for either 8 wk or 12 wk achieved high rates of sustained virol. response among patients with HCV genotype 1 or 3 infection who did not have cirrhosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpODsBNSDJYN7Vg90H21EOLACvtfcHk0lhugRqLD9cFRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFSgsrs%253D&md5=29bb370c8a59263f9f6a56406c20ef2d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1702417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1702417%26sid%3Dliteratum%253Aachs%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DAsatryan%26aufirst%3DA.%26aulast%3DGane%26aufirst%3DE.%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DRuane%26aufirst%3DP.%2BJ.%26aulast%3DWedemeyer%26aufirst%3DH.%26atitle%3DGlecaprevir%25E2%2580%2593pibrentasvir%2520for%25208%2520or%252012%2520weeks%2520in%2520HCV%2520genotype%25201%2520or%25203%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D354%26epage%3D369%26doi%3D10.1056%2FNEJMoa1702417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feld, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hézode, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asselah, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruane, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruener, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abergel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. L.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">2599</span>– <span class="NLM_lpage">2607</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1512610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1056%2FNEJMoa1512610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=26571066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2599-2607&author=J.+J.+Feldauthor=I.+M.+Jacobsonauthor=C.+H%C3%A9zodeauthor=T.+Asselahauthor=P.+J.+Ruaneauthor=N.+Gruenerauthor=A.+Abergelauthor=A.+Mangiaauthor=C.-L.+Laiauthor=H.+L.+Chan&title=Sofosbuvir+and+velpatasvir+for+HCV+genotype+1%2C+2%2C+4%2C+5%2C+and+6+infection&doi=10.1056%2FNEJMoa1512610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection</span></div><div class="casAuthors">Feld, J. J.; Jacobson, I. M.; Hezode, C.; Asselah, T.; Ruane, P. J.; Gruener, N.; Abergel, A.; Mangia, A.; Lai, C.-L.; Chan, H. L. Y.; Mazzotta, F.; Moreno, C.; Yoshida, E.; Shafran, S. D.; Towner, W. J.; Tran, T. T.; McNally, J.; Osinusi, A.; Svarovskaia, E.; Zhu, Y.; Brainard, D. M.; McHutchison, J. G.; Agarwal, K.; Zeuzem, S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">2599-2607</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A simple treatment regimen that is effective in a broad range of patients who are chronically infected with the hepatitis C virus (HCV) remains an unmet medical need.  We conducted a phase 3, double-blind, placebo-controlled study involving untreated and previously treated patients with chronic HCV genotype 1, 2, 4, 5, or 6 infection, including those with compensated cirrhosis.  Patients with HCV genotype 1, 2, 4, or 6 were randomly assigned in a 5:1 ratio to receive the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir in a once-daily, fixed-dose combination tablet or matching placebo for 12 wk.  Because of the low prevalence of genotype 5 in the study regions, patients with genotype 5 did not undergo randomization but were assigned to the sofosbuvir-velpatasvir group.  The primary end point was a sustained virol. response at 12 wk after the end of therapy.  Of the 624 patients who received treatment with sofosbuvir-velpatasvir, 34% had HCV genotype 1a, 19% genotype 1b, 17% genotype 2, 19% genotype 4, 6% genotype 5, and 7% genotype 6.  A total of 8% of patients were black, 19% had cirrhosis, and 32% had been previously treated for HCV.  The rate of sustained virol. response among patients receiving sofosbuvir-velpatasvir was 99% (95% confidence interval, 98 to >99).  Two patients receiving sofosbuvir-velpatasvir, both with HCV genotype 1, had a virol. relapse.  None of the 116 patients receiving placebo had a sustained virol. response.  Serious adverse events were reported in 15 patients (2%) in the sofosbuvir-velpatasvir group and none in the placebo group.  Once-daily sofosbuvir-velpatasvir for 12 wk provided high rates of sustained virol. response among both previously treated and untreated patients infected with HCV genotype 1, 2, 4, 5, or 6, including those with compensated cirrhosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIaLSuQe4dW7Vg90H21EOLACvtfcHk0ljnaj729hsOXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlurjO&md5=cb66c57f7845aff86567d3b59705faf6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1512610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1512610%26sid%3Dliteratum%253Aachs%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DRuane%26aufirst%3DP.%2BJ.%26aulast%3DGruener%26aufirst%3DN.%26aulast%3DAbergel%26aufirst%3DA.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DC.-L.%26aulast%3DChan%26aufirst%3DH.%2BL.%26atitle%3DSofosbuvir%2520and%2520velpatasvir%2520for%2520HCV%2520genotype%25201%252C%25202%252C%25204%252C%25205%252C%2520and%25206%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2599%26epage%3D2607%26doi%3D10.1056%2FNEJMoa1512610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">R Buonomo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, G.</span></span> <span> </span><span class="NLM_article-title">Dasabuvir: a non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infection</span>. <i>Rev. Recent Clin. Trials</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.2174/1574887109666140529222602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.2174%2F1574887109666140529222602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=24882169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGqu7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=115-123&author=I.+Gentileauthor=A.+R+Buonomoauthor=G.+Borgia&title=Dasabuvir%3A+a+non-nucleoside+inhibitor+of+NS5B+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.2174%2F1574887109666140529222602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Gentile, Ivan; Buonomo, Antonio R.; Borgia, Guglielmo</div><div class="citationInfo"><span class="NLM_cas:title">Reviews on Recent Clinical Trials</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-123</span>CODEN:
                <span class="NLM_cas:coden">RRCTB2</span>;
        ISSN:<span class="NLM_cas:issn">1574-8871</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) chronically infects about 2% of the world's population.  Approx. a quarter of these patients will develop, during their life, liver cirrhosis, which entails a high risk of complications and death.  Successful antiviral therapy can reduce the risk of disease progression, but it is feasible only in a minority of patients because it includes interferon which is contraindicated in the most advanced stages of the disease and in patients with severe impairment of other organs.  Consequent to the launch of the first direct antiviral agents (DAA), namely the protease inhibitors telaprevir and boceprevir, several mols. are in an advanced phase of clin. development to be used in assocn. with interferon or with other DAA (in interferon-free combinations).  This review focuses on the mechanism of action, pharmacokinetics, efficacy, safety and resistance of dasabuvir, a non-nucleoside inhibitor of NS5B viral RNA-dependent RNA polymerase.  Thanks to its pharmacokinetics, dasabuvir can be administered twice daily.  In combinations with other oral DAAs, dasabuvir results in very high rates of SVR (about 95%) in patients with HCV genotype 1 infection with a good tolerability and safety.  In conclusion, dasabuvir is a good agent to be used in interferon-free combinations for the treatment of chronic hepatitis C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUMZrbnwVJvrVg90H21EOLACvtfcHk0ljnaj729hsOXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGqu7vJ&md5=75f136bd5bccdf288697d8aba73ba037</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F1574887109666140529222602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1574887109666140529222602%26sid%3Dliteratum%253Aachs%26aulast%3DGentile%26aufirst%3DI.%26aulast%3DR%2BBuonomo%26aufirst%3DA.%26aulast%3DBorgia%26aufirst%3DG.%26atitle%3DDasabuvir%253A%2520a%2520non-nucleoside%2520inhibitor%2520of%2520NS5B%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DRev.%2520Recent%2520Clin.%2520Trials%26date%3D2014%26volume%3D9%26spage%3D115%26epage%3D123%26doi%3D10.2174%2F1574887109666140529222602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pol, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghalib, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustgi, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martorell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everson, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatum, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hézode, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronowicki, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, G. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(12)70138-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1016%2FS1473-3099%2812%2970138-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=22714001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GlsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=671-677&author=S.+Polauthor=R.+H.+Ghalibauthor=V.+K.+Rustgiauthor=C.+Martorellauthor=G.+T.+Eversonauthor=H.+A.+Tatumauthor=C.+H%C3%A9zodeauthor=J.+K.+Limauthor=J.-P.+Bronowickiauthor=G.+A.+Abrams&title=Daclatasvir+for+previously+untreated+chronic+hepatitis+C+genotype-1+infection%3A+a+randomised%2C+parallel-group%2C+double-blind%2C+placebo-controlled%2C+dose-finding%2C+phase+2a+trial&doi=10.1016%2FS1473-3099%2812%2970138-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial</span></div><div class="casAuthors">Pol, Stanislas; Ghalib, Reem H.; Rustgi, Vinod K.; Martorell, Claudia; Everson, Greg T.; Tatum, Harvey A.; Hezode, Christophe; Lim, Joseph K.; Bronowicki, Jean-Pierre; Abrams, Gary A.; Braeu, Norbert; Morris, David W.; Thuluvath, Paul J.; Reindollar, Robert W.; Yin, Philip D.; Diva, Ulysses; Hindes, Robert; McPhee, Fiona; Hernandez, Dennis; Wind-Rotolo, Megan; Hughes, Eric A.; Schnittman, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">671-677</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Several direct-acting antivirals for chronic hepatitis C virus (HCV) infection are available, but they are limited by tolerability and dosing schedules.  Once-daily daclatasvir, a potent NS5A replication complex inhibitor, was generally well tolerated in phase 1 studies.  We assessed daclatasvir in combination with pegylated interferon (peginterferon) and ribavirin for chronic HCV.  Methods: In this double-blind, parallel-group, dose-finding, phase 2a study, treatment-naive patients with HCV genotype-1 infection (without cirrhosis) from 14 centers in the USA and France were randomly assigned (1:1:1:1) to receive peginterferon alfa-2a (180 μg per wk) and ribavirin (1000-1200 mg daily) plus placebo or 3 mg, 10 mg, or 60 mg of daclatasvir taken once daily, for 48 wk.  The primary efficacy endpoint was undetectable HCV RNA at 4 wk and 12 wk after start of treatment (extended rapid virol. response, eRVR).  Anal. was of all participants who received one dose of study drug.  We used descriptive analyses to compare results.  This study is registered with ClinicalTrials.gov, no. NCT00874770.  Findings: 48 patients were randomly assigned (12 per group); all received at least one dose of study drug. 15 patients discontinued treatment before week 48.  Five of 12 patients (42%, 80% CI 22-64%) who received 3 mg daclatasvir achieved eRVR, compared with ten of 12 (83%, 61-96%) who received 10 mg daclatasvir, nine of 12 (75%, 53-90%) who received 60 mg daclatasvir, and one of 12 (8%, 1-29%) who received placebo.  Adverse events and discontinuations as a result of adverse events occurred with similar frequency across groups.  Interpretation: Daclatasvir seems to be a potent NS5A replication complex inhibitor that increases the antiviral potency of peginterferon and ribavirin.  Our findings support the further development of regimens contg. 60 mg daclatasvir for the treatment of chronic genotype-1 HCV infection.  Funding: Bristol-Myers Squibb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0jrF6ixurObVg90H21EOLACvtfcHk0ljnaj729hsOXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GlsL%252FJ&md5=fb310d15629ecd376196a92faa8291ba</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2812%2970138-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252812%252970138-X%26sid%3Dliteratum%253Aachs%26aulast%3DPol%26aufirst%3DS.%26aulast%3DGhalib%26aufirst%3DR.%2BH.%26aulast%3DRustgi%26aufirst%3DV.%2BK.%26aulast%3DMartorell%26aufirst%3DC.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DTatum%26aufirst%3DH.%2BA.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DBronowicki%26aufirst%3DJ.-P.%26aulast%3DAbrams%26aufirst%3DG.%2BA.%26atitle%3DDaclatasvir%2520for%2520previously%2520untreated%2520chronic%2520hepatitis%2520C%2520genotype-1%2520infection%253A%2520a%2520randomised%252C%2520parallel-group%252C%2520double-blind%252C%2520placebo-controlled%252C%2520dose-finding%252C%2520phase%25202a%2520trial%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2012%26volume%3D12%26spage%3D671%26epage%3D677%26doi%3D10.1016%2FS1473-3099%2812%2970138-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feld, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowdley, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coakley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiland, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilot-Matias, T.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Treatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">1594</span>– <span class="NLM_lpage">1603</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1315722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1056%2FNEJMoa1315722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=24720703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnt1Grsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1594-1603&author=J.+J.+Feldauthor=K.+V.+Kowdleyauthor=E.+Coakleyauthor=S.+Sigalauthor=D.+R.+Nelsonauthor=D.+Crawfordauthor=O.+Weilandauthor=H.+Aguilarauthor=J.+Xiongauthor=T.+Pilot-Matias&title=Treatment+of+HCV+with+ABT-450%2Fr%E2%80%93ombitasvir+and+dasabuvir+with+ribavirin&doi=10.1056%2FNEJMoa1315722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin</span></div><div class="casAuthors">Feld, Jordan J.; Kowdley, Kris V.; Coakley, Eoin; Sigal, Samuel; Nelson, David R.; Crawford, Darrell; Weiland, Ola; Aguilar, Humberto; Xiong, Junyuan; Pilot-Matias, Tami; Da Silva-Tillmann, Barbara; Larsen, Lois; Podsadecki, Thomas; Bernstein, Barry</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1594-1603</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The interferon-free combination of the protease inhibitor ABT-450 With ritonavir (ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the non-nucleoside polymerase inhibitor dasabuvir (also known as ABT-333) and ribavirin has shown efficacy against the hepatitis C virus (HCV) in patients with HCV genotype 1 infection.  In this phase 3 trial, we evaluated this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis.  METHODS In this multicenter, randomized, double-blind, placebo-controlled trial, we assigned previously untreated patients with HCV genotype 1 infection, in a 3:1 ratio, to an active regimen consisting of a single-tablet coformulation of ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), and dasabuvir (250 mg twice daily) with ribavirin (in doses detd. according to body wt.) (group A) or matching placebos (group B).  The patients received the study treatment during a 12-wk double-blind period.  The primary end point was sustained virol. response at 12 wk after the end of treatment.  The primary anal. compared the response rate in group A with the response rate (78%) in a historical control group of previously untreated patients without cirrhosis who received telaprevir with peginterferon and ribavirin.  Adverse events occurring during the double-blind period were compared between group A and group B.  RESULTS A total of 631 patients received at least one dose of the study drugs.  The rate of sustained virol. response in group A was 96.2% (95% confidence interval, 94.5 to 97.9), which was superior to the historical control rate.  Virol. failure during treatment and relapse after treatment occurred in 0.2% and 1.5%, resp., of the patients in group A.  The response rates in group A were 95.3% among patients with HCV genotype 1a infection and 98.0% among those with HCV genotype 1b infection.  The rate of discontinuation due to adverse events was 0.6% in each study group.  Nausea, pruritus, insomnia, diarrhea, and asthenia occurred in significantly more patients in group A than in group B (P < 0.05 for all comparisons).  Redns. in the Hb level were all of grade 1 or 2; redns. of grade 1 and 2 occurred in 47.5% and 5.8%, resp., of the patients in group A, whereas grade 1 redns. occurred in 2.5% of the patients in group B.  CONCLUSIONS In previously untreated patients with HCV genotype 1 infection and no cirrhosis, a 12-wk multitargeted regimen of ABT-450/r-ombitasvir and dasabuvir with ribavirin was highly effective and was assocd. with a low rate of treatment discontinuation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGvK9K2P4sJ7Vg90H21EOLACvtfcHk0liWQ030nvB6lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnt1Grsrg%253D&md5=0e5e8ff9c7ebd43fe755c3d3c77f3462</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1315722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1315722%26sid%3Dliteratum%253Aachs%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DCoakley%26aufirst%3DE.%26aulast%3DSigal%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DCrawford%26aufirst%3DD.%26aulast%3DWeiland%26aufirst%3DO.%26aulast%3DAguilar%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.%26aulast%3DPilot-Matias%26aufirst%3DT.%26atitle%3DTreatment%2520of%2520HCV%2520with%2520ABT-450%252Fr%25E2%2580%2593ombitasvir%2520and%2520dasabuvir%2520with%2520ribavirin%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1594%26epage%3D1603%26doi%3D10.1056%2FNEJMoa1315722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Afdhal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeuzem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chojkier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitlin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puoti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero-Gomez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarski, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggisch, P.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">1889</span>– <span class="NLM_lpage">1898</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1402454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1056%2FNEJMoa1402454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=24725239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1889-1898&author=N.+Afdhalauthor=S.+Zeuzemauthor=P.+Kwoauthor=M.+Chojkierauthor=N.+Gitlinauthor=M.+Puotiauthor=M.+Romero-Gomezauthor=J.-P.+Zarskiauthor=K.+Agarwalauthor=P.+Buggisch&title=Ledipasvir+and+sofosbuvir+for+untreated+HCV+genotype+1+infection&doi=10.1056%2FNEJMoa1402454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</span></div><div class="casAuthors">Afdhal, Nezam; Zeuzem, Stefan; Kwo, Paul; Chojkier, Mario; Gitlin, Norman; Puoti, Massimo; Romero-Gomez, Manuel; Zarski, Jean-Pierre; Agarwal, Kosh; Buggisch, Peter; Foster, Graham R.; Brau, Norbert; Buti, Maria; Jacobson, Ira M.; Subramanian, G. Mani; Ding, Xiao; Mo, Hongmei; Yang, Jenny C.; Pang, Phillip S.; Symonds, William T.; McHutchison, John G.; Muir, Andrew J.; Mangia, Alessandra; Marcellin, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1889-1898, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virol. response among previously untreated patients with hepatitis C virus (HCV) genotype 1 infection.  Methods: We conducted a phase 3, open-label study involving previously untreated patients with chronic HCV genotype 1 infection.  Patients were randomly assigned in a 1:1:1:1 ratio to receive ledipasvir and sofosbuvir in a fixed-dose combination tablet once daily for 12 wk, ledipasvir-sofosbuvir plus ribavirin for 12 wk, ledipasvir- sofosbuvir for 24 wk, or ledipasvir-sofosbuvir plus ribavirin for 24 wk.  The primary end point was a sustained virol. response at 12 wk after the end of therapy.  Results: Of the 865 patients who underwent randomization and were treated, 16% had cirrhosis, 12% were black, and 67% had HCV genotype 1a infection.  The rates of sustained virol. response were 99% (95% confidence interval [CI], 96 to 100) in the group that received 12 wk of ledipasvir-sofosbuvir; 97% (95% CI, 94 to 99) in the group that received 12 wk of ledipasvir-sofosbuvir plus ribavirin; 98% (95% CI, 95 to 99) in the group that received 24 wk of ledipasvir-sofosbuvir; and 99% (95% CI, 97 to 100) in the group that received 24 wk of ledipasvir-sofosbuvir plus ribavirin.  No patient in either 12-wk group discontinued ledipasvir-sofosbuvir owing to an adverse event.  The most common adverse events were fatigue, headache, insomnia, and nausea.  Conculsions: Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 wk was highly effective in previously untreated patients with HCV genotype 1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroadkxw2jRR7Vg90H21EOLACvtfcHk0liWQ030nvB6lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnM&md5=e433fd7d493c1c0f9dfef37c1527388f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402454%26sid%3Dliteratum%253Aachs%26aulast%3DAfdhal%26aufirst%3DN.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DKwo%26aufirst%3DP.%26aulast%3DChojkier%26aufirst%3DM.%26aulast%3DGitlin%26aufirst%3DN.%26aulast%3DPuoti%26aufirst%3DM.%26aulast%3DRomero-Gomez%26aufirst%3DM.%26aulast%3DZarski%26aufirst%3DJ.-P.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DBuggisch%26aufirst%3DP.%26atitle%3DLedipasvir%2520and%2520sofosbuvir%2520for%2520untreated%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1889%26epage%3D1898%26doi%3D10.1056%2FNEJMoa1402454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMonagle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludmerer, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jumes, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingravallo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6922</span>– <span class="NLM_lpage">6929</span>, <span class="refDoi"> DOI: 10.1128/AAC.01390-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1128%2FAAC.01390-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=26303801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtVynt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=6922-6929&author=R.+Liuauthor=S.+Curryauthor=P.+McMonagleauthor=W.+W.+Yehauthor=S.+W.+Ludmererauthor=P.+A.+Jumesauthor=W.+L.+Marshallauthor=S.+Kongauthor=P.+Ingravalloauthor=S.+Black&title=Susceptibilities+of+genotype+1a%2C+1b%2C+and+3+hepatitis+C+virus+variants+to+the+NS5A+inhibitor+elbasvir&doi=10.1128%2FAAC.01390-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir</span></div><div class="casAuthors">Liu, Rong; Curry, Stephanie; McMonagle, Patricia; Yeh, Wendy W.; Ludmerer, Steven W.; Jumes, Patricia A.; Marshall, William L.; Kong, Stephanie; Ingravallo, Paul; Black, Stuart; Pak, Irene; Di Nubile, Mark J.; Howe, Anita Y. M.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6922-6929</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Elbasvir is an investigational NS5A inhibitor with in vitro activity against multiple HCV genotypes.  Antiviral activity of elbasvir was measured in replicons derived from wild-type or resistant variants of genotypes 1a, 1b, and 3.  The barrier to resistance was assessed by the no. of resistant colonies selected by exposure to various elbasvir concns.  In a phase 1b dose-escalating study, virol. responses were detd. in 48 noncirrhotic adult men with chronic genotype 1 or 3 infections randomized to placebo or elbasvir from 5 to 50 mg (genotype 1) or 10 to 100 mg (genotype 3) once daily for 5 days.  The NS5A gene was sequenced from plasma specimens obtained before, during, and after treatment.  Elbasvir suppressed the emergence of resistance-assocd. variants (RAVs) in vitro in a dose-dependent manner.  Variants selected by exposure to high elbasvir concns. typically encoded multiple amino acid substitutions (most commonly involving loci 30, 31, and 93), conferring high-level elbasvir resistance.  In the monotherapy study, patients with genotype 1b had greater redns. in HCV RNA levels than patients with genotype 1a at all elbasvir doses; responses in patients with genotype 3 were generally less pronounced than for genotype 1, particularly at lower elbasvir doses.  M28T, Q30R, L31V, and Y93H in genotype 1a, L31V and Y93H in genotype 1b, and A30K, L31F, and Y93H in genotype 3 were the predominant RAVs selected by elbasvir monotherapy.  Virol. findings in patients were consistent with the preclin. observations.  NS5A-RAVs emerged most often at amino acid positions 28, 30, 31, and 93 in both the lab. and clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqww8cEyKUq57Vg90H21EOLACvtfcHk0ljTsqGCKcrGzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtVynt7w%253D&md5=c112597ce683add1024b594b502a8c4c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FAAC.01390-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01390-15%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DCurry%26aufirst%3DS.%26aulast%3DMcMonagle%26aufirst%3DP.%26aulast%3DYeh%26aufirst%3DW.%2BW.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DJumes%26aufirst%3DP.%2BA.%26aulast%3DMarshall%26aufirst%3DW.%2BL.%26aulast%3DKong%26aufirst%3DS.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DBlack%26aufirst%3DS.%26atitle%3DSusceptibilities%2520of%2520genotype%25201a%252C%25201b%252C%2520and%25203%2520hepatitis%2520C%2520virus%2520variants%2520to%2520the%2520NS5A%2520inhibitor%2520elbasvir%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D6922%26epage%3D6929%26doi%3D10.1128%2FAAC.01390-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwo, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poordad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asatryan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyles, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassanein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felizarta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulkowski, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maliakkal, B.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">271</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2017.03.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1016%2Fj.jhep.2017.03.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=28412293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFeks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2017&pages=263-271&author=P.+Y.+Kwoauthor=F.+Poordadauthor=A.+Asatryanauthor=S.+Wangauthor=D.+L.+Wylesauthor=T.+Hassaneinauthor=F.+Felizartaauthor=M.+S.+Sulkowskiauthor=E.+Ganeauthor=B.+Maliakkal&title=Glecaprevir+and+pibrentasvir+yield+high+response+rates+in+patients+with+HCV+genotype+1%E2%80%936+without+cirrhosis&doi=10.1016%2Fj.jhep.2017.03.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis</span></div><div class="casAuthors">Kwo, Paul Y.; Poordad, Fred; Asatryan, Armen; Wang, Stanley; Wyles, David L.; Hassanein, Tarek; Felizarta, Franco; Sulkowski, Mark S.; Gane, Edward; Maliakkal, Benedict; Overcash, J. Scott; Gordon, Stuart C.; Muir, Andrew J.; Aguilar, Humberto; Agarwal, Kosh; Dore, Gregory J.; Lin, Chih-Wei; Liu, Ran; Lovell, Sandra S.; Ng, Teresa I.; Kort, Jens; Mensa, Federico J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-271</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) therapy that is highly efficacious, pangenotypic, with a high barrier to resistance and short treatment duration is desirable.  The efficacy and safety of 8- and 12-wk treatments with glecaprevir (ABT-493; NS3/4 A protease inhibitor) and pibrentasvir (ABT-530; NS5A inhibitor) were evaluated in non-cirrhotic patients with chronic HCV genotype 1-6 infection.  SURVEYOR-I and SURVEYOR-II were phase II, open-label, multicenter, dose-ranging trials including patients with chronic HCV genotype 1-6 infection who were either previously untreated or treated with pegylated interferon plus ribavirin.  Patients received once-daily glecaprevir plus pibrentasvir at varying doses with or without ribavirin for 8 or 12 wk.  The primary efficacy endpoint was the percentage of patients with a sustained virol. response at post-treatment week 12 (SVR12).  Of the 449 patients who received varying doses of glecaprevir plus pibrentasvir, 25%, 29%, 39%, and 8% had HCV genotype 1, 2, 3, and 4-6 infection, resp.  Twelve-week treatment achieved SVR12 in 97-100%, 96-100%, 83-94%, and 100% in genotypes 1, 2, 3, and 4-6, resp.  Eight-week treatment with 300 mg glecaprevir plus 120 mg pibrentasvir in genotype 1-, 2-, or 3-infected patients yielded 97-98% SVR12 with no virol. failures.  Three (0.7%) patients discontinued treatment due to adverse events; most events were mild (grade 1) in severity.  No post-nadir alanine aminotransferase elevations were obsd.  Glecaprevir plus pibrentasvir was well tolerated and achieved high sustained virol. response rates in HCV genotypes 1-6-infected patients without cirrhosis following 8- or 12-wk treatment durations.  The combination of direct-acting antivirals glecaprevir and pibrentasvir comprise a once-daily, all-oral, pangenotypic treatment for HCV genotype 1-6 infection.  This article describes results from two phase II trials investigating a range of doses at treatment durations of 8 or 12 wk in 449 patients without cirrhosis.  Efficacy of the optimal dose, as detd. by rates of sustained virol. response at post-treatment week 12, ranged from 92%-100%; treatment was well tolerated and significant lab. abnormalities were rare.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY1_YC2ck4e7Vg90H21EOLACvtfcHk0ljTsqGCKcrGzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFeks70%253D&md5=33971ab16202fe91408b866cc8b02490</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2017.03.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2017.03.039%26sid%3Dliteratum%253Aachs%26aulast%3DKwo%26aufirst%3DP.%2BY.%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DAsatryan%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWyles%26aufirst%3DD.%2BL.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DFelizarta%26aufirst%3DF.%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DGane%26aufirst%3DE.%26aulast%3DMaliakkal%26aufirst%3DB.%26atitle%3DGlecaprevir%2520and%2520pibrentasvir%2520yield%2520high%2520response%2520rates%2520in%2520patients%2520with%2520HCV%2520genotype%25201%25E2%2580%25936%2520without%2520cirrhosis%26jtitle%3DJ.%2520Hepatol.%26date%3D2017%26volume%3D67%26spage%3D263%26epage%3D271%26doi%3D10.1016%2Fj.jhep.2017.03.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eisenman, T.</span></span> <span> </span><span class="NLM_article-title">FDA Approves Epclusa for Treatment of Chronic Hepatitis C Virus Infection</span>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-epclusa-treatment-chronic-hepatitis-c-virus-infection" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-epclusa-treatment-chronic-hepatitis-c-virus-infection</a> (accessed March 11, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=T.+Eisenman&title=FDA+Approves+Epclusa+for+Treatment+of+Chronic+Hepatitis+C+Virus+Infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DEisenman%26aufirst%3DT.%26atitle%3DFDA%2520Approves%2520Epclusa%2520for%2520Treatment%2520of%2520Chronic%2520Hepatitis%2520C%2520Virus%2520Infection%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">US
Food and Drug Administration</span>, <span> </span><span class="NLM_article-title">FDA Approves
Zepatier for Treatment of Chronic Hepatitis C Genotypes 1 and 4</span>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-zepatier-treatment-chronic-hepatitis-c-genotypes-1-and-4" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-zepatier-treatment-chronic-hepatitis-c-genotypes-1-and-4</a> (accessed March 11, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=US%0AFood+and+Drug+Administration&title=FDA+Approves%0AZepatier+for+Treatment+of+Chronic+Hepatitis+C+Genotypes+1+and+4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DFDA%2520Approves%250AZepatier%2520for%2520Treatment%2520of%2520Chronic%2520Hepatitis%2520C%2520Genotypes%25201%2520and%25204%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlich, D. R.</span></span> <span> </span><span class="NLM_article-title">Glecaprevir/pibrentasvir (Mavyret) for the treatment of chronic hepatitis C</span>. <i>Am. Fam. Physician</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">601</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=30365290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A280%3ADC%252BB3cvjslaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2018&pages=601&author=A.+Groverauthor=D.+R.+Erlich&title=Glecaprevir%2Fpibrentasvir+%28Mavyret%29+for+the+treatment+of+chronic+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Glecaprevir/Pibrentasvir (Mavyret) for the Treatment of Chronic Hepatitis C</span></div><div class="casAuthors">Grover Anupriya; Erlich Deborah R</div><div class="citationInfo"><span class="NLM_cas:title">American family physician</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">601-602</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSR2DQeGejR8JQHPYJuLg8TfW6udTcc2ea3U-BNoe7CbLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvjslaqsg%253D%253D&md5=98c24218c245c109d2b0c3006fd9f842</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrover%26aufirst%3DA.%26aulast%3DErlich%26aufirst%3DD.%2BR.%26atitle%3DGlecaprevir%252Fpibrentasvir%2520%2528Mavyret%2529%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2018%26volume%3D98%26spage%3D601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheel, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, C. M.</span></span> <span> </span><span class="NLM_article-title">Understanding the hepatitis C virus life cycle paves the way for highly effective therapies</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">837</span>, <span class="refDoi"> DOI: 10.1038/nm.3248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1038%2Fnm.3248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=23836234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKru7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=837&author=T.+K.+Scheelauthor=C.+M.+Rice&title=Understanding+the+hepatitis+C+virus+life+cycle+paves+the+way+for+highly+effective+therapies&doi=10.1038%2Fnm.3248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the hepatitis C virus life cycle paves the way for highly effective therapies</span></div><div class="casAuthors">Scheel, Troels K. H.; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">837-849</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  More than two decades of intense research has provided a detailed understanding of hepatitis C virus (HCV), which chronically infects 2% of the world's population.  This effort has paved the way for the development of antiviral compds. to spare patients from life-threatening liver disease.  An exciting new era in HCV therapy dawned with the recent approval of two viral protease inhibitors, used in combination with pegylated interferon-α and ribavirin; however, this is just the beginning.  Multiple classes of antivirals with distinct targets promise highly efficient combinations, and interferon-free regimens with short treatment duration and fewer side effects are the future of HCV therapy.  Ongoing and future trials will det. the best antiviral combinations and whether the current seemingly rich pipeline is sufficient for successful treatment of all patients in the face of major challenges, such as HCV diversity, viral resistance, the influence of host genetics, advanced liver disease and other co-morbidities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpde8altGxkeLVg90H21EOLACvtfcHk0lgmtemtxIkjcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKru7rI&md5=dabc9fbc7dc0bc56115d5ede0d8ae072</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnm.3248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3248%26sid%3Dliteratum%253Aachs%26aulast%3DScheel%26aufirst%3DT.%2BK.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DUnderstanding%2520the%2520hepatitis%2520C%2520virus%2520life%2520cycle%2520paves%2520the%2520way%2520for%2520highly%2520effective%2520therapies%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D837%26doi%3D10.1038%2Fnm.3248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D. R.,  II</span></span> <span> </span><span class="NLM_article-title">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>465</i></span>,  <span class="NLM_fpage">96</span>, <span class="refDoi"> DOI: 10.1038/nature08960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1038%2Fnature08960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=20410884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=96&author=M.+Gaoauthor=R.+E.+Nettlesauthor=M.+Belemaauthor=L.+B.+Snyderauthor=V.+N.+Nguyenauthor=R.+A.+Fridellauthor=M.+H.+Serrano-Wuauthor=D.+R.+Langleyauthor=J.-H.+Sunauthor=D.+R.+O%E2%80%99Boyle&title=Chemical+genetics+strategy+identifies+an+HCV+NS5A+inhibitor+with+a+potent+clinical+effect.&doi=10.1038%2Fnature08960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span></div><div class="casAuthors">Gao, Min; Nettles, Richard E.; Belema, Makonen; Snyder, Lawrence B.; Nguyen, Van N.; Fridell, Robert A.; Serrano-Wu, Michael H.; Langley, David R.; Sun, Jin-Hua; O'Boyle, Donald R., II; Lemm, Julie A.; Wang, Chunfu; Knipe, Jay O.; Chien, Caly; Colonno, Richard J.; Grasela, Dennis M.; Meanwell, Nicholas A.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7294</span>),
    <span class="NLM_cas:pages">96-100</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estd. to be approaching 200 million people.  Current therapy relies upon a combination of pegylated interferon-α and ribavirin, a poorly tolerated regimen typically assocd. with less than 50% sustained virol. response rate in those infected with genotype 1 virus.  The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B.  Here we describe the profile of BMS-790052, a small mol. inhibitor of the HCV NS5A protein that exhibits picomolar half-max. effective concns. (EC50) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture.  In a phase I clin. trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was assocd. with a 3.3 log10 redn. in mean viral load measured 24 h post-dose that was sustained for an addnl. 120 h in two patients infected with genotype 1b virus.  Genotypic anal. of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants obsd. had substitutions at amino-acid positions identified using the in vitro replicon system.  These results provide the first clin. validation of an inhibitor of HCV NS5A, a protein with no known enzymic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAY7Lig0xT9LVg90H21EOLACvtfcHk0lgmtemtxIkjcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D&md5=620427e987f2bccd153270cde2ef5027</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnature08960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08960%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26atitle%3DChemical%2520genetics%2520strategy%2520identifies%2520an%2520HCV%2520NS5A%2520inhibitor%2520with%2520a%2520potent%2520clinical%2520effect.%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D96%26doi%3D10.1038%2Fnature08960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S. O.</span></span> <span> </span><span class="NLM_article-title">Organosilicon molecules with medicinal applications</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.1021/jm3010114</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3010114" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSgs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=388-405&author=A.+K.+Franzauthor=S.+O.+Wilson&title=Organosilicon+molecules+with+medicinal+applications&doi=10.1021%2Fjm3010114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Organosilicon Molecules with Medicinal Applications</span></div><div class="casAuthors">Franz, Annaliese K.; Wilson, Sean O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">388-405</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The incorporation of silicon and synthesis of organosilicon small mols. provide unique opportunities for medicinal applications.  The biol. investigation of organosilicon small mols. is particularly interesting because of differences in their chem. properties that can contribute to enhanced potency and improved pharmacol. attributes.  Applications such as inhibitor design, imaging, drug release technol., and mapping inhibitor binding are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVagNko6ifK7Vg90H21EOLACvtfcHk0lgmtemtxIkjcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSgs7bJ&md5=ffca8660a9a619e474b64624ad5705d0</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm3010114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3010114%26sid%3Dliteratum%253Aachs%26aulast%3DFranz%26aufirst%3DA.%2BK.%26aulast%3DWilson%26aufirst%3DS.%2BO.%26atitle%3DOrganosilicon%2520molecules%2520with%2520medicinal%2520applications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D388%26epage%3D405%26doi%3D10.1021%2Fjm3010114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, D. S.</span></span> <span> </span><span class="NLM_article-title">Quest for novel chemical entities through incorporation of silicon in drug scaffolds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3779</span>– <span class="NLM_lpage">3798</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00718</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00718" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1KnsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3779-3798&author=R.+Rameshauthor=D.+S.+Reddy&title=Quest+for+novel+chemical+entities+through+incorporation+of+silicon+in+drug+scaffolds&doi=10.1021%2Facs.jmedchem.7b00718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Quest for Novel Chemical Entities through Incorporation of Silicon in Drug Scaffolds</span></div><div class="casAuthors">Ramesh, Remya; Reddy, D. Srinivasa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3779-3798</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to optimize a lead mol. for further development, bioisosteric replacements are generally adopted as one of the strategies.  Silicon appears to be the right choice as a carbon isostere because of the similarity in chem. properties.  Silicon can be strategically introduced in a mol. to modulate its druglike properties, providing medicinal chemists with an unconventional strategy for replacing a carbon atom.  Silicon can also be introduced to replace other heteroatoms and can act as a surrogate of functional groups such as olefin and amide as well.  The present Perspective focuses on the opportunities that silicon incorporation offers in drug discovery, with an emphasis on case studies where introduction of silicon has created a benefit over its analog.  We have tried to highlight all the recent developments in the field and briefly discuss the challenges assocd. with them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjk4JZC1BTKLVg90H21EOLACvtfcHk0lggTg0uvx7s0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1KnsbvM&md5=fa3da0fddb955d156d410eb68030e78a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00718%26sid%3Dliteratum%253Aachs%26aulast%3DRamesh%26aufirst%3DR.%26aulast%3DReddy%26aufirst%3DD.%2BS.%26atitle%3DQuest%2520for%2520novel%2520chemical%2520entities%2520through%2520incorporation%2520of%2520silicon%2520in%2520drug%2520scaffolds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3779%26epage%3D3798%26doi%3D10.1021%2Facs.jmedchem.7b00718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=10.1016%2Fj.ejmech.2018.02.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=29454920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtVWru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=95-105&author=B.+Liuauthor=K.+Gaiauthor=H.+Qinauthor=X.+Liuauthor=Y.+Caoauthor=Q.+Luauthor=D.+Luauthor=D.+Chenauthor=H.+Shenauthor=W.+Songauthor=Y.+Zhangauthor=X.+Wangauthor=H.+Xuauthor=Y.+Zhang&title=Design%2C+synthesis+and+identification+of+silicon-containing+HCV+NS5A+inhibitors+with+pan-genotype+activity&doi=10.1016%2Fj.ejmech.2018.02.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity</span></div><div class="casAuthors">Liu, Baomin; Gai, Kuo; Qin, Hui; Liu, Xushi; Cao, Yuan; Lu, Qin; Lu, Dandan; Chen, Deyang; Shen, Hengqiao; Song, Wei; Zhang, Yang; Wang, Xiaojin; Xu, Hongjiang; Zhang, Yinsheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">95-105</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Modification of a HCV NS5A inhibitor, ombitasvir, led to the identification of 10d with improved pan-genotype NS5A inhibition and better pharmacokinetic properties.  The key structural changes to ombitasvir include bioisosteric replacement of carbon with silicon atom.  Compared with ombitasvir, the activity of anti-HCV genotypes (GT 1 to 6) of 10d is increased to some extent, esp. the inhibitory activity against genotype 3a and 6a is increased by more than seven times, and the dog's in vivo pharmacokinetics properties were also superior to ombitasvir.  Further drug evaluation showed that 10d was similar to ombitasvir on plasma protein binding and liver distribution profiles, with no cytotoxicity and no inhibitory effect on both CYP 450 and hERG ligand binding.  However, permeability assay results indicated that 10d was not the substrate of P-gp or BCRP transporter, which is different from that of ombitasvir.  The results of a 14-day repeat-dose toxicity study identified no toxicity with 10d.  Our findings in preclin. tests suggest that the silicon-contg. compd. 10d could be worthy of continued study as a potential drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPr6ylPm7KrLVg90H21EOLACvtfcHk0lggTg0uvx7s0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtVWru7g%253D&md5=a48300812980be663870fa1cf54793ac</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DGai%26aufirst%3DK.%26aulast%3DQin%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%2520and%2520identification%2520of%2520silicon-containing%2520HCV%2520NS5A%2520inhibitors%2520with%2520pan-genotype%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D148%26spage%3D95%26epage%3D105%26doi%3D10.1016%2Fj.ejmech.2018.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeGoey, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randolph, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulenko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motter, C. E.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2047</span>– <span class="NLM_lpage">2057</span>, <span class="refDoi"> DOI: 10.1021/jm401398x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401398x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2047-2057&author=D.+A.+DeGoeyauthor=J.+T.+Randolphauthor=D.+Liuauthor=J.+Prattauthor=C.+Hutchinsauthor=P.+Donnerauthor=A.+C.+Kruegerauthor=M.+Matulenkoauthor=S.+Patelauthor=C.+E.+Motter&title=Discovery+of+ABT-267%2C+a+pan-genotypic+inhibitor+of+HCV+NS5A&doi=10.1021%2Fjm401398x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A</span></div><div class="casAuthors">DeGoey, David A.; Randolph, John T.; Liu, Dachun; Pratt, John; Hutchins, Charles; Donner, Pamela; Krueger, A. Chris; Matulenko, Mark; Patel, Sachin; Motter, Christopher E.; Nelson, Lissa; Keddy, Ryan; Tufano, Michael; Caspi, Daniel D.; Krishnan, Preethi; Mistry, Neeta; Koev, Gennadiy; Reisch, Thomas J.; Mondal, Rubina; Pilot-Matias, Tami; Gao, Yi; Beno, David W. A.; Maring, Clarence J.; Molla, Akhter; Dumas, Emily; Campbell, Andrew; Williams, Laura; Collins, Christine; Wagner, Rolf; Kati, Warren M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2047-2057</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe here N-phenylpyrrolidine-based inhibitors of HCV NS5A with excellent potency, metabolic stability, and pharmacokinetics.  Compds. with 2S,5S stereochem. at the pyrrolidine ring provided improved genotype 1 (GT1) potency compared to the 2R,5R analogs.  Furthermore, the attachment of substituents at the 4-position of the central N-Ph group resulted in compds. with improved potency.  Substitution with tert-Bu, as in compd. 38 (ABT-267)(I), provided compds. with low-picomolar EC50 values and superior pharmacokinetics.  It was discovered that compd. 38 was a pan-genotypic HCV inhibitor, with an EC50 range of 1.7-19.3 pM against GT1a, -1b, -2a, -2b, -3a, -4a, and -5a and 366 pM against GT6a.  Compd. 38 decreased HCV RNA up to 3.10 log10 IU/mL during 3-day monotherapy in treatment-naive HCV GT1-infected subjects and is currently in phase 3 clin. trials in combination with an NS3 protease inhibitor with ritonavir (r) (ABT-450/r) and an NS5B non-nucleoside polymerase inhibitor (ABT-333), with and without ribavirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQLXZPjB144rVg90H21EOLACvtfcHk0lguWWIzPBocCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKhsQ%253D%253D&md5=70f0d0f8e9751b533617fecc1b4a8016</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm401398x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401398x%26sid%3Dliteratum%253Aachs%26aulast%3DDeGoey%26aufirst%3DD.%2BA.%26aulast%3DRandolph%26aufirst%3DJ.%2BT.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DPratt%26aufirst%3DJ.%26aulast%3DHutchins%26aufirst%3DC.%26aulast%3DDonner%26aufirst%3DP.%26aulast%3DKrueger%26aufirst%3DA.%2BC.%26aulast%3DMatulenko%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DMotter%26aufirst%3DC.%2BE.%26atitle%3DDiscovery%2520of%2520ABT-267%252C%2520a%2520pan-genotypic%2520inhibitor%2520of%2520HCV%2520NS5A%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2047%26epage%3D2057%26doi%3D10.1021%2Fjm401398x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randolph, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulenko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keddy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donner, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flentge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betebenner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockway, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maring, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilot-Matias, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekhtyar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolarik, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beno, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kati, W. M.</span></span> <span> </span><span class="NLM_article-title">Highlights of the structure-activity relationships of benzimidazole linked pyrrolidines leading to the discovery of the hepatitis C virus NS5A inhibitor pibrentasvir (ABT-530)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4052</span>– <span class="NLM_lpage">4066</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00082</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00082" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsF2rsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4052-4066&author=R.+Wagnerauthor=J.+T.+Randolphauthor=S.+V.+Patelauthor=L.+Nelsonauthor=M.+A.+Matulenkoauthor=R.+Keddyauthor=J.+K.+Prattauthor=D.+Liuauthor=A.+C.+Kruegerauthor=P.+L.+Donnerauthor=D.+K.+Hutchinsonauthor=C.+Flentgeauthor=D.+Betebennerauthor=T.+Rockwayauthor=C.+J.+Maringauthor=T.+I.+Ngauthor=P.+Krishnanauthor=T.+Pilot-Matiasauthor=C.+Collinsauthor=N.+Panchalauthor=T.+Reischauthor=T.+Dekhtyarauthor=R.+Mondalauthor=D.+F.+Stolarikauthor=Y.+Gaoauthor=W.+Gaoauthor=D.+A.+Benoauthor=W.+M.+Kati&title=Highlights+of+the+structure-activity+relationships+of+benzimidazole+linked+pyrrolidines+leading+to+the+discovery+of+the+hepatitis+C+virus+NS5A+inhibitor+pibrentasvir+%28ABT-530%29&doi=10.1021%2Facs.jmedchem.8b00082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530)</span></div><div class="casAuthors">Wagner, Rolf; Randolph, John T.; Patel, Sachin V.; Nelson, Lissa; Matulenko, Mark A.; Keddy, Ryan; Pratt, John K.; Liu, Dachun; Krueger, A. Chris; Donner, Pamela L.; Hutchinson, Douglas K.; Flentge, Charles; Betebenner, David; Rockway, Todd; Maring, Clarence J.; Ng, Teresa I.; Krishnan, Preethi; Pilot-Matias, Tami; Collins, Christine; Panchal, Neeta; Reisch, Thomas; Dekhtyar, Tatyana; Mondal, Rubina; Stolarik, DeAnne F.; Gao, Yi; Gao, Wenqing; Beno, David A.; Kati, Warren M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4052-4066</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Curative interferon and ribavirin sparing treatments for hepatitis C virus (HCV)-infected patients require a combination of mechanistically orthogonal direct acting antivirals.  A shared component of these treatments is usually an HCV NS5A inhibitor.  First generation FDA approved treatments, including the component NS5A inhibitors, do not exhibit equiv. efficacy against HCV virus genotypes 1-6.  In particular, these first generation NS5A inhibitors tend to select for viral drug resistance.  Ombitasvir is a first generation HCV NS5A inhibitor included as a key component of Viekira Pak for the treatment of patients with HCV genotype 1 infection.  Since the launch of next generation HCV treatments, functional cure for genotype 1-6 HCV infections has been achieved, as well as shortened treatment duration across a wider spectrum of genotypes.  In this paper, we show how we have modified the anchor, linker, and end-cap architecture of our NS5A inhibitor design template to discover a next generation NS5A inhibitor pibrentasvir (ABT-530), which exhibits potent inhibition of the replication of wild-type genotype 1-6 HCV replicons, as well as improved activity against replicon variants demonstrating resistance against first generation NS5A inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM7hUxmbEpArVg90H21EOLACvtfcHk0lguWWIzPBocCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsF2rsrw%253D&md5=450645ee6f484479478f549a0d07b7ae</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00082%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DR.%26aulast%3DRandolph%26aufirst%3DJ.%2BT.%26aulast%3DPatel%26aufirst%3DS.%2BV.%26aulast%3DNelson%26aufirst%3DL.%26aulast%3DMatulenko%26aufirst%3DM.%2BA.%26aulast%3DKeddy%26aufirst%3DR.%26aulast%3DPratt%26aufirst%3DJ.%2BK.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DKrueger%26aufirst%3DA.%2BC.%26aulast%3DDonner%26aufirst%3DP.%2BL.%26aulast%3DHutchinson%26aufirst%3DD.%2BK.%26aulast%3DFlentge%26aufirst%3DC.%26aulast%3DBetebenner%26aufirst%3DD.%26aulast%3DRockway%26aufirst%3DT.%26aulast%3DMaring%26aufirst%3DC.%2BJ.%26aulast%3DNg%26aufirst%3DT.%2BI.%26aulast%3DKrishnan%26aufirst%3DP.%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DPanchal%26aufirst%3DN.%26aulast%3DReisch%26aufirst%3DT.%26aulast%3DDekhtyar%26aufirst%3DT.%26aulast%3DMondal%26aufirst%3DR.%26aulast%3DStolarik%26aufirst%3DD.%2BF.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DBeno%26aufirst%3DD.%2BA.%26aulast%3DKati%26aufirst%3DW.%2BM.%26atitle%3DHighlights%2520of%2520the%2520structure-activity%2520relationships%2520of%2520benzimidazole%2520linked%2520pyrrolidines%2520leading%2520to%2520the%2520discovery%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitor%2520pibrentasvir%2520%2528ABT-530%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4052%26epage%3D4066%26doi%3D10.1021%2Facs.jmedchem.8b00082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i45"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00082">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_80506"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00082?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00082</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings, HPLC spectrum of targeted compounds; <sup>1</sup>H and <sup>13</sup>C NMR spectra for compound <b>11</b>; body and organ weights; hematology data for mouse orally treated with <b>11</b> for 14 days; blood chemistry data for mouse orally treated with <b>11</b> for 14 days (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00082/suppl_file/jm0c00082_si_001.zip">ZIP</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00082/suppl_file/jm0c00082_si_001.zip">jm0c00082_si_001.zip (1.43 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00082&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00082%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-10" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00082" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67993e9068913d76","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
